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C h a p t e r 
o n e 
Introduction 
In this thesis the effects of radioiodine treatment in patients with toxic 
and non-toxic multinodular goiter and in patients with toxic autonomous 
thyroid nodules are studied. This first chapter contains a short review 
of current knowledge of the pathogenesis and natural history of both 
entities and a summary of the cell biological effects of radioiodine on 
the thyroid gland. 
o o o o o o o · 
In this thesis the effects of radioiodine treatment in patients with toxic and non-
toxic multinodular goiter and in patients with toxic autonomous thyroid nodules 
are studied. This first chapter contains a short review of current knowledge of 
the pathogenesis and natural history of both entities and a summary of the cell 
biological effects of radioiodine on the thyroid gland. 
1.1 Definitions 
Goiter may be defined as any enlargement of the thyroid gland [1]. It is called 
endemic when the prevalence in a population is more than 10%. Endemic goiter 
is usually associated with iodine deficiency. The term sporadic goiter is used 
when goiter prevalence in a population is 10% or less [2]. 
Multinodular goiter is defined as a structurally and functionally heteroge-
neous thyroid enlargement [3]. According to Studer [4-6], multinodular goiter 
arises from excessive replication of thyroid epithelial cells with subsequent gen-
eration of new follicles of widely differing structure and function. The size of 
such a goiter tends to increase with age and, although the thyroid may be dif-
fusely enlarged in the first phase of goitrogenesis, it will become more nodular 
with time. Moreover, euthyroidism may gradually change into hyperthyroidism 
in these patients. 
A solitary autonomous thyroid nodule is a discrete thyroid nodule that se-
cretes thyroid hormone independently of any known extrathyroidal stimulus [7]. 
It may exist in close approximation to and within normal thyroid parenchyma 
that remains subject to the functional regulation of the pituitary. As a solitary 
autonomous thyroid nodule is generated from follicular cells with, probably ge-
netically determined, high replication rate and iodinating capacity, its size tends 
to increase with time, not infrequently leading to hyperthyroidism. 
1.2 Pathogenesis of multinodular goiter 
Increased cell replication as basis for goitrogenesis 
Studer's group in Bern clearly demonstrated that nodular goiter is caused by 
excessive replication of thyroid epithelial cells with subsequent generation of 
new follicles. For example, Ramelli et al. [8] showed a highly significant, lin-
ear correlation between the total DNA content of multinodular goiters and the 
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weight of these goiters indicating that new cells must be generated during goi-
ter growth. Histologically, these cells appeared to be mainly thyroid follicular 
epithelial cells. 
The process of excessive cell replication and formation of new follicles is, 
however, not exclusive for multinodular goiters. It is also the basis for the 
formation of diffuse goiters in patients with Graves' disease. It seems that 
after a strong growth stimulation as in Graves' disease thyroid growth will be 
diffuse and follicle formation will be uniform because replication and metabolic 
function of all follicular cells are stimulated. In contrast, chronic, and possibly 
intermittent, mild stimulation gives rise to the very heterogeneous growth of 
nodular goiters [4]. 
Factors which may be involved in increased cell replication (growth 
stimulating factors) 
Goitrogenesis can be stimulated by a number of factors. Thyroid-stimulating 
hormone (TSH) is the most potent thyroid growth stimulating factor in vivo [9, 
10]. Thyroid growth due to iodine deficiency, exposure to goitrogens or the pres-
ence of inherited metabolic defects within the thyroid follicular cell is probably 
mediated by an increase of serum TSH levels, caused by a decrease of serum 
thyroid hormone levels. 
Iodine deficiency is world-wide the most common cause of goiter. Iodine ki-
netics during iodine deficiency have been studied extensively in humans [11-18] 
and in animals [19-21]. A decrease in the intrathyroidal iodine pool leads to 
decreased iodination of thyroglobulin [14, 15, 17-19, 22] and diminished release 
of iodinated thyroid hormones. This subsequently causes a small increase in the 
serum TSH level, which results in a rise of iodine uptake and organification, thy-
roid hormone secretion and in thyroid growth. Although goitrogenesis in iodine 
deficiency is largely dependent on TSH stimulation, there is evidence that part 
of the process is TSH-independent [19]. In iodine deficient individuals thyroid 
growth is enhanced by ingestion of antithyroid substances, naturally occurring 
in certain plants (thiocyanates and thioglucosides). It is uncertain whether these 
agents are ever ingested in large enough quantities to cause goiter in the ab-
sence of iodine deficiency. Thyrostatic agents and some other drugs (e.g., amino-
glutethimide, phenylbutazone, ethionamide, iodine-containing agents, lithium, 
resorcinol, para-aminosalicylic acid) also occasionally cause goiter [3]. Various 
metabolic disorders at the level of the follicular cell, most of which are partial 
enzymatic defects, may cause familial goitrogenesis [23]. 
More recently, experimental evidence has been presented that growth fac-
tors like epidermal growth factor and insulin-like growth factor-1 and -2 may 
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be important for stimulation of goitrogenesis, partly via TSH-independent path-
ways [24-27]. Furthermore, the presence of thyroid growth stimulating immu-
noglobulins has been reported in serum of patients with non-toxic goiter [28]. 
Various reports favouring the existence of such thyroid growth stimulating im-
munoglobulins, using different methods for the assessment of growth, have been 
published [29-34]. Other studies could not confirm a pathogenetic role of thy-
roid growth stimulating immunoglobulins in nodular goiter [35-38]. There are 
many pitfalls in the methods used for growth assessment and purification of 
immunoglobulins [39]. Zakarija and McKenzie [40] concluded, therefore, that 
the existence and possible growth-promoting role of thyroid growth stimulating 
immunoglobulins in nodular goiter are still to be proved. 
In addition to and possibly modulated by these extracellular stimulators of 
thyroid growth, some intracellular mechanisms have been proposed as possibly 
contributing to the growth of multinodular goiters. Studer et al. [41] reported 
on the presence in nodular goiters of clusters of thyroid follicular cells, heavily 
loaded with the protein product of the ras protooncogene. This protein partici-
pates in the transduction of growth-promoting signals and increased expression 
of the ras protooncogene is associated with increased cell replication [42, 43]. 
Recently, high intracellular levels of stimulatory guanine nucleotide binding 
(Gs) proteins in a fraction of cells of growing nodular goiters have been reported 
[44]. Gs proteins may stimulate growth by activation of the cyclic AMP cascade. 
Resistance of subpopulations of thyroid follicular cells to the antiproliferative 
effect of transforming growth factor ßj may be another mechanism in goitroge-
nesis [45]. 
Heterogeneity between and within follicles and nodules in multinod-
ular goiters 
The heterogeneity of nodular goiter follicles is based on the fact that, even in in-
dividual follicles, thyroid cells may originate from different mother cells [46-48]. 
The polyclonal origin of epithelial cells in normal human thyroid tissue and in 
nodular goiter tissue has recently been confirmed by the X inactivation approach 
[49, 50]. Individual traits are transferred from a mother cell to all daughter cells 
[9, 51]. Especially those cells in a follicle, that have an inherited propensity to 
replicate at a higher rate than other cells, give rise to the generation of new folli-
cles. In the course of goitrogenesis, therefore, the heterogeneity between follicles 
is amplified. Furthermore, during every replication cycle new metabolic traits, 
not present in the mother cell, can be acquired. Various mechanisms for the ex-
tragenetic acquirement of new cell qualities have been proposed [52-56]. These 
acquired traits may be transferred to subsequent generations of cells. 
INTRODUCTION 
Experimental evidence of differences in replicating activity between thy­
roid cells in the normal thyroid gland as well as in multinodular goiters 
Studer's group demonstrated differences in the replicating activity of individual 
cells of the rat thyroid cell line РІПЪ-5. This individual multiplication rate was 
reproducible in daughter cells, even after separation from the mother cell [5]. 
The same group also studied the replicating activity of thyroid cells by autora­
diography showing the incorporation of a [3H]thymidine label in cell nuclei dur­
ing mitosis [9, 51, 58, 59]. Experiments in L-thyroxine (T4) treated mice [58] 
demonstrated that in mouse thyroid glands the number of autonomously (i.e. in 
the absence of TSH stimulation) proliferating cells gradually declines with in­
creasing age. [3H]thymidine labelling was also used in experiments in human 
thyroid tissue (fetal and normal adult thyroid tissue and nodular goiter tissue) 
transplanted onto T4 treated nude mice. Considerable autonomous proliferation 
of human fetal thyroid tissue was demonstrated [58]. Up to 36% of the fetal 
follicular cell nuclei incorporated the [3H] thymidine label in the absence of TSH 
in the blood. For normal adult thyroid tissue the fraction of autonomously repli­
cating cells was less than 1% and for human nodular goiter it ranged from 0.5% 
to 7% [9]. The authors hypothesized that the cells with high growth potential in 
the fetal thyroid gland are the same cells that replicate at a higher than average 
rate in the adult gland. During maturation, fetal cells acquire mechanisms that 
make them gradually less autonomous and more dependent on growth factors 
(like TSH). However, a few cells may fail to do so. The fraction of these growth 
prone cells in the individual adult gland may be important for the chance of 
developing nodular goiter. 
Using autoradiography it was shown that in mouse thyroids, after growth 
stimulation by hemithyroidectomy, the majority of [3H] thymidine labelled cells 
were clustered in groups of three or more, rather than being randomly dis­
tributed [59]. For human nodular goiter tissue grafted onto nude mice a large 
interregional variability of growth was observed with very dense clustering of 
[3H]thymidine labelled cells in a few distinct regions. Individual follicles con­
tained variable numbers of labelled cell clusters consisting of only a few cells 
to a multitude of replicating cells [9, 51]. The newly formed cells closely stayed 
together to form large families. Therefore, it appeared that the growth advan­
tage of these cells is conveyed from mother to daughter cells. The replicating 
potential of individual cells was not correlated with any specific cell morphology. 
TSH stimulation by feeding the nude mice methimazole resulted in an in­
crease of the fraction of [3H]thymidine labelled cells in both normal and goitrous 
human thyroid tissue. A TSH-dependent recruitment of follicular cells was 
found [9] : upon a small increase in TSH levels a further set of cells, not au­
tonomously replicating but with a low threshold for TSH response, starts to 
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proliferate and with increasing intensity and duration of the stimulus the per-
centage of replicating cells expands gradually. 
Experimental evidence for differences in metabolic functions between 
thyroid cells in the normal thyroid gland as well as in multinodular 
goiters 
Intercellular diversity of various metabolic functions has been demonstrated 
within and between follicles and nodules in multinodular goiters. In vitro, con-
siderable intercellular differences in activities of enzymes needed for thyroid 
metabolism [peroxidase, deiodinase, thyroglobulin acid hydrolases and adenyl-
cyclase] have been reported [51, 60-63]. Furthermore, in vitro intercellular 
differences in thyroglobulin synthesis have been shown using plaque-forming 
assays with single thyrocytes [64] and the in situ hybridization technique [65]. 
In vivo, different aspects of metabolic heterogeneity have been evaluated. 
A variable degree of autonomous, i.e. TSH-independent, iodide uptake in normal 
follicles was found in hypophysectomized animals [20] and in the extranodu-
lar thyroid tissue of patients with a toxic solitary autonomous nodule [66-68]. 
Diversity of iodination of intraluminal iodoproteins was also demonstrated by 
autoradiography after 131I or 125I labelling of mouse thyroids [4, 69], surgical 
specimens of feline goiters [70] and of human goiters [51] and feline and human 
goiters transplanted onto nude mice [9, 70]. The degree of autonomous iodide or-
ganification during TSH suppression differs between cells or cell groups within 
a single follicle [9, 51]. Moderate TSH stimulation increases 125I uptake in both 
hot and cold follicles. Heavy stimulation, like in Graves' disease, will gradually 
level off the heterogeneity in iodine metabolism, because an upper limit to the 
iodine turnover is reached. 
Endocytosis of colloid is characterized by pseudopods protruding into the fol-
licular lumen followed by the appearance of thyroglobulin-filled droplets within 
follicular cells [51]. In the absence of TSH the number of droplet-containing 
cells and the droplet count per cell, as studied in rat and mouse thyroids, are 
very low. With increasing TSH concentrations, the number of droplet-containing 
cells as well as the number of droplets per cell gradually increase up to a plateau 
[21]. Increasing endocytosis with rising TSH concentrations was also reported 
using electron microscopical quantification of pseudopod number and size [71]. 
An age dependent failure of TSH-responsive endocytosis has been observed in an 
increasing number of follicles of aging mice [72]. Subsequent overfilling of the 
follicular lumina with colloid leads to a cease of iodine uptake and irreversibly 
"cold" follicles. 
The colloid content of a follicle depends on the total thyroglobulin synthesis 
of the individual follicle cells and on their endocytotic activity. In human goiters 
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diversity of thyroglobulin synthesis and endocytosis is apparent from marked 
differences in size and thyroglobulin content of follicles. In the normal thyroid, 
every follicular cell contributes a rather constant share to the total luminal store 
of colloid, resulting in a constant thyroglobulin content of about 4% of the dry 
weight of a thyroid tissue sample. In contrast, thyroglobulin content in nodular 
goiters differs widely between regions [4]. 
Consequences of increased cell replication and cellular heterogeneity 
During goiter growth the fraction of cells with a high growth rate expands at the 
expense of slower growing cells. Due to this growing fraction of rapidly replicat-
ing cells the growth rate of the whole goiter increases. New follicular cells may 
form new follicles or they may be used to enlarge the envelope of the mother 
follicle [41]. Large colloid rich follicles and microfollicular regions may coexist 
in the same goiter. The newly formed thyroid tissue requires expansion of the 
capillary network which is often grossly different from normal vessels [4]. The 
abnormal capillaries may fail to adequately supply the newly formed thyroid 
cells. Scattered haemorrhagic necroses with collaps and destruction of follicles 
and with interspersed strands of connective tissue are characteristic results of 
this process [73]. Necrotic areas are invaded by granulation tissue and ulti-
mately poorly cellular scars may form, creating a fibrous network interfering 
with smooth growth which will further enhance (pseudo-)nodularity. 
In nodular goiter the fine balance between cell functions which prevails in 
normal glands is lost [74]. Any metabolic function may be autonomous. Small 
follicles with suppressible iodide uptake result when only replication and endo-
cytosis are autonomous. When iodide uptake is also autonomous, small follicles 
with non-suppressible iodide uptake result. When thyroglobulin synthesis and 
iodine organification but not endocytosis are autonomous, large colloid rich folli-
cles will form with non-suppressible iodide uptake [73]. Thus, metabolic function 
cannot be deduced from the microscopical appearance of follicles or individual 
cells [9, 51, 72, 75, 76]. 
Autonomous iodine turnover in thyroid follicles is essentially a physiological 
phenomenon. However, when the number of follicles with autonomous iodine 
turnover increases in a nodular goiter, the total amount of thyroid hormones se-
creted by these and by TSH-dependent follicles may exceed the amount needed 
by the organism. TSH levels will become suppressed (autonomous thyroid func-
tion) and ultimately overt hyperthyroidism will develop [77, 78]. 
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1.3 Natural history of multinodular goiter 
The aforementioned cell biological data suggest that the natural history of (nodu-
lar) goiter is characterized by growth, increasing nodularity and increasing au-
tonomy of thyroid metabolic functions. Berghout et al. [37, 79] indeed found 
evidence for continuous growth and increasing nodularity in non-toxic goiter. In 
a cross-sectional study of 102 consecutive patients with sporadic non-toxic goiter 
[79] they showed that patients with a multinodular goiter were older and had a 
larger thyroid volume than patients with a diffuse or uninodular goiter (ultra-
sonography measurements). Thyroid volume was positively correlated with age 
and duration of goiter. They calculated an annual increase of thyroid volume 
of 4.5%. In a longitudinal placebo-controlled study on the effects of L-thyroxine 
on thyroid volume in patients with non-toxic goiter the same group observed 
a steady increase in thyroid volume in the 26 subjects who were treated with 
placebo [37]. In this group the mean increase of thyroid volume at 18 months 
was 27%, probably reflecting a selection of patients with faster growing goiters 
for participation in this trial. 
Thyroid function in nodular goiter was studied cross-sectionally by several 
authors. Miller et al. [66] reported the presence of functional autonomy, as 
assessed by insufficient suppression of thyroid radioactive iodide uptake after 
exogenous triiodothyronine administration, in 66% of patients with euthyroid 
multinodular goiter, especially in elderly patients. Gemsenjäger et al. [80] and 
Emrich et al. [81] observed thyroid functional autonomy, defined as an absent 
or subnormal TSH rise after injection of thyrotropin releasing hormone (TRH), 
in a lower percentage (approximately 20%) of patients with non-toxic goiter 
in endemic as well as in sporadic areas. The cross-sectional study by Berg-
hout et al. [79] showed that plasma free T4 levels and total T3 levels were higher 
and TSH levels were lower in patients with non-toxic goiter compared with nor-
mal subjects. The subgroup with multinodular goiter had a significantly lower 
TSH response to an injection of TRH in comparison with that in the subgroups 
with diffuse or uninodular goiter. Plasma TSH was negatively correlated with 
thyroid volume. An increase in the frequency of thyroid functional autonomy 
with age, duration of goiter, goiter weight and nodularity was also observed by 
other authors in cross-sectional studies [80-83]. 
Cross-sectional data in support of increasing functional autonomy of nodular 
goiter with time were confirmed in longitudinal studies. Elte et al. [84] followed 
90 patients with a nodular goiter for a mean duration of 5 years. At the time 
of diagnosis, 64 patients had autonomous thyroid function, defined as a TSH 
increase after TRH injection of less than 4 пШЛ in combination with normal 
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T3 and free T4 levels. Six patients showed a transition from normal to auton-
omous function, and eight patients with autonomous function became overtly 
hyperthyroid within 1 to 7 years. In one patient the complete transition from 
nonautonomous function via functional autonomy to hyperthyroidism was ob-
served. Wiener [85] reported on the follow-up (5 to 22 years) of 28 patients with 
euthyroid multinodular goiter. Four of 28 patients developed hyperthyroidism 
during follow-up, thus confirming increasing functional autonomy. 
1.4 Pathogenesis of solitary autonomous thyroid nodules 
Solitary autonomous thyroid nodules can be classified as either true adenomas 
or adenomatous nodules [86]. True thyroid adenomas are benign, cellular tu-
mors consisting of follicular cells with an abnormal but uniform architectural 
pattern. They have a well-defined fibrous capsule. Adenomatous nodules are 
solitary lesions which typically contain areas of normal follicular architecture 
but have no capsule. True adenomas have a monoclonal origin, while adenoma-
tous nodules are polyclonal [87]. In countries where the overall goiter incidence 
is low, solitary autonomous thyroid nodules are more often of the clonal, encap-
sulated type than in (sub-)endemic areas [73, 88]. 
Although it has been suggested that solitary autonomous thyroid nodules 
may be caused by thyroid-stimulating immunoglobulins [30, 32], these nodules 
are more probably caused by an intrathyroidal defect and not by a circulating 
factor: they coexist with normal (suppressed) thyroid tissue and hyperactivity 
persists in solitary autonomous thyroid nodules grafted onto nude mice [89] and 
in cell culture [90]. Solitary autonomous thyroid nodules are likely to be gener-
ated from follicular cells with genetically determined high replication rate and 
iodinating capacity [91, 92]. Indeed, somatic mutations of the Gsa gene [93] 
as well as somatic mutations of the TSH receptor gene have been reported in 
a number of solitary autonomous thyroid nodules [94, 95]. Hyperthyroidism 
develops when the number of follicles with non-suppressible thyroid hormone 
production is large enough to produce more thyroid hormone than is needed by 
the organism. In this way solitary autonomous thyroid nodules can be consid-
ered an extreme and localized type of nodular growth and autonomous function. 
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1.5 Natural history of solitary autonomous thyroid nodules 
The incidence of solitary autonomous thyroid nodules appears to be higher in 
Europe (9% of thyrotoxic patients in a prospective study in six European coun-
tries) [96] than in the United States (only 1% of patients referred to a thyroid 
clinic) [97]. This higher incidence is possibly related to former or current iodine 
deficiency in European countries [96, 98]. 
Solitary autonomous thyroid nodules tend to increase with age. Cross-
sectional studies [99, 100] showed a positive correlation between age and nodule 
size. Longitudinal studies demonstrate similar results. Hamburger et al. [97] 
observed an increase in diameter of solitary autonomous thyroid nodules of more 
than 1 cm in 9% of 159 patients after a follow-up up to 15 years. 
The function of the autonomous nodule is inversely related to that of the 
extranodular tissue. Non-toxic autonomous nodules are much more common 
than toxic ones [97, 99, 101, 102]. The presence of hyperthyroidism corre-
lates with age and nodule size [99, 100, 103-106]. Progression to hyperthy-
roidism in patients with non-toxic solitary autonomous thyroid nodules occurred 
in 14 of 159 patients during a follow-up of 1 to 6 years in a study by Ham-
burger et al. [97]. The same group reported development of hyperthyroidism in 
21% of 127 patients with a non-toxic solitary autonomous thyroid nodule during 
a follow-up up to 6 years and in 14% of patients who were followed for 7 to 
15 years [106]. In a study by Wiener [85], 17% of 46 patients became hyperthy-
roid during a follow-up of 5 to 22 years. Belfiore et al. [98] reported development 
of hyperthyroidism in 4 of 14 patients (29%) with a non-toxic solitary autonom-
ous nodule in an iodine deficient area and in 11 of 58 patients (19%) in an 
iodine sufficient area during a follow-up of 1 to 6 years. In contrast, Burman 
et al. [101] observed no development of hyperthyroidism in 46 patients with 
a non-toxic solitary autonomous thyroid nodule after a follow-up of more than 
6 years. 
Degeneration of the nodule may preclude the development of hyperthy-
roidism [7, 85, 101, 107]. The highly cellular nodules are prone to central 
haemorrhage and subsequent cyst formation because they contain only few, thin 
walled vessels almost without any connective tissue support. On scintigraphy 
this phenomenon is known as the "owl eye" sign, a cold centre surrounded by a 
rim of high iodine uptake [107] which should not be confused with a true cold 
nodule. 
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1.6 Effects of radioiodine treatment on the thyroid gland 
The first reports on treatment of hyperthyroidism with radioactive iodine, ad-
ministered as sodium iodide, date from 1942 [108, 109]. Since cyclotron pro-
duced iodine-131 (131I) was released for distribution within the United States 
by the National Energy Commission in 1946, its use in diagnostic tests and 
therapy has rapidly increased. 131I désintégrâtes to Xenon-131 with a physical 
half-life of 8.04 days [110]. During désintégration of 131I beta particles (elec-
trons) are emitted, which in 90% of désintégrations have an average energy of 
190 keV. Furthermore, gamma particles (photons) are emitted. In 80% of tran-
sitions these photons have an energy of 364 keV (energies range between 30 and 
723 keV). Radiation energy is transferred to atoms during collisions of the ra-
diation particles with atomic electrons in substances, e.g., human tissues. Beta 
particles transfer kinetic energy to atoms by ionization (an electron is emitted 
from the atom) and excitation (an electron is removed from an inner shell to an 
outer shell of the atom). Gamma particles are scattered (Compton scatter) or 
absorbed (photo-electric effect) within tissues and lose part or all of their energy 
during these processes, thereby also inducing ionization and excitation of atoms. 
On the molecular level, the primary event in the initiation of biological 
damage is the radiolysis of water (H20), the most abundant molecule in all 
biological systems. Within a fraction of a second hydroxyl and hydrogen free 
radicals (OH* and H') are formed, which contain unpaired electrons [111, 112]. 
Free radicals may undergo many reactions. Two OH* free radicals may combine 
to form hydrogen peroxide (H202), a powerful oxidizing agent. Reactions of free 
radicals with other components of the cell lead to the production of excited ions 
and molecules and other types of free radicals. Reactions of free radicals with 
proteins cause changes in the secondary or tertiary structure of proteins by dis-
ruption of hydrogen bounds which produce severe alterations of the biological 
properties of these molecules such as complete loss of enzymatic activity. Other 
important reactions occur with the deoxyribonucleic acids (DNA) of the cell nu-
cleus. The breakage or cross-linking of DNA molecules may have particularly 
serious effects, ranging from loss of the cell's capacity to divide to the production 
of mutations [112]. Three types of cellular changes, caused by these chemical 
changes of proteins and DNA, are recognized, namely early cell death, preven-
tion or delay of cell division and permanent, inheritable changes which may be 
passed on to daughter cells. Cellular changes may lead to other changes which 
affect the whole organism, showing a most variable time scale from a few hours 
to many years. 
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In the case of radioiodine, an administered activity of 131I follows the natural 
biokinetic pathway of iodine. The high specific activity of 131I (111-185 megabec-
querel per microgram (MBq^g) or 3-5 millicurie per microgram (mC^g)) allows 
that the total amount of iodine is negligibly low in comparison to the daily in-
take of iodine. Part of the administered dose, corresponding to thyroid iodide 
uptake, is deposited in the thyroid, organified and stored in the colloid of thyroid 
follicles. Beta particles emitted by 131I in the thyroid will irradiate almost exclu-
sively thyroid cells and their immediate environment because they transfer their 
kinetic energy within a maximal distance of 3 mm, whereas their average range 
in tissues is even smaller, only 0.3 mm. Gamma particles emitted by 131I in the 
thyroid gland are less important for the therapeutic irradiation of the thyroid, 
because their energy is transferred over a much longer distance (photons have 
less interaction with tissue atoms because they have no charge or mass). How-
ever, gamma radiation does contribute considerably to the irradiation burden of 
the rest of the body. 
Therapeutic activities of 131I cause radiation-induced destruction of thyroid 
parenchyma. Within the first few weeks after treatment, epithelial swelling 
and necrosis occur, accompanied by disruption of the follicular architecture, 
edema and infiltration with leucocytes [113, 114]. This radiation thyroiditis may 
cause local tenderness and in rare cases thyrotoxicosis due to excessive thyroid 
hormone release. Resolution of the acute inflammation is followed by fibrosis, 
vascular narrowing and lymphocytic infiltration [113, 115]. These structural 
changes are responsible for the early response to radioiodine treatment and, 
when excessive, they cause early hypothyroidism. 
Apart from early effects of radioiodine, late effects on thyroid function have 
been recognized, especially in patients with Graves' disease. There is an in-
creasing incidence of hypothyroidism in these patients, even several years after 
therapy. The rate of early hypothyroidism in radioiodine treated Graves' pa-
tients is dose related. However, late hypothyroidism (.i.e. occurring more than 
two years after radioiodine therapy) appears to be dose-independent. Various 
mechanisms may contribute to the development of late hypothyroidism, such 
as damage to follicular cell nuclei, resulting in failure to replicate, reaching of 
an upper limit of the proliferative capacity of the population of mitotically com-
petent cells, progressive impairment of blood supply and the natural history of 
Graves' disease [116]. 
The incidence of early as well as of late hypothyroidism after treatment 
with radioiodine is probably much lower in patients with toxic nodular goiter 
than in patients with Graves' disease. This may be related to the diversity in 
radioiodine uptake between nodular goiter follicles. Autonomously functioning 
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thyroid follicles with high uptake of radioiodine will be eradicated preferentially, 
whereas radioiodine uptake in normal, TSH-dependent follicles is low in the 
presence of suppressed TSH levels. Furthermore, cells with a high replication 
rate are destroyed more effectively. These mechanisms can be observed most 
clearly in the treatment of solitary autonomous thyroid nodules (chapter three 
of this thesis). 
Other possible late consequences of radioiodine therapy are radiation-indu-
ced carcinogenic and teratogenic effects due to mutations of the DNA. This will 
be discussed in more detail in chapter eight of this thesis. Suffice it now to 
mention that no carcinogenic or teratogenic effects of radioiodine in the dosages 
administered in Graves' disease have been observed in large series with follow-
up up to 35 years [117-119]. 
1.7 Outline of the present thesis 
Results of radioiodine therapy have been evaluated extensively in patients with 
Graves' disease. Considerably less reports have been published on radioiodine 
treatment in patients with nodular goiter. In this thesis, attention is paid to 
various aspects of radioiodine treatment of patients with toxic and non-toxic 
multinodular goiter and of patients with toxic solitary autonomous thyroid nod-
ules. Seven studies are presented (chapters two to eight). 
Chapter two 
The value of thallium-201 scintigraphy to visualize extranodular thyroid tis-
sue in patients with a toxic solitary autonomous thyroid nodule was studied 
prospectively and compared with results obtained by 123I scintigraphy after TSH 
stimulation. Demonstration of suppressed extranodular tissue in these patients 
is important, because when it is present higher amounts of radioiodine can be 
administered without causing hypothyroidism. 
Chapter three 
In our hospital a standard dose of 20 mCi (740 MBq) of 131I is administered to 
treat patients with a toxic solitary autonomous thyroid nodule. In this study we 
evaluated the long-term results of this treatment schedule. 
Chapter four 
A study on the long-term effects of two schedules of radioiodine treatment in 
patients with toxic multinodular goiter. Low, standard doses of radioiodine and 
higher, calculated doses are compared with regard to the time to reach euthy-
roidism and the incidence of post-therapy hypothyroidism. 
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Chapter five 
In the study described in chapter four 30% of euthyroid patients had a subnormal 
serum TSH level at the time of the last evaluation. As the significance of the 
combination of a normal fT4 and T3 level with a subnormal TSH level in a patient 
treated with radioiodine with respect to the risk of recurrent hyperthyroidism 
is unknown, we followed thyroid function for another year in the whole group 
of euthyroid patients and for another two years in a subgroup of patients, who 
had been rendered euthyroid after a single calculated dose of radioiodine. 
Chapter six 
Thyroid volume measurements by palpation or scintigraphy are known to be 
inaccurate. Ultrasound is a more precise technique, but it cannot be used for 
volume measurements of large multinodular goiters because of intrathoracic ex-
tension of the goiter in most patients. In patients with a large multinodular 
goiter we compared thyroid volume measurements with magnetic resonance 
imaging (MRI) with those obtained with the commonly used planar scintigraphic 
technique. 
Chapter seven 
A prospective study is described on thyroid volume reduction by radioiodine 
therapy in patients with a large, compressive multinodular goiter. In this study 
MRI was used for accurate evaluation of thyroid volume reduction and decrease 
of tracheal compression. 
Chapter eight 
For volume reduction of large multinodular goiters high doses of radioiodine 
are needed. We gathered data on radiation absorbed doses after radioiodine 
treatment in patients with large toxic and non-toxic multinodular goiters, in 
order to get an impression of the radiation burden. 
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Thallium-201 scintigraphy 
of the suppressed thyroid: 
an alternative for iodine-123 scanning 
after TSH stimulation 
Published as: 
Thallium-201 Scintigraphy of the Suppressed Thyroid: An 
Alternative for Iodine-123 Scanning After TSH Stimulation 
Corstens FHM, Huysmans DAKC, Kloppenborg PWC 
Journal of Nuclear Medicine 1988 ; 29:1360-3 
Thallium-201 scintigraphy of the thyroid gland suppressed by an aut-
onomous nodule was compared with 123I scintigraphy after TSH stimu-
lation. In all patients, similar images were obtained by both methods. 
In 20 patients, the contralateral lobe was visualized on both scans and 
in 14 of these, the upper pole of the ipsilateral lobe was also visualized. 
In one patient, neither 123I scanning after TSH nor zoifl scintigraphy 
showed any extranodular tissue. This study suggests that 201T1 scinti-
graphy is a reliable alternative for scanning after TSH. It is a relatively 
simple method, not inducing any TSH-related allergic reactions. Iodine 
uptake in extranodular tissue is not stimulated and therefore, zoifi scin-
tigraphy and radioiodine therapy can be combined on one day, without 
increasing the risk of radiation damage to the normal thyroid tissue 
with a resultant post-treatment hypothyroidism. 
o o o o o o · · 
2.1 Introduction 
The solitary autonomous thyroid nodule is "a discrete nodular structure with 
function both independent of pituitary stimulation and unrelated to that of the 
remaining thyroid tissue" [1]. It is suspected when palpation of the neck re-
veals a single nodule and preliminary iodine-scintigraphy shows a hot nodule. 
Other possibilities to differentiate from are thyroidal anomalies such as thyroid 
hemigenesis. Therefore, the diagnosis of a solitary autonomous thyroid nodule 
depends upon the visualization of suppressed extranodular thyroid tissue. 
Stimulation of iodine uptake in the suppressed tissue by thyroid-stimulating 
hormone (TSH) leads to visualization of the suppressed parts on iodine-scinti-
graphy. TSH stimulation, however, has considerable disadvantages. The bovine 
proteins may induce allergic reactions either systemic or local [2]. It is a time-
consuming investigation because of the need of intramuscular TSH injections. 
On top of this, TSH is no longer available in regular pharmacies in The Nether-
lands. The production was stopped by the manufacturer because of low demand. 
Ultrasonography is another method to visualize thyroid tissue. However, 
it does not provide any physiological information. A lobe may be present but 
nonfunctional because of a number of reasons. Ultrasonography can only give 
additional information provided that it is performed by a radiologist with am-
ple experience and having at his disposal a special transducer for superficial 
structures. 
The use of thallium-201 (201T1) for diagnosis and follow-up of thyroid carci-
noma is well established. In 1979, Fukuchi et al. [3] reported significant thal-
lium uptake in patients with various diseases causing thyroid enlargement. In 
1984, Müller-Brand et al. [4] proposed 201T1 scintigraphy as a new way to visu-
alize suppressed tissue in benign thyroid diseases. 
In our clinic from October 1985 onward 2°іТ1 scintigraphy as well as 
iodine-123 (123I) scintigraphy after TSH stimulation were performed in all pa­
tients presenting with a hot nodule on 1 2 3 I scintigraphy. The purpose of the 
study was to investigate the quality of 201T1 scintigraphy as an alternative for 
scanning after TSH stimulation. 
2.2 Materials and methods 
Twenty one patients, 17 women and 4 men aged 59.5 ± 12.8 yr (mean ± SD), 
were studied prospectively. Biochemical manifestations of hyperthyroidism 
were present in every patient. Serum levels of thyroxine were 178 ± 19 птоІЛ 
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(normal range 54-154 nmol/1), of free thyroxine 38 ± 24 pmol/1 (normal range 
9-17 pmol/1), of triiodothyronine 3.9 ±0.6 nmol/1 (normal range 1.5-3.5 nmol/1). 
In all patients the serum TSH level was <0.2 mU/1 (normal range 0.4—4.0 mU/1). 
The 3-hour thyroid 131I uptake was 32% ± 14% (normal range 5%-30%). 
Scintigraphic methods 
Baseline Iodine-123 scan 
0.7 mCi (30 MBq) of [123I]sodium iodide (high purity 123I) were injected intra-
venously. One hour later, the thyroid region was imaged in the anterior and in 
the right and left oblique position using a gamma camera (Picker Dyna camera 
4/15) with a pinhole collimator. Antithyroid drugs, if used, were stopped at least 
2 days previously. 
Thallium-201 scan 
Carried out 1 to 14 days after baseline 123I scintigraphy and 1 week before TSH 
stimulation. 2 mCi (74 MBq) of [201Tl]thallous chloride were injected intra-
venously. Fifteen minutes later scintigraphy of the neck from the anterior view 
followed. A converging collimator was used because its efficiency is five times 
as high as that of the pinhole collimator. 
Iodine-123 scan after TSH stimulation 
On three subsequent days 10 IU of TSH were injected intramuscularly. On the 
third day, 1 hour after the intravenous administration of 0.7 mCi (30 MBq) of 
123I, an anterior image of the thyroid region was obtained. 
The surface of each nodule on the baseline 123I scan was measured planimet-
rically. In order to estimate the real size of the nodules (in cm2) the obtained 
values were corrected for diminution caused by the pinhole collimator using the 
known distance between two radioactive markers as a reference. 
Comparing the sizes of the lobes on both scans was not attempted because 
of the use of two collimators, causing different and not very reliable factors 
of diminution. For that reason, only the presence of a contralateral lobe and 
the visibility of the upper or lower pole of the ipsilateral lobe (not shown on 
the baseline 123I scan) were accounted for as evidence of the visualization of 
suppressed thyroid tissue. 
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In all patients the baseline 123I scan showed a hot nodule with suppression of 
supposedly remaining thyroid tissue. The size of the nodules was 16 ± 5 cm2 
(mean ± SD). The nodules did not necessarily have a homogeneous uptake. 
Figure 2.1 Visualization of the thyroid (anterior view) in three patients with 
a solitary autonomous thyroid nodule with 123I (A), with 123I af-
ter 3 days of 10 IU of TSH i.m. (B) and with 201Tl (C). Patient 1 
(upper row): Equal uptake in the nodule and extranodular tis-
sue. Patient 2 (middle row): Higher uptake in extranodular tis-
sue compared to the nodule. Patient 3 (lower row): Non-uniform 
uptake in the nodule and lower uptake in extranodular tissue 
compared to the nodule. + represents sternal notch 
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In twenty of the patients the 1 2 3 I scan after TSH stimulation visualized 
previously suppressed extranodular thyroid tissue. These patients were consid­
ered to have a solitary autonomous thyroid nodule. In 17 out of 20 patients the 
nodule was clearly localized in the lower pole of the lobe. In three patients no 
differentiation between lower and upper pole was possible. In one hyperthyroid 
patient with a hot nodule on baseline 1 2 3 I scintigraphy, the 1 2 3 I scintigraphy 
after TSH stimulation showed no extranodular tissue. 
Examples of the scans in three patients are shown in Figure 2.1. On visual 
interpretation of the scans the sizes of the lobes both on 201T1 scintigraphy and 
on
 1 2 3 I scintigraphy after TSH were similar. In all 20 patients with a solitary 
autonomous thyroid nodule the contralateral lobe was visible on the 201T1 scan as 
well as on the 1 2 3 I scan after TSH stimulation. The upper pole of the ipsilateral 
lobe was visualized with both methods in 14 patients. Both 2017Л scans and 
1 2 3 I scans after TSH stimulation provided sufficient visualization of the thyroid 
gland, including the previously suppressed tissue. Delineation of the thyroid 
gland was slightly better on 1 2 3 I scintigraphy after TSH in ten patients. In 
nine patients the images were equal and in one case the 2оіТЛ scan proved to be 
superior. In 17 patients the tracer uptake in the nodule was similar to that in the 
surrounding thyroid tissue, on the thallium-scan as well as on the iodine-scan 
after TSH. In three patients the tracer uptake in the nodule was significantly 
higher than that in the extranodular tissue on both scans. Photopenic zones 
in the nodule, already visible on baseline 1 2 3 I scintigraphy, were seen on both 
scans in 12 patients. 
In the patient with a hot nodule on the baseline 1 2 3 I scan, in whom 1 2 3 I scin­
tigraphy after TSH stimulation did not show extranodular thyroid tissue, the 
201T1 scintigraphy was in complete agreement with this finding, as was ultraso­
nography. 
2.4 Discussion 
This study emphasizes that suppressed thyroid tissue in patients with a solitary 
autonomous thyroid nodule can be visualized by 2oiTl scintigraphy equally well 
as by 1 2 3 I scintigraphy after TSH stimulation. In this series an upper pole and a 
contralateral lobe were seen on both scans with the same frequency and always 
in the same patients. The target to non-target ratio was unequivocally better 
in iodine-scintigraphy after TSH stimulation. Nevertheless there was a good 
delineation of the thyroid tissue on 2<ΊΤ1 scans too. In one patient with a hot 
nodule on a baseline 1 2 3 I scan neither 201T1 scintigraphy nor 1 2 3 I scintigraphy 
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after TSH stimulation showed any extranodular tissue. Ultrasonography find-
ings were in agreement with the scintigraphic observations. This patient in all 
probability has agenesia of one thyroid lobe. 
The female preponderance in our series has also been observed in other 
studies on solitary autonomous thyroid nodules [1, 4]. The older age and hyper-
thyroid state of our patients as well as the relatively large size of the nodules 
in our series are in accordance with the natural history of solitary autonomous 
thyroid nodules. Hyperthyroidism in patients with a solitary autonomous thy-
roid nodule is seen more often in elderly people with larger nodules [1, 5]. In 
17 out of 20 patients the nodule was clearly localized in the lower pole of the 
lobe. We could not find a convincing explanation for the observed preferential 
localization of hot nodules in the lower part of the thyroid. 
Thallium uptake in the thyroid has been assumed to depend upon a factor 
other than mere blood flow. Thallium forms a gradient in thyroid tissue which is 
similar to the gradient of potassium and which is probably mediated by Na+-K+ 
ATPase, since it can be inhibited by ouabaine and potassium [6]. Thallium up-
take is not inhibited by Perchlorate, indicating that the anionic side of the iodide 
pump is not used in concentrating thallium [7]. Our study is in accordance with 
these findings, for in 17 scans uptakes in the nodule and in the surrounding thy-
roid tissue in which the iodide trapping mechanism was suppressed were equal. 
In only three out of 20 201T1 scans the extranodular tissue showed less activity 
than the nodule. Photopenic zones in the nodules can probably be accounted 
for by cystic degeneration of the nodules [1, 8]. Some authors [6, 9] concluded 
that the entry not only of anions such as iodide, but also of cations, for example 
thallium, is controlled by TSH. Others could not prove a statistically significant 
correlation between TSH stimulation and thallium uptake [3, 7]. In our study 
201T1 scans were performed in patients with low serum concentrations of TSH 
(<0.2 mU/1) and prior to exogenous TSH administration. Therefore, the clear 
imaging of thyroid tissue resulting from sufficient 2°iTl uptake suggests that 
TSH is not a major determinant of thallium uptake. 
Every method has its pitfalls. Unilateral thyroiditis, a rare occurrence in 
our area, may mimic a solitary autonomous thyroid nodule: 123I uptake is lim-
ited to one lobe (the contralateral lobe) on the preliminary 123I scan and the 
complete thyroid gland is visualized on 2oiTl scintigraphy. Therefore, additional 
information like radioactive iodine uptake, search for thyroid antibodies and 
erythrocyte sedimentation rate is still not superfluous. 
On the basis of this study we conclude that 201T] scintigraphy can be used 
to visualize suppressed thyroid tissue in patients with a "hot" nodule on prelim-
inary 123I scintigraphy. A disadvantage of this technique, compared to ultraso-
nography, is the radiation burden. The effective dose equivalent from 74 MBq 
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of 2 0 1T1 is 7 mSv, compared to 5 mSv from 30 MBq of 1 2 3 I [10]. However, most 
of these patients will subsequently be treated with a high dose of radioactive 
iodine. 
There are some considerable advantages of 2 0 1T1 scintigraphy over 1 2 3 I scan­
ning after TSH. It does not induce systemic or local allergic reactions which can 
be caused by bovine TSH, and it can be performed without discontinuation of an­
tithyroid drug therapy. Furthermore, a therapeutic dose of radioiodine ( 1 3 1I) can 
be administered immediately after 2oiTl scintigraphy since iodine uptake in the 
extranodular tissue has not been stimulated. After TSH stimulation radioiodine 
treatment should be postponed for several weeks in order to reduce the chance 
of post-treatment hypothyroidism due to TSH stimulation of the extranodular 
tissue. In fact, suppression of the extranodular tissue has to be ascertained 
again immediately before the administration of the therapeutic 1 3 1 I dose. The 
use of 2°iTl scintigraphy enables one physician in one department of nuclear 
medicine to combine reliable diagnostics and 1 3 1 I therapy in a short space of 
time. Thallium-201 scintigraphy can be performed in approximately one-half 
hour by a laboratory assistant. This makes it a relatively simple investiga­
tion, whereas ultrasonography can only be performed in a hospital having a 
specialist with experience in thyroid imaging at its disposal. Most departments 
of nuclear medicine doing cardiac examinations with radio-thallium have 20ΐχ] 
readily available. 
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The long-term effects of radioiodine treatment on thyroid function in pa-
tients with a toxic solitary autonomous thyroid nodule were evaluated. 
Fifty-two patients received a therapeutic dose of 20 mCi of iodine-131 
(131I). Duration of follow-up was 10 ± 4 yr. Follow-up data included a 
biochemical evaluation of thyroid function. The failure rate (recurrent 
hyperthyroidism) was 2%. The incidence of hypothyroidism was 6% and 
was not related to the dose per gram of nodular tissue. Oral adminis-
tration of 20 mCi of radioiodine is a simple and highly effective method 
for the treatment of patients with a toxic autonomous thyroid nodule. 
The risk of development of hypothyroidism is low if extranodular up-
take of 131I is prevented. This can be achieved by not treating euthyroid 
patients, by no longer using injections of exogenous thyroid-stimulating 
hormone in the diagnostic work-up of the patients and by always per-
forming radioiodine imaging shortly before treatment. 
o o o o o · · · 
3.1 Introduction 
Two subgroups of nodular thyroid diseases with autonomous hyperfunction are 
currently recognized as clinically distinct entities. Toxic multinodular goiter 
is a disease in which there is a large multinodular goiter. It predominantly 
afflicts elderly people. The goiter and autonomous function often precede the 
onset of hyperthyroidism by many years [1]. Goetsch's disease or the solitary 
autonomous thyroid nodule is characterized by a single thyroid adenoma which 
is functioning autonomously and independently of pituitary stimulation or any 
other extrathyroidal stimulator. The thyroid hormone secreted by the nodule has 
a negative feedback on the production of thyroid-stimulating hormone (TSH) by 
the pituitary gland. By this mechanism, the function of the TSH-dependent 
extranodular tissue is suppressed to a variable degree [1]. 
Many patients with a solitary autonomously functioning thyroid nodule are 
euthyroid. Progression to persisting hyperthyroidism occurs in only a small 
number of patients. Moreover, spontaneous degeneration of the nodule is pos-
sible [2]. Therefore, non-toxic autonomous thyroid nodules are regularly left 
untreated in The Netherlands. 
Radioactive iodine is a generally accepted method for the treatment of hy-
perthyroidism, especially in patients with a solitary autonomous thyroid nodule. 
Post-treatment hypothyroidism seems less likely if iodine uptake in the extra-
nodular thyroid tissue is sufficiently suppressed, which means that the nodule 
is the only visible thyroid tissue on iodine scintigraphy. 
There are few reports on the long-term follow-up of patients with hyperthy-
roidism, due to a solitary autonomous thyroid nodule, treated with iodine-131 
(1311) [3-9]. Recently, we have studied the long-term effects of radioiodine treat-
ment on thyroid function in patients with hyperthyroidism due to Goetsch's 
disease treated in our hospital. 
3.2 Patients and methods 
Iodine-131 therapy 
Between 1970 and 1985, 52 patients with a solitary autonomous thyroid nodule 
received an oral standard therapeutic dose of 20 mCi (740 MBq) of 131I as sodium 
iodide at the University Hospital, Nijmegen. The female-to-male ratio was 3.3:1 
and the age range was 58.2 ± 11.2 yr (mean ± SD). All patients had clinical signs 
and symptoms of hyperthyroidism as well as elevated levels of thyroid hormones 
(thyroxine (T4) 186 ±44 nmol/1, triiodothyronine (T3) 4.3 ± 1.1 nmol/1). The 24-h 
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thyroid 1 3 1 I uptake was 52% ±12%. Thyroid scans using [131I]sodium iodide, 
[123I] sodium iodide or (in 9 patients) technetium-99m-pertechnetate showed sin­
gle hot nodules with total suppression of extranodular tissue in 48 patients and 
near-total suppression in four. The weight of the nodules was estimated from 
the thyroid scan using the formula: | π xy2 where χ is the longest and y is the 
shortest diameter of the nodule. For each nodule, the total 1 3 1 I dose delivered 
was divided by this estimated nodular weight and multiplied by the fractional 
24-h 1 3 1 I uptake in order to calculate the 1 3 1 I dose per gram of functional thy­
roid tissue [6]. Iodine scintigraphy after injections of exogenous TSH was used 
to visualize extranodular thyroid tissue. Therapy was postponed for at least 
4 days after imaging with TSH stimulation. Twelve patients were on antithy­
roid medication (thiamazole) prior to 1 3 1 I therapy. They concomitantly used a 
thyromimetic drug to avoid elevation of the serum TSH level. The antithyroid 
drug was discontinued for at least three days prior to 1 3 1 I administration till 
three days afterwards. 
In our laboratory, normal values for the various tests used are: serum T4 
65-140 птоІЛ, serum T3 1.8-2.9 птоІЛ, serum free T4 9-19 pmol/1, serum TSH 
0.4-4.0 т Ш , and 24-h 1 3 1 I uptake 10%-59%. 
Follow-up 
The patients were followed for a period of 4-17.5 yr (mean 10 ± 4 yr). Five of 
them had died of unrelated causes and one patient had emigrated. The last 
available data from the medical records of these patients were used. All other 
patients were seen by their own physician or by ourselves. A short medical 
interview and physical examination were carried out. Serum T4 and TSH levels 
were measured utilizing standard methods. Criteria for hyperthyroidism were a 
serum T4 level over 140 nmol/1 together with a suppressed TSH. Hypothyroidism 
was diagnosed in patients with a serum T4 level of less than 65 nmol/1 together 
with a serum TSH level over 4.9 т Ш . In patients with an elevated TSH, the 
serum free T4 level was also measured. 
3.3 Results 
All 52 patients became euthyroid within 6 months after radioiodine therapy 
and antithyroid medication was stopped. In one patient, thyrotoxic symptoms 
recurred 1.5 yr later. Iodine scintigraphy showed the same hot nodule. This 
patient was successfully treated with a second dose of 20 mCi of 1 3 1 I . Hyperthy­
roidism did not recur in any of the other patients. 
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During the follow-up period, thyroxine therapy was started in six patients. 
In two of these patients, therapy was started 3 and 7 yr after radioiodine ther­
apy because of mild clinical and biochemical hyperthyroidism (T4 level, 56 and 
58 nmoVl, respectively; TSH level, 16.9 and 19.1 mlM, respectively). In a third 
patient, thyroxine therapy was started in another hospital after 15 yr (no fur­
ther data available). Two other patients became hypothyroid (T4 level 42 and 
60 nmol/1, respectively; TSH level 54 and 33 mlM, respectively) 2 and 6 yr after 
they had been treated with 1 3 1 I . However, they had been treated at an inap­
propriate moment, while the effects of the injected exogenous TSH were still 
present. In the sixth patient, thyroxine therapy was started unnecessarily after 
3 yr (serum TSH level at the start of thyroxine therapy 1.4 mU/1). The remain­
ing 46 patients, including the patient who had received 20 mCi twice, were, 
without replacement therapy, clinically and biochemically euthyroid at the end 
of the follow-up period. Of these patients, six had a slightly elevated serum TSH 
level (5.2-8.1 mlM) together with a normal serum T4 level (80-102 nmol/1), and 
free T4 level (8.6-11.5 ртоИ). 
The development of hypothyroidism in our series was not related to the dose 
per gram of nodular tissue corrected for radioiodine uptake (399 ± 242 μΟί^ in 
the 46 patients who remained euthyroid and 408 ± 295 цСі/g in the six patients 
who became hypothyroid (p > 0.10, Wilcoxon's test). No antithyroid antibodies 
were present in the patients in whom hypothyroidism developed. The prior use 
of antithyroid medication, stopped at least three days before 1 3 1 I administration, 
in 12 patients, seems not to have influenced the development of hypothyroidism. 
One of these patients became hypothyroid. This patient had a suppressed serum 
TSH level on the day of therapy. 
In order to reveal a process of slowly diminishing thyroid function after 
radioiodine therapy, we compared serum T4 levels as measured in 1984 and 
1988 in 29 patients who had not become hypothyroid. In 1984, the T4 level was 
90 ±21 птоИ, in 1988 93 ± 19 птоІЛ (ρ > 0.10, Wilcoxon's test). None of these 
patients showed a decline of the serum T4 level. 
3.4 Discussion 
In the present study, patients with a solitary autonomous thyroid nodule were 
treated with radioiodine only when they were clinically and biochemically hy-
perthyroid. The high mean age (58.2 ± 11.2 yr), the suppression of extranodular 
tissue, and the rather large size of most nodules are in accordance with the 
hyperthyroid state [1, 2, 10-12]. 
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All of our 52 patients became euthyroid within 0.5 yr after a standard dose 
of 20 mCi of 131I and during a mean follow-up of 10 yr hyperthyroidism recurred 
in only one patient. This patient received a second dose of 20 mCi of 131I 1.5 yr 
after the first dose. The failure rate found in our study (2%) is lower than that 
found in the study of Ratcliffe et al. [8]. In their study, hyperthyroidism recurred 
in 7 of 48 patients after a standard oral dose of 15 mCi of 131I. Other authors 
[3, 4, 6, 7, 13] not using a standard dose, but a dose adjusted according to the 
individual size of the nodule, also reported higher incidences of therapy failures 
(7%-52%; Table 3.1). 
Table 3.1 Failure rate of131I therapy in patients with solitary autonomous 
thyroid nodules and hyperthyroidism (primary therapy failures 
and recurrences) * 
Author 
Fontana 
Heinze 
Hegedüs 
Mariotti 
Ratcliffe 
Ross 
This study 
Nr. of 
pat. 
23 
188 
27 
138 
48 
45 
52 
Failure 
rate 
52% 
9% 
7% 
15% 
15% 
13% 
2% 
Follow-up 
(yr) 
Life-table 
2.5 ±? 
1 (all patients) 
3.2 ± 2.2 (1-11) 
3.1 ±? (2-10) 
4.9 ±3.2 (0.5-13.5) 
10 ± 4 (4.0-17.5) 
Method of 
calculation 
200-800 Gy 
300-І00 Gy 
100 μΟΙ£ 
180 \iCVg 
Standard dose 
160 цСі/g 
Standard dose 
Dose of 13i] 
(mCi) 
? 
18.9 ±9.6 
7.5 ±? 
12.6 ±4.1 
15 
10.3 ± ? 
20 
Mean ± SD (range) 
Not mentioned 
During the follow-up period, thyroxine therapy was started in 6 of our 52 pa­
tients. However, in one of these patients thyroxine therapy was started while 
the patient was not hypothyroid. In two patients, treatment with 1 3 1 I was 
given while the effects of injected exogenous TSH were still present. Ex­
cluding these three patients the incidence of hypothyroidism in our series is 
3/49 or 6%. Other investigators found similarly low percentages, although 
during shorter follow-up periods. Mariotti et al. [7] reported five cases of 
hypothyroidism after treatment of 126 patients with a dose of 180 \id of 
1 3 1 I per gram of nodular tissue (duration of follow-up 3.2 ±2.2 yr). Eyre-
Brooke et al. [14] found two cases of hypothyroidism out of 37 patients treated 
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with 1.2-15 mCi of 131I (mean duration of follow-up 6.5 yr) while none of 
the 48 patients of Ratcliffe et al. [8] developed hypothyroidism after treat-
ment with 15 mCi of 131I (mean duration of follow-up 3.1 yr, range 2-10 yr). 
In two studies, rather high incidences of hypothyroidism have been reported. 
In the study of Goldstein et al. [5], 8 of 22 patients became hypothyroid after 
treatment with 15-55 mCi of radioiodine. However, it has to be noted that 
16 of these patients were euthyroid at the time of treatment and 12 of them had 
incomplete suppression of uptake in the extranodular tissue. Fontana et al. [4] 
reported an incidence of hypothyroidism of 17% at 10 yr and 44% at 20 yr 
after treatment of 29 patients with 20,000-80,000 rads (these authors used a life 
table method). But none of their patients who had (almost) complete suppression 
of the function of the extranodular parenchyma developed hypothyroidism. 
One might think that the amount of administered 131I plays a major 
role in the development of hypothyroidism after radioiodine treatment in thy-
rotoxic patients with a solitary autonomous thyroid nodule. However, the 
data in our study and in those of Goldstein et al. [5] and Fontana et al. [4] 
strongly suggest that it is not the dose of radioiodine but the presence of 
incomplete suppression of iodine uptake in the extranodular tissue that de-
termines the incidence of hypothyroidism. Extranodular iodine uptake is, of 
course, frequently seen in patients with a solitary autonomous thyroid nod-
ule who are not thyrotoxic. In order to prevent the development of hypothy-
roidism, radioiodine treatment should not be given to these patients. In-
complete suppression of uptake in extranodular tissue is also present after 
exogenous TSH injections, sometimes even months afterwards. Therefore, to 
visualize extranodular thyroid tissue, we recommended imaging with thallium-
201-chloride or ultrasonography of the thyroid instead of imaging with 131I 
after pretreatment with injections of exogenous TSH [15]. The latter pro-
cedure is no longer in use in The Netherlands. In our opinion, visualiza-
tion of suppressed normal thyroid tissue is relevant. If suppressed extra-
nodular tissue is present, we assume that this parenchyma will take over 
thyroid function after ablation of the nodule with a relatively high dose of 
20 mCi of 131I. If there is no extranodular tissue, we routinely administer 
a lower dose calculated according to the method described by DeGroot [16] 
in order to diminish the risk of post-treatment hypothyroidism. 
We conclude that oral administration of 20 mCi of radioiodine is a sim-
ple and highly effective method for the treatment of patients with a toxic 
autonomous thyroid nodule. The risk of development of hypothyroidism is 
low if the uptake of 131I in the extranodular tissue is prevented. This can 
be done by not treating euthyroid patients, by no longer using injected exogenous 
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TSH in the diagnostic work-up of the patients, and by always performing 
radioiodine imaging immediately before treatment. When this pretreatment 
radioiodine image reveals uptake of iodine in extranodular parenchyma, therapy 
has to be postponed. 
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The long-term effects of two schedules of radioiodine therapy in pa­
tients with toxic multinodular goiter were evaluated. Forty-five pa­
tients (group A) were treated with low doses and fifty-eight patients 
(group B) with calculated doses adjusted for thyroid weight (1.85-3.70 
MBq/g) and radioactive iodine uptake. Follow-up (mean ± SEM) was 
4.3 ± 0.2 years and 5.2 ± 0.3 years, respectively (p > 0.1). At the end of 
follow-up, hyperthyroidism was successfully reversed in 73% (group A) 
and 88% (group B). In each group, hypothyroidism was present in 7%. 
The total dose per gram of thyroid tissue was not significantly different 
in groups A and В (2.1 ± 0.2 versus 2.7 ± 0.2 MBq/g). However, for pa­
tients treated with calculated doses the number of 1 3 1 I administrations 
was significantly lower (1.3 ±0.1) than for patients treated with low 
doses (2.2 ± 0.2), and the percentage of patients who were adequately 
treated with a single dose was more than twice as high (66% in group В 
versus 27% in group A). Euthyroidism was reached within a signifi­
cantly shorter time after treatment with calculated doses (median time 
0.6 years in group В versus 1.5 years in group A; life table analysis). 
It is concluded that radioiodine is an effective treatment for toxic mul­
tinodular goiter with a low risk of post-treatment hypothyroidism and 
that calculated (higher) doses appear to be preferable to low doses. 
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4.1 Introduction 
Since the early 1940s, radioactive iodine has frequently been administered to 
patients with hyperthyroidism. In earlier reports on the results of this treat-
ment, different types of thyrotoxicosis were not distinguished. Later studies 
on radioiodine therapy of Graves' disease showed that regardless of the dosage 
schedule used, patients with Graves' disease are at high risk of becoming hy-
pothyroid [1-2]. In studies on the results of radioiodine treatment of patients 
with toxic uni- and multinodular goiters, incidences of hypothyroidism are ex-
tremely varied, ranging from 1% to 64% [3-20]. However, interpretation of 
literature data is difficult for several reasons. First, some studies do not differ-
entiate between toxic multinodular goiter and toxic solitary autonomous thyroid 
nodules [4-6, 8, 14]. In one study, even patients with Graves' ophthalmopathy 
were not excluded [4]. Second, sometimes only palpation is used to determine 
thyroid nodularity and weight [3-8, 19]. Moreover, in many reports duration of 
follow-up is not exactly stated [3-7,10,11,13]. Therefore, we studied the results 
of radioiodine treatment in patients with toxic multinodular goiter treated in our 
hospital. Criteria for hyperthyroidism, multinodularity and absence of ophthal-
mopathy were strictly defined. Two different dosage schedules have been used in 
recent years. In the first regimen, low doses, irrespective of thyroid weight and 
thyroid radioactive iodine uptake, were administered. In the second, doses were 
adjusted for thyroid weight and radioactive iodine uptake. The long-term results 
of these two dosage schedules were evaluated and compared with studies in the 
literature with respect to duration of therapy, remission of hyperthyroidism and 
incidence of hypothyroidism. 
4.2 Patients and methods 
Patients 
One hundred and three patients with toxic multinodular goiter treated with 
radioactive iodine were studied. Only patients with a follow-up of more than 
6 months after the first dose of iodine-131 (131I), given between 1979 and 1990, 
were included. Four patients had had adverse reactions on antithyroid drugs, 
necessitating early termination of drug treatment. In all other patients, previ-
ous therapy with antithyroid drugs for at least 6 months had not resulted in a 
permanent remission of hyperthyroidism. 
The diagnosis of hyperthyroidism was based on clinical evaluation and lab-
oratory tests including serum levels of thyroid-stimulating hormone (TSH), thy-
roxine (T4), triiodothyronine (T3) and free thyroxine (fT4). 
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The diagnosis of multinodular goiter was based on the presence of one or 
more thyroid nodules at palpation and an irregular distribution of 1 2 3 I or 1 3 1 I 
as sodium iodide or technetium-99m pertechnetate on a thyroid scan. Patients 
with a solitary hot nodule were excluded, as were patients with signs of Graves' 
ophthalmopathy. 
Radioiodine treatment schedules 
Patients were offered two forms of radioiodine treatment: low doses without 
regard to individual variables such as thyroid radioiodine uptake (RAIU) and 
thyroid weight (on an out-patient basis) or calculated doses adjusted for thy­
roid weight and thyroid RAIU (on an in-patient basis for those who received 
>150 MBq). There was a tendency for larger goiters to be treated with calcu­
lated doses. 
Forty-five patients were treated with low doses. The first therapeutic dose 
was 150 MBq of Ш І . Antithyroid drugs were not taken for at least three days 
before and after therapy. The effect of the first dose was evaluated 6 months 
later. For patients who were not treated with antithyroid drugs, a second low 
dose of 1 3 1 I (150 MBq) was given to those who were still clinically and biochem­
ically thyrotoxic. For patients on antithyroid drugs, a second dose of 1 3 1 I (150 
MBq) was administered to those who still had an elevated thyroid RAIU, mea­
sured 3 hours after oral ingestion of 0.37 MBq of 1 3 1 I (3-h RAIU, normal range 
5%-30%), after stopping the antithyroid drug for at least 3 days. If the 3-h 
RAIU was <30%, antithyroid medication was stopped and 1 3 1 I therapy was only 
repeated if the patient became clinically and biochemically thyrotoxic again dur­
ing subsequent follow-up. The effect of the second and of every subsequent dose 
of 1 3 1 I was evaluated 6 months later, using the same parameters as with the 
first dose. A possible third or fourth dose was also 150 MBq. Exceptions were 
four patients who received 300 MBq as the third or fourth dose. Two patients 
were treated more than four times: in one patient the dose was doubled after 
five doses of 150 MBq (two times 300 MBq) and one patient received six doses 
of 150 MBq of radioiodine. In this dosage schedule, the radiation absorbed dose 
per treatment was far below 100 Gy in all patients. 
The second option, administration of a calculated dose of radioiodine, was 
used for 58 patients. The administered dose was calculated according to the 
method described by DeGroot [21], which is based on two variables (thyroid 
weight and RAIU) and on the use of a higher retained dose per gram of thy­
roid tissue for larger glands. Thyroid weight was estimated from the plani­
metrie surface on the thyroid scan using the formula of Doering: thyroid 
weight = 0.326 χ (surface)3/2 [22]. Thyroid RAIU was measured 24 hours af­
ter oral ingestion of 0.37 MBq of 1 3 1 I (24-h RAIU, normal range 10%-59%). The 
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retained dose at 24 hours ranges from 1.85 MBq (50 \iCi)/g for thyroids weighing 
less than 40 g to 3.70 MBq (100 цСі)^ for thyroids weighing more than 100 g. 
The following formula was used: 
A • • + A ^ ·*. /nu ^ thyroid weight (g) χ (1.85-3.7)MBq/g 
administered a c u i t y (GBq) =
 2 4 - h RAIU(%) χ 10 
Assuming an effective half-life of 1 3 1 I of 6 days [21], radiation absorbed doses 
in this dosage schedule ranged from 50 Gy per treatment in thyroids weighing 
less than 40 g to 100 Gy in thyroids weighing more than 100 g. 
Six months after the first dose, the effect was evaluated using the parame­
ters mentioned in the scheme of low doses. If further treatments were needed, 
calculated doses were again administered. 
Follow-up after radioiodme therapy 
Endpoint analysis 
All living patients (n = 94) were invited for a single visit to our hospital in Febru­
ary 1992. A short medical interview and physical examination were performed 
and blood samples were obtained. Serum TSH, T4, T3 and fT4 levels were mea­
sured using standard methods. Normal values for our laboratory are: TSH (flu-
oroimmunoassay, Delfia hTSH, Pharmacia) 0.40-4.00 mU/1, T4 (radioimmunoas­
say, Amerlex-M T4) 54-154 nmol/1, T3 (radioimmunoassay, Amerlex-M T3) 1.5-
3.5 nmol/1 and fT4 (SPAC ET.FT4, Mallinckrodt Diagnostica) 9.0-17.0 pmol/1. 
Patients who were examined at this time were classified as euthyroid when they 
had normal fT4 and T3 levels and were not taking thyrostatic or thyromimetic 
drugs. Patients with a subnormal or elevated TSH level together with normal 
fT4 and T3 levels were included in the group of euthyroid patients. The criterion 
for hyperthyroidism was a TSH level below 0.40 mU/1 along with a fT4 level 
above 17.0 ртоІЛ and/or a T3 level above 3.5 nmol/1. Patients on antithyroid 
medication at the time of the examination were also classified as hyperthyroid. 
Hypothyroidism was diagnosed if the serum TSH level was above 4.00 mU/1 with 
a serum fT4 level below 9.0 ртоІЛ and in patients who were on thyromimetic 
therapy. 
Two of the patients treated with low doses had died before February 1992: 
one of a cardiovascular cause and one of primary biliary cirrhosis. Seven of the 
patients treated with calculated doses had died: two of cardiovascular causes, 
one of sudden death and four of unknown causes. Three of the four patients 
with cardiovascular-related deaths (including one sudden death) were still hy­
perthyroid at the time of death. 
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For the nine patients who had died before February 1992, hyperthyroidism 
was diagnosed in those who were on antithyroid medication at the last thyroid 
evaluation recorded in the medical records and hypothyroidism in those who 
received thyroid hormone replacement at that time. For the patients not on 
thyrostatic or thyromimetic drugs the last biochemical analyses showed normal 
serum levels of thyroid hormones. Therefore, these patients were classified as 
euthyroid. 
Life table analysis 
Data from the endpoint analysis were used to determine the presence of euthy-
roidism (or hypothyroidism). Patients who were hyperthyroid at endpoint were 
classified as never having reached euthyroidism during follow-up. For euthy­
roid and hypothyroid patients, the last day of antithyroid drug treatment, as 
recorded in the medical records, was assumed to be the moment euthyroidism 
was achieved. For those patients who had not used antithyroid medication after 
the last administration of radioiodine, euthyroidism was achieved on the date 
3 months after the last radioiodine therapy. For each patient, the time between 
the first radioiodine treatment and the moment of reaching euthyroidism was 
calculated. Univariate analysis of the time to reach euthyroidism, with the date 
of reaching euthyroidism serving as an endpoint, was performed using Kaplan-
Meier survival distribution estimates. In this analysis, information from obser­
vations with incomplete follow-up (censored data) is appropriately used. 
Statistical analyses 
The mean values ± SEM are given. Homogeneity between groups was tested 
non-parametrically by means of the Wilcoxon two-sample test or the Kruskall 
Wallis test for multiple groups (level of significance denoted as ρ and p*, respec­
tively). For qualitative relations the chi-square test for contingency tables was 
used (level of significance denoted as p**). Subsequent to life table analysis, the 
log-rank test was used to test for homogeneity across strata (level of significance 
denoted as p***). Calculations were made using SAS statistical software [23]. 
4.3 Results 
Radioiodine therapy 
Patient characteristics and 1 3 1 I therapy details are provided in Table 4.1. Al­
though almost all patients had previously used antithyroid drugs for at least 
6 months, only ca. two-thirds of patients in each group were on antithyroid med­
ication 1 week before the first radioiodine therapy. Mean thyroid weight was 
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higher (ρ < 0.001) in group В, treated with calculated doses, than in group A, 
treated with low doses, as a result of a preference to treat larger goiters with 
calculated doses. There were no significant differences in 3-h and 24-h RAIU 
between both groups (p > 0.1). 
Table 4.1 Patient characteristics and radioiodine therapy data 
Low doses 
(group A) 
Number of patients 
Sex (female : male) 
Age (уг) a 
Time between diagnosis 
of hyperthyroidism and 
first 1 3 1 I therapy (yr) 
Thyroid surgery before 
first 1 3 1 I therapy 
Patients on antithyroid 
medication 1 wk before 
first 1 3 1 I therapy 
Thyroid weight (g) a 
3-h RAIU a* 
24-h RAIU «.ь 
Number of 1 3 1 I doses 
Total dose (MBq) 
Total dose per gram 
retained at 3 h (MBq/g) 
45 
41:4 
65.9 ±1.4 (42.3-80.6) 
5.3 ±0.8 (0-30) 
0/45 
27/45 
73 ± 6 (31-207) 
(n=43) 
42 ± 2 (17-75) 
(n=46) 
68 ± 10 (40-83) 
(n=4) 
2.2 ± 0.2 (1-7) 
371 ±45 (75-1332) 
2.1 ±0.2 (0.3-7.9) 
Calculated doses 
(group B) 
58 
54:4 
63.3 ±1.3 (41.2-80.1) 
4.8 ±0.8 (0-30) 
6/58 
38/58 
140 ±13 (33-395) 
(n=58) 
41 ± 2 (9-74) 
(n=58) 
61 ± 2 (37-92) 
(n=58) 
1.3 ±0.1 (1-3) 
903 ±93 (96-4107) 
2.7 ±0.2 (0.8-8.6) 
* Values represent mean ± SEM. Numbers in parentheses are ranges 
a
 Time of the first 1 3 1I therapy 
b
 Thyroid RAIU, measured 3 and 24 h, respectively, after oral ingestion of 0.37 MBq 
of 1311 
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The number of doses of 1 3 1 I was significantly lower for group В (p < 0.001). 
In both groups of patients, the dose per gram retained at 3 hours was calculated 
for every treatment (24-h RAIU was available in only a minority of group A 
patients). The total dose per gram of thyroid tissue is the sum of these doses. 
Although the total administered dose was more than twice as high in group В 
as in group A (p < 0.001), the total dose per gram of thyroid tissue was not 
significantly different in both groups. 
Follow-up after radioiodine therapy 
Endpoint analysis 
The interval between the first administration of radioiodine and the endpoint 
of follow-up was 4.3 ± 0.2 years (range 1.4-7.2) for group A and 5.2 ± 0.3 years 
(range 1.7-12.2) for group B. This difference in follow-up was not significant 
(p > 0.1). Duration from the last radioiodine treatment to the endpoint of 
follow-up was more than 1 year in all but three patients in group A and in all 
but one patient in group B. No patient had had thyroid surgery after the last 
radioiodine therapy. 
Euthyroidism 
At the end of follow-up, 30 group A patients (66%) and 47 group В patients 
(81%) were euthyroid. The total dose per gram of thyroid tissue did not dif­
fer significantly between the two groups of euthyroid patients (2.3 ± 0.3 MBq/g 
versus 2.7 ±0.2 MBq/g; ρ > 0.1). 
Persistent or Recurrent Hyperthyroidism 
Twelve group A patients (27%) and seven group В patients (12%) were thyrotoxic 
at the end of follow-up. Of these 19 patients, 13 were on antithyroid medication 
and six were not treated for hyperthyroidism. Two patients, one in group A and 
one in group B, had received the last dose of radioiodine less than 0.5 years 
previously and still used antithyroid medication. The medical records revealed 
that seven of the other 11 patients in group A and five of the other six patients 
in group В had never reached euthyroidism or had become hyperthyroid again 
within 6 months after stopping antithyroid medication following the last ra­
dioactive iodine treatment. In these patients, persistent hyperthyroidism seems 
a more appropriate classification than recurrent hyperthyroidism. For varying 
reasons these patients were not retreated with radioactive iodine (seven patients 
or their treating physicians did not aim at further 1 3 1 I therapy, in three patients 
mild, persistent hyperthyroidism was not recognized and in two the reason is 
not known). Four patients in group A had recurrent hyperthyroidism, 0.7, 0.8, 
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0.9 and 1 year after stopping antithyroid medication following the last radio-
iodine therapy. In group B, hyperthyroidism recurred in one patient 5 years 
after the last radioiodine therapy. 
Hypothyroidism 
In group A, mild, previously undiagnosed hypothyroidism was found in one pa­
tient at the end of follow-up (TSH level 7.4 mU/1, fT4 level 8.5 pmol/1, 3.2 years 
after the last therapy). Clinically, she was euthyroid. Another two patients were 
on L-thyroxine therapy. In one patient, L-thyroxine was started 1.9 years after 
the last 1 3 1 I treatment. Shortly before the start of replacement therapy, the 
serum TSH level was 29.1 mU/1. In the other patient L-thyroxine was started 
at a normal TSH level (0.6 mU/1) 2.1 years after the last dose of radioiodine. 
In group B, two patients showed biochemical evidence of mild hypothy­
roidism at the end of follow-up (TSH 5.3 т Ш , fT4 8.6 pmol/1, 6.6 years after 
the last therapy; TSH 8.3 mU/1, fT4 8.0 ртоИ, 9.1 years after the last dose). 
Clinically, there were no signs or symptoms of hypothyroidism. Another two pa­
tients were on L-thyroxine therapy at the end of follow-up. In the first patient, 
the serum TSH level was 50.0 mU/1 at the start of L-thyroxine therapy 1.3 years 
after the last dose of radioiodine. In the other, L-thyroxine had been started 
0.7 years after the last dose at a TSH level of only 0.90 т Ш . 
With the inclusion of two patients in whom L-thyroxine therapy was started 
at normal TSH levels, the overall rate of hypothyroidism was 3/45 (7%) in the 
group of patients treated with low doses and 4/58 (7%) in the group treated 
with calculated doses. Excluding these two patients, the totals are 2/44 (5%) 
and 3/57 (5%), respectively. More severe hypothyroidism (TSH level >10 mU/1, 
η = 2) was only diagnosed during the first 2 years after the last administration of 
radioiodine. Three of the patients with proven hypothyroidism in groups A and В 
were on antithyroid medication until 3 days prior to the last 1 3 1 I administration. 
TSH levels at that time were below 1.0 mU/1 in two and not known in one. 
At the end of follow-up, frequencies of hypo-, eu- and hyperthyroidism did 
not differ significantly between groups A and В (p**= 0.163). In group B, thy­
roid weight was about twice as low in the patients who became hypothyroid 
(79 ±21 g) as in the ones who were hyperthyroid (158 ±37 g) and euthyroid 
(140 ± 14 g) at endpoint. This difference did not, however, reach statistical sig­
nificance (p*> 0.1). In all 103 patients, there was no significant difference with 
respect to thyroid weight and administered dose per gram of thyroid tissue be­
tween patients who were hyper-, eu- and hypothyroid at the end of follow-up 
(p*> 0.1). Furthermore, ages, sex ratios and number of therapies were similar 
in patients who were hyper-, hypo- or euthyroid at the end of follow-up in both 
group A and group B. 
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The number of patients who were adequately treated (i.e. not hyperthyroid 
at the end of follow-up) with a single dose was more than twice as high in 
group В (38/58 = 66%) as in group A (12/45 = 27%) (p**< 0.001). 
Life table analysis (Figure 4.1) 
Univariate analysis of the time between the first radioiodine therapy and the 
achievement of euthyroidism showed that the time to reach euthyroidism was 
significantly shorter in patients treated with calculated doses than in patients 
treated with low doses (median time 0.6 years (mean ± SEM 1.0 ±0.1 years) 
versus 1.5 years (mean ± SEM 2.4 ±0.3 years; p***< 0.001)). 
Figure 4.1 Percentage of hyperthyroid patients after treatment with low 
doses (A) and after treatment with calculated doses (B) plotted 
against time since the first radioiodine therapy (Kaplan-Meier 
method) 
years 
4.4 Discussion 
In two types of hyperthyroidism (toxic multinodular goiter (Plummer's disease) 
and toxic solitary autonomous thyroid nodule (Goetsch's disease)), the toxic thy­
roid nodules are supposed to secrete thyroid hormone autonomously, i.e. inde-
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pendently of extrathyroidal stimulators. In an earlier study, we reported on re-
sults of radioiodine therapy in toxic solitary autonomous nodules [24]. In these 
patients, a standard dose of 740 MBq (20 mCi) of 131I was highly effective, and 
after a mean follow-up of 10 years, the incidence of hypothyroidism was only 
6%. In the present study, long-term results of two dosage schedules of radio-
iodine therapy are described in 103 patients with toxic multinodular goiter. The 
higher mean age of our patients and the clear predominance of women are in 
accordance with other reports in the literature on toxic multinodular goiter [25]. 
Remission of hyperthyroidism had been reached in 73% of the patients 
treated with low doses (group A) and in 88% of the patients treated with calcu-
lated doses (group B) at the end of follow-up. At that time, 27% (n = 12) and 
12% (n = 7), respectively, were, still or again, thyrotoxic (13 of whom were on an-
tithyroid medication). There was no significant difference with respect to initial 
thyroid weight or total administered dose of radioiodine per gram of thyroid tis-
sue between these 19 hyperthyroid patients and the 84 patients in whom hyper-
thyroidism was successfully reversed. Table 4.2 shows a summary of data in the 
literature with respect to the percentage of patients with (multi-)nodular goiter 
in whom radioiodine did not result in permanent remission of hyperthyroidism. 
The incidence of therapy failure (persistent or recurrent hyperthyroidism) found 
in our study is within the range of l%-30% reported in other studies. A compar-
ison of these studies is difficult, however, for the reasons previously mentioned. 
Better results than ours with respect to reversal of hyperthyroidism were re-
ported by Kinser et al. [18] and Moser et al. [16]. However, follow-up was short 
in these reports and fairly high doses were used. In contrast to these favourable 
results Berding and Schicha [20] reported a considerably higher incidence of hy-
perthyroidism after 1 year, despite the use of equally high doses. 
It appears from our study that recurrent hyperthyroidism is less frequent 
than persistent hyperthyroidism after 131I therapy for toxic multinodular goiter. 
Only five patients (four in group A and one in group B) had recurrent hyperthy-
roidism. Twelve patients (seven in group A and five in group B) had persistent 
hyperthyroidism. The doses we administered were not very high (50-100 Gy per 
treatment with a calculated dose and certainly less per treatment with a low 
dose). Higher doses of radioiodine may diminish the incidence of persistent hy-
perthyroidism [16,18]. There is no reason to assume that remission of hyperthy-
roidism would not have been reached with further 131I treatment in the patients 
with persistent hyperthyroidism: in the majority of these hyperthyroid patients 
radioiodine therapy was not repeated for reasons of patients' or physicians' 
preferences or because mild, persistent hyperthyroidism was not recognized. 
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Table 4.2 Summary of data in the literature on the percentage of patients 
with (multi-)nodular goiter in whom radioiodine did not result 
in permanent remission of hyperthyroidism 
Author 
Seed [3] 
Eller [4] а.ь 
Lamberg [5] b 
Heinze [10] 
Holm [12] 
Hoeschel [13] 
Wiener [14] ь 
Moser [16] d 
Rinser [18] 
Veneman [19] 
Berding [20] 
Number 
of 
patients 
55 
282 
98 
160 
2123 
130 
88 
118 
176 
29 
48 
34 
Dose per 
treatment 
n.m. 
80 Gy 
5.9 MBq/g 
60-100 Gy 
100 Gy 
60-150 Gy 
7.4 MBq/g c 
150 Gy 
400 Gy c 
300 Gy c 
1.5 MBq/g 
150-250 Gy 
Follow-up (yr) 
mean 
n.m. 
n.m. 
n.m. 
n.m. 
1 
n.m. 
5.3 
0.9 
0.8 
1 
9« 
1 
(range) 
(0.5-2) 
(1-10) 
(0.3->2) 
(0-14) 
(1-1) 
(0.5-5.5) 
(1-17) 
(0.3-4.2) 
(0.3-5.7) 
(1-1) 
(5-14) 
(1-1) 
Recurrent/ 
persistent 
hyperthyroidism 
31% 
1.4% 
6.1% 
19% 
18% 
6.2% 
13.6% 
3% 
1% 
0% 
33% 
24% 
Graves' ophthalmopathy not excluded 
Toxic autonomously functioning thyroid nodules not excluded 
per gram of hyperactive thyroid tissue 
Comparison of two dosage schedules 
Median 
Not mentioned 
The overall rate of hypothyroidism in our study was 7% (n = 3) in the group of 
patients treated with low doses and 7% (n = 4) in the group treated with cal­
culated doses, or, excluding the two patients in whom L-thyroxine replacement 
therapy was started unnecessarily, 5% in each group. We could not demon­
strate a significant relationship between development of hypothyroidism and 
initial thyroid weight or total dose per gram of thyroid tissue. In patients on 
antithyroid drugs, a theoretically possible cause of hypothyroidism is the irradi­
ation of normal TSH-dependent thyroid cells when the serum TSH level is not 
suppressed at the time of radioiodine treatment. Three of the five patients with 
proven hypothyroidism were on antithyroid drugs until 3 days prior to the last 
radioiodine administration. In two of them, this cause for hypothyroidism could 
be excluded because TSH was suppressed at the time of the last radioiodine 
administration. In one patient the TSH level at that time is not known. 
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Table 4.3 Summary of data in the literature on the incidence of hypothy­
roidism after therapy with radioactive iodine in patients with 
toxic (multi-)nodular goiter 
Author Number of Dose per Follow-up (yr) Hypothyroid 
patients treatment mean range 
Seed [3] 
Eller [4] a 
Lamberg [5] a 
Dunn [6] a 
Nofal [7] 
Viherkoski [8] a 
Heinze [10] 
Bliddal [11] 
Hoeschel [13] 
Wiener [14] a 
Moser [16] * 
Kinser [18] 
Veneman [19] 
Berding [20] 
Glanzmann [9] 
Holm [12] 
Jensen [15] 
Danaci [17] 
55 
436 
98 
109 
15 b 
145 
313 
160 
53 
130 
88 
118 
176 
29 
48 
34 
722 
2123 
89 
21 
n.m. 
80 Gy 
>5.9 MBq/g 
7.4 MBq/g c 
167 Gy 
5.2-5.9 MBq/g 
60-100 Gy 
5.6 MBq/g 
60-150 Gy 
7.4 MBq/g β 
150 Gy 
400 Gy * 
300 Gy β 
1.5 MBq/g 
150-250 Gy 
100-120 Gy 
100 Gy 
233-5550 MBq 
555-740 mCi 
n.m. 
n.m. 
n.m. 
n.m. 
n.m. 
n.m. 
n.m. 
n.m. 
n.m. 
5.3 
0.9 
0.8 
9 
9 ' 
1 
n.m. 
n.m. 
1 
n.m. 
0.5-2 
1-10 
0.4->2 
0-15 
>10-15 
<1-16 
1-8 
0-14 
n.m. 
0.5-5.5 
1-17 
0.3-4.2 
0.3-5.7 
9-9 
5-14 
1-1 
n.m.-10 
1-24 
0-10 
1-5 
3.6% 
7.8% 
8.2% 
7% 
40% 
35.9% 
18% 
8.8% 
5.7% 
3.8% 
1.1% 
3% 
4% 
7% 
8.3% 
9% 
6% 
64% 
16% 
24% 
a
 Tbxic autonomously functioning thyroid nodules not excluded 
b
 Subgroup of patients with follow-up for more than 10 years 
c
 Not corrected for 24-h thyroid RAIU 
d
 Comparison of two dosage schedules 
e
 Per gram hyperactive thyroid tissue 
f
 Median 
e Life table method 
n.m. Not mentioned 
In Table 4.3, a summary of data in the literature on the incidence of hypothy­
roidism after therapy with radioactive iodine in patients with toxic ( m u l t i n o d ­
ular goiter is shown. The low overall incidence of hypothyroidism in our study 
is in accordance with most other reports with long-term follow-up in the litera-
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ture [4, 6, 10, 18, 19]. A much higher overall incidence of hypothyroidism was 
reported by Nofal et al. [7], who used fairly high doses. A high incidence of 
hypothyroidism occurring late after radioiodine therapy for toxic multinodular 
goiter was reported by Holm et al. (based on life table analysis) [12] and Dunn 
et al. [6]. In contrast, late hypothyroidism was not found in two studies by 
Danari et al. [17] and Glanzmann et al. [9] (both based on life table analysis). It 
seems that in our patients, late hypothyroidism was infrequent. In four of seven 
patients, hypothyroidism developed within 2 years of the last administration of 
radioiodine. In three patients (one treated with low doses and two treated with 
calculated doses), hypothyroidism was diagnosed for the first time at the end 
of follow-up, 3.2, 6.6 and 9.1 years after the last radioiodine therapy. The time 
of development of hypothyroidism in these patients is not exactly known. Hy-
pothyroidism appeared to be mild in these three patients (serum TSH levels 
below 10 mU/1 and no signs or symptoms of hypothyroidism). 
Frequencies of hyper-, eu- and hypothyroidism did not differ significantly 
between the patients treated with low doses and those treated with calculated 
doses. The number of 131I administrations in the patients treated with cal-
culated doses was about half that in the patients treated with low doses and 
the percentage of patients who were adequately treated with a single dose was 
more than twice as high for the group treated with calculated doses as for the 
group treated with low doses (66% versus 27%). Consequently, life table analysis 
showed that euthyroidism was reached within a significantly shorter time after 
treatment with calculated doses than after treatment with low doses (median 
time 0.6 years versus 1.5 years). 
We conclude that patients with toxic multinodular goiter can be effectively 
treated with radioiodine. In our experience, the long-term risk of post-treatment 
hypothyroidism is rather low. Euthyroidism can be reached significantly faster 
with doses of radioiodine calculated on the basis of thyroid weight and RAIU 
than by administration of low doses without increasing the risk of hypothy-
roidism. Since many of the patients with toxic multinodular goiter are elderly, 
both rapid and permanent relief of hyperthyroidism, especially in those with 
co-existent coronary artery disease, may be essential. Control visits in the first 
year after radioiodine therapy and every 1-2 years thereafter are important, as 
are subsequent treatments for cases of persistent thyrotoxicosis. 
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Significance of Serum TSH levels Below the Normal Range 
in Patients Treated with Radioiodine for Toxic Multinodular 
Goiter 
Huysmans DAKC, Hennus ARMM, Ross HA, Corstens FHM, 
Kloppenborg PWC 
In a recent study (Eur J Nucl Med 1993 ; 20:1056-62) we reported that 
most patients with toxic multinodular goiter after treatment with ei­
ther low doses of 1 3 1 I (group A) or calculated doses adjusted for thyroid 
weight and radioactive iodide uptake (group B) were euthyroid (normal 
free thyroxine (fT4) and triiodothyronine (T3) levels and not using thy-
rostatic or thyromimetic drugs) at the last visit (follow-up, mean ± SD, 
4.3 ± 1.3 yr for group A and 5.2 ± 2.3 yr for group B). However, it ap­
peared that 30% of the euthyroid patients had a serum TSH level below 
the normal range at that time. Furthermore, significant inverse corre­
lations between serum fT4 and T3 levels on one hand and serum TSH 
levels on the other were observed in the euthyroid patients. These ob­
servations suggest that, in spite of normal serum levels of fT4 and T3, 
autonomous thyroid function was still present in (a number of) these 
patients and that they are at risk of recurrent hyperthyroidism. 
Forty-nine of these euthyroid patients were re-examined 1 yr later (Feb 
1993). Patients of group B, rendered euthyroid after a single dose of 
radioiodine in the past, were also evaluated in Feb 1994 (group В select; 
η = 21). The follow-up data demonstrate significant decreases of serum 
fT4 and T3 levels and a significant increase in serum TSH levels after 
1 yr. In the majority of patients, fT4 levels had decreased (34 of 49 pa­
tients) or stayed at the same level (3 of 49 patients) after 1 yr. Even in 
13 of 18 patients, who had a TSH value below normal in 1992, fT4 levels 
had decreased 1 yr later. Significant decreases in serum fT4 and T3 lev­
els were also observed between Feb 1992 and Feb 1994 in group В select. 
In 19 of 21 patients fT4 levels in 1994 were lower than in 1992. On the 
other hand, in 12 patients of the whole group of 49 euthyroid patients 
and in 3 of the subgroup of 18 patients with a TSH level below normal 
in 1992, fT4 levels had increased after 1 yr. An increase to fT4 levels just 
above the normal range was seen in only 3 of all 49 euthyroid patients. 
It is concluded that in patients, treated with 1 3 1 I for toxic multinodular 
goiter in the past, who have normal fT4 and T3 levels, a further decrease 
of thyroid hormone levels can be anticipated, at least in the first decade 
after 1 3 1 I therapy. This applies even for the subgroup of patients with a 
serum TSH level below normal. In these patients, an expectative policy 
is indicated. Additional 1 3 1 I treatment has to be considered in patients 
with a serum TSH level below normal, when serial measurements show 
a further decrease in TSH levels in combination with increasing fT4 and 
T3 levels, especially when signs and symptoms of thyrotoxicosis recur. 
о о о 
5.1 Introduction 
In the preceding study we reported that most patients with toxic multinod­
ular goiter who had been treated with either low doses of radioiodine (group A) 
or calculated doses adjusted for thyroid weight and radioactive iodide uptake 
(group B) were euthyroid (denned as a normal free thyroxine (fT4) and a normal 
triiodothyronine (T3) level and not using thyrostatic or thyromimetic drugs) at 
the time of the last visit. However, it appeared that a considerable number of 
these euthyroid patients had a serum thyroid-stimulating hormone (TSH) level 
below the normal range at the time of the last evaluation in February 1992 (10 of 
29 euthyroid patients in group A and 11 of 42 euthyroid patients in group B). 
The significance of the combination of a normal fT4 and T3 level with a TSH level 
below the normal range in a patient treated with radioiodine with respect to the 
risk of recurrent hyperthyroidism is unknown. Therefore, we reinvestigated 
this group of euthyroid patients one year later (February 1993). Furthermore, 
a subgroup of patients of group B, those who were rendered euthyroid after a 
single dose of radioiodine in the past, were also evaluated in February 1994. 
5.2 Patients and methods 
In the follow-up study in February 1993, 22 euthyroid patients of group A 
(20 women and 2 men, aged 69 ± 9 years, mean ± SD; range 51-85 years) and 
27 euthyroid patients of group В (25 women and 2 men, aged 66 ± 9 years; range 
46-82 years) were included. In February 1992, the time since the last dose of 
radioiodine was 3.8 ± 1.4 years for the 22 patients of group A and 5.2 ± 2.8 years 
for the 27 patients of group B. Reasons why patients were not included in the 
follow-up study in February 1993 were death in the preceding year (n = 2), re­
fusal of the patient to cooperate (n = 1) and impossibility to analyze samples 
obtained in 1992 and 1993 of the same person in one assay run due to short­
age of serum obtained in 1992 (n = 19). Twenty-one of 32 patients of group В 
(19 women and 2 men, aged 68 ± 8 years; range 48-82 years), who were eu­
thyroid in 1992 after a single dose of radioiodine in the past, were included in 
the study in February 1994 (group В select; follow-up in 1992 5.5 ± 3.0 years). 
Evaluation consisted of a short medical interview and blood sampling for mea­
surement of serum levels of TSH, T3, T4 and fT4 (for assays and normal ranges 
see Chapter 4). 
Statistical analyses were performed using the Wilcoxon sign-rank test for 
paired observations (p-values denoted as p) and the Spearman rank-correlation 
test (p-values denoted as p*). The mean values ± SD are given. 
61 
LOW SERUM TSH LEVELS AFTER "ii FOR TOXIC MULTINODULAR GOITER 
5.3 Results 
In February 1992, significant inverse correlations were present between serum 
levels of fT4 and TSH (r = -0.409, p*< 0.001) and between serum levels of T3 
and TSH (r = -0.320, p* < 0.01) in the total group of 71 euthyroid patients 
of groups A (n = 29) and Β (η = 42). When the data of the 49 patients of 
groups A and В who participated in the follow-up study in February 1993 were 
combined, a significant inverse correlation between serum levels of fT4 and TSH 
was present both in February 1992 (r = -0.473, p* < 0.001; Figure 5.1, left 
panel) and in February 1993 (r = -0.477, p*< 0.001; Figure 5.1, right panel). 
In this group of 49 patients the inverse correlation between serum levels of T3 
and TSH was significant in 1992 (r = -0.363, p*< 0.02) but not significant in 
1993 (r = -0.151, p*> 0.1). No significant correlations could be demonstrated 
between serum levels of TSH, T3, T4 or fT4 on one hand and the time since the 
last radioiodine therapy on the other, neither for groups A and В separately, nor 
when the data for both groups were combined. 
Figure 6.1 Serum TSH levels (on a logarithmic scale) of 49 patients of groups 
A and В combined, plotted against serum fT4 levels in February 
1992 (left panel) and February 1993 (right panel) 
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Changes in thyroid function during 1 year follow-up (groups A and B) 
Table 5.1 shows levels of TSH, T3, T4 and fT4 as measured in serum samples ob­
tained in 1992 and 1993. No antithyroid or thyromimetic medication was started 
between February 1992 and February 1993 in any patient of groups A and B. In 
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both groups, TSH levels increased and T3, T4 and fT4 levels decreased, changes 
being statistically significant for T3 in group A, for TSH and T4 in group В and 
for 1T4 in both groups. When groups A and В were combined, changes in all 
hormone levels were highly significant (p < 0.01). 
Table 5.1 
Group A 
(n=22) 
Group В 
(n=27) 
Serum levels (mean ± SD) 
1992 and February 1993 
groups A and В combined 
1992 
1993 
P 
1992 
1993 
P 
Groups A and В 1992 
(n=49) 
Figure 5.2 
1993 
Ρ 
Serum free 
TSH 
1.16 ±2.05 
1.34 ±2.27 
OS 
1.30 ±1.66 
1.51 ±1.89 
<0.04 
1.24 ±1.82 
1.43 ± 2.05 
< 0.008 
of TSH, T3, T4 and fT* in February 
in patients in group A, group В and 
T3 
2.0 ±0.4 
1.7 ±0.3 
<0.006 
1.8 ±0.3 
1.7±0.3 
ne 
1.9 ±0.4 
1.7 ±0.3 
<0.001 
T4 
104 ±17 
101 ±15 
ns 
106 ±20 
102 ± 17 
<0.03 
105 ± 19 
101 ±16 
<0.004 
fT4 
13.0 ±1.9 
12.0 ±2.1 
< 0.002 
12.9 ±2.5 
12.3 ±2.5 
<0.04 
13.0 ±2.2 
12.2 ±2.3 
<0.001 
T4 levels in February 1992 and February 1993 plotted 
against the time since the last radioiodine therapy, for group A 
(left panel) and group В (right panel) 
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Figure 5.2 shows fT4 levels in 1992 and 1993 for the individual patients in 
groups A (Figure 5.2, left panel) and В (Figure 5.2, right panel) plotted against 
the time since the last radioiodine therapy. In the majority of patients, fT4 levels 
decreased (17 patients of each group) or stayed at the same level (1 patient of 
group A and 2 of group B). In only 12 patients (4 of group A and 8 of group B) 
1T4 levels increased, which was accompanied by a decrease in the serum TSH 
level in 5 patients while in one patient the serum TSH level stayed undetectable. 
For patients who had been treated with radioiodine more than 5 years ago, fT4 
levels decreased in 5 of 8 patients in group A and in 10 of 15 patients of group B. 
Table 5.2 Serum levels (mean ± SD) of TSH, T& T4 and fT4 in February 
1992 and February 1993 in patients of group A, group В and 
groups A and В combined, who had a serum TSH level below the 
normal range in 1992 
Group A 
TSH<0,4 in 1992 
(n=10) 
Group В 
TSH<0.4 in 1992 
(n=8) 
Groups A and В 
TSH<0.4 in 1992 
(n=18) 
1992 
1993 
P 
1992 
1993 
P 
1992 
1993 
Ρ 
TSH 
0.12 ±0.12 
0.23 ±0.29 
ne 
0.12 ±0.13 
0.30 ±0.33 
<0.05 
0.12 ±0.12 
0.26 ±0.30 
<0.04 
Тз 
2.0 ±0.5 
1.7 ±0.4 
<0.02 
2.0 ±0.4 
1.9 ±0.4 
ne 
2.0 ±0.4 
1.8 ±0.4 
<0 01 
T4 
105 ± 2 1 
100 ±18 
ne 
111 ±21 
108 ± 17 
ns 
108 ±21 
103 ±18 
<0.05 
fT4 
14.4 ±1.6 
13.3 ±2.3 
<0.02 
13.5 ±1.7 
12.8 ±2.2 
ns 
14.0 ±1.7 
13.1 ±2.2 
<0.03 
Changes in thyroid function in the subgroup of patients, who had a serum TSH 
level below normal (<0.4 т Ш ) in 1992 were similar to those of the whole group 
(Table 5.2). When data from patients of groups A and В were combined, a 
significant increase in the serum TSH level as well as significant decreases in 
serum levels of T3, T4 and fT4 were observed. In Figure 5.3, serum levels of 
T3, fT4 and TSH in the individual patients of the combined subgroups in 1992 
and 1993 are plotted against the time since the last radioiodine therapy. Only 
4 patients had an increasing fT4 level; in 13 patients fT4 decreased from 1992 to 
1993 and in one patient it stayed at the same level. In 3 of the 4 patients with 
an increasing fT4 level the serum TSH level decreased or stayed undetectable. 
A decreasing or constant fT4 level was accompanied by an increasing TSH level 
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in 11 of 14 patients and by a decreasing T3 level in 9 of 14 patients. For 3 of the 
18 patients with a TSH level below normal in 1992, a normal TSH value was 
found in 1993, whereas none of the patients with a normal TSH level in 1992 
had a TSH level below the normal range in the next year. 
Figure 5.3 Serum T3 (upper left panel), free T4 (upper right panel) and TSH 
levels (lower panel), in February 1992 and February 1993 in pa­
tients with a serum TSH level below the normal range in 1992, 
plotted against the time since the last radioiodine therapy. Pa­
tients of group A are indicated by bold lines and patients of group 
В by hairlines 
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In 1993, marginally elevated fT4 levels were found in one patient of group A 
(TSH < 0.01 mU/1 and fT4 16.3 pmol/1 in 1992; TSH < 0.01 т Ш and fT4 
17.1 р т о И in 1993) and in two patients of group В (TSH 0.23 т Ш and fT4 
15.5 р т о И in 1992 and TSH 0.19 т Ш and fT4 17.3 р т о И in 1993 for one 
patient; TSH 0.65 т Ш and fT4 16.8 ртоІЛ in 1992 and TSH 0.62 mU/1 and 
fT4 17.4 pmol/1 in 1993 for the other). In none of the patients of groups A and 
В hypothyroidism (TSH level elevated and fT4 level below normal) developed 
during the year of follow-up. 
Changes in thyroid function during 2 years follow-up (group В select) 
Table 5.3 (upper panel) shows levels of TSH, T3, T4 and fT4 for group В select in 
serum samples of 1992 and 1994. Significant decreases in serum levels of T3, T4 
and fT4 were found, although the increase of the TSH level was not significant. 
The same data for the 6 patients of group В select who had a serum TSH level 
below the normal range in 1992 are shown in the lower panel of Table 5.3. 
In 19 of 21 patients fT4 levels in 1994 were lower than in 1992 (Figure 5.4). 
Notably, in the two patients with a rising fT4 level, fT4 levels in 1992 were the 
highest of all patients of group В select. 
Table 5.3 Serum levels (mean ± SD) of TSH, T& T4 and fT4 in February 
1992 and February 1993 in patients of group B, who had been 
rendered euthyroid by a single, calculated dose of radioiodine in 
the past (group В select; upper panel) and from the subgroup of 
these patients who had a serum TSH level below the normal range 
in 1992 (group В select, TSH < 0.4; lower panel) 
Group В select 
(n=21) 
Group В select 
TSH<0.4 
(n=6) 
1992 
1994 
P 
1992 
1994 
P 
TSH 
0.95 ±1.07 
0.98 ±1.00 
na 
0.13 ±0.14 
0.25 ±0.18 
<0.04 
T3 
1.8 ±0.4 
1.7 ±0.3 
<0.03 
2.0 ±0.4 
1.8 ±0.4 
<0.04 
T4 
108 ±18 
99 ±14 
<0.003 
109 ±22 
100 ±21 
na 
fT4 
13.5 ±2.0 
12.0 ±2.5 
<0.002 
13.5 ±1.8 
12.4 ±2.6 
ne 
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Figure 5.4 Serum free T4 levels in February 1992 and February 1994 in pa­
tients of group В select, plotted against the time since the last 
radioiodine therapy 
Group В select 
0 2 4 β β IO 12 14 16 
Time since last radioiodine therapy (years) 
5.4 Discussion 
Significant inverse correlations between serum fT4 and T3 levels on one hand 
and serum TSH levels on the other were observed in a group of 71 patients, 
who were euthyroid in February 1992, 1 to 12 years after radioiodine treatment 
for toxic multinodular goiter. This is in contrast to the normal population in 
which fT4 and TSH serum levels are independent parameters [1]. Furthermore, 
21 (30%) of these patients had a serum TSH level below the normal range at that 
time. These observations suggest that autonomous thyroid function was still 
present in this group of radioiodine treated patients, notwithstanding normal 
serum levels of fT4 and T3. The question then arises, whether the administered 
dose of radioiodine in these patients has sufficiently destroyed the autonomously 
functioning thyroid tissue. Therefore, we followed changes in thyroid function 
during 1 or 2 years of follow-up in these patients. 
Our follow-up data in 49 patients demonstrated significant decreases of 
serum fT4 and T3 levels and a significant increase in serum TSH levels after 
1 year. In the majority of patients, fT4 levels had decreased (34 of 49 patients) 
or stayed at the same level (3 of 49 patients). Even in 13 of 18 patients, who 
had a TSH value below the normal range and normal fT4 and T3 levels in 1992, 
fT4 levels had decreased 1 year later. Furthermore, after 2 years, significant 
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decreases in serum fT4 and T3 levels were observed in the group of 21 patients, 
who had been rendered euthyroid by a single, calculated dose of radioiodine in 
the past. In 19 of these patients fT4 levels in 1994 were lower than in 1992. 
We speculate that the decrease in thyroid hormone levels as observed in the 
majority of patients in this study is a late consequence of radioiodine treatment 
[2]. Our findings are similar to those of Davies et al. [3]. In the latter study, 
however, no distinction was made between patients with Graves' disease, toxic 
multinodular goiter or toxic solitary autonomous nodules. 
On the other hand, in six of the whole group of 49 euthyroid patients and 
in three of the subgroup of 18 patients with a TSH level below normal in 1992, 
fT4 levels had increased and serum TSH levels had decreased after 1 year. 
However, in only three of all 49 euthyroid patients an increase of fT4 levels 
to (marginally) elevated values was seen. Further follow-up will learn whether 
radioiodine treatment has insufficiently destroyed the autonomously functioning 
thyroid tissue in these patients. 
We conclude that in patients, who have been treated with radioiodine for 
toxic multinodular goiter in the past and who have fT4 and T3 levels within the 
normal range, a further decrease of thyroid hormone levels can be anticipated, 
at least in the first decade after radioiodine therapy. This applies also for the 
subgroup of patients with serum TSH levels below the normal range. Therefore, 
in patients who show the combination of normal T3 and fT4 levels and a TSH 
level below normal after radioiodine treatment for toxic multinodular goiter in 
the past, yearly control visits with an expectative policy is indicated. Additional 
131I treatment has to be considered in patients with a serum TSH level below the 
normal range, when serial measurements show a further decrease in TSH levels 
(or TSH levels below the detection limit of the assay) in combination with in-
creasing fT4 and T3 levels, especially when signs and symptoms of thyrotoxicosis 
recur. 
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As a result of increasing interest in non-surgical treatment for the re-
duction of goiter size the use of magnetic resonance (MR) imaging for 
volume estimation of large multinodular goiters was evaluated in 20 pa-
tients (three males and 17 females; age 61 ± 21 years) with a multinod-
ular goiter larger than 100 ml. In addition, MR measurements were 
compared with scintigraphic (SC) volume estimations. Intraobserver 
coefficient of variation (CV) of MR measurements was 2.2% ±2.0% (Ob-
server 1) and interobserver CV 4.1% ±2.2% (Observers 1 and 2). In 
all 20 patients signs of mechanical complications were shown on MR 
images. For SC measurements intraobserver CV was 7.5% ±5.7% 
(Observer 3) and 5.4% ±5.1% (Observer 4). Interobserver CV was 
10.1% ± 6.1%. The correlation between measurements with both meth-
ods was not strong (r = 0.665) and the resulting CV was 17.3% ± 14.2%. 
Underestimation of SC volumes could not be explained by the presence 
of cysts at the surface of the thyroid. It is concluded that MR imaging 
can be used for in vivo thyroid volume estimation in large multinodular 
goiters. The high precision of MR measurements makes this technique 
potentially useful for the evaluation of thyroid growth and non-surgical 
treatment for reducing goiter size. Scintigraphic volume measurements 
do not suffice for this purpose. An additional advantage of MR imag-
ing is the detailed anatomical information it provides with regard to 
mechanical complications of large goiters. 
о о 
6.1 Introduction 
In recent years interest in non-surgical treatment of goiters (administration 
of thyroid hormone or radioiodine) has grown. Precise measurements of gland 
volume are necessary for the evaluation of the effects of thyroid volume reducing 
therapy. 
Palpation is an imprecise method in the estimation of thyroid size [1, 2], as 
it is influenced by the neck architecture and by the experience of the observer. 
In the 1950s, thyroid scintigraphy was introduced to estimate thyroid volume. 
For diffuse goiters this method proved to be more accurate than palpation and 
has been used widely [3-10]. More recently, the use of ultrasound for thyroid 
volume estimations has been extensively studied, again chiefly in normal thy­
roids and diffuse goiters [10-18]. Ultrasound provides more accurate volume 
measurements than scintigraphy for diffuse thyroid glands [11, 12, 14, 15] and 
probably also for smaller multinodular goiters [19]. 
For large multinodular goiters, however, ultrasound becomes less reliable 
because of frequent intrathoracic extension [20, 21]. Despite obvious advantages 
of magnetic resonance (MR) imaging over ultrasound and computed tomography, 
such as a high soft tissue contrast, multiplanar imaging capabilities, absence of 
ionizing radiation and superior anatomic detail, its application for volume esti­
mations of goiters has thus far not been reported. The purpose of the present 
study is to evaluate the use of MR imaging in volume estimation of large mul­
tinodular goiters. These measurements were compared with scintigraphic (SC) 
volume estimations in order to determine if the precision of a simple technique 
like planar scintigraphy is sufficient for the evaluation of the effects of thyroid 
volume reducing treatment in patients with large multinodular goiters. 
6.2 Patients and methods 
Twenty patients (three males and 17 females) were studied (age 61 ± 21 years; 
mean ± SD). Sixteen patients were euthyroid and four hyperthyroid. All patients 
had a large multinodular goiter which was estimated by palpation to be larger 
than 100 ml. 
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MR imaging 
MR imaging was performed on a whole-body MR scanner (Siemens H15, Siemens 
AG, Erlangen, FRG), operating at a field strength of 1.5 Tesla. Tj-weighted 
images (TR = 270 ms, TE = 15 ms; matrix 128 χ 256, 7 acquisitions) were 
obtained using a Helmholz neck coil and covering the entire goiter in the coronal, 
sagittal and axial planes. The slice thickness was 8 mm with a 0.8 mm slice 
gap. T2-weighted images (TR = 1710 ms, TE = 80 ms) were obtained in the axial 
plane. 
The thyroid outline was drawn manually on each slice of the Tj-weighted 
images. A computer program was used to calculate the surface of the traced 
areas. The sum of the traced surfaces in each plane was multiplied by the slice 
distance (0.88 cm) in order to calculate the thyroid volume. 
MR measurements in the coronal plane were performed by two independent 
observers (Observers 1 and 2). Observer 1 repeated the measurement in the 
coronal plane after an interval of at least 1 month and, in addition, measured 
thyroid volumes in the sagittal and axial plane. 
Scintigraphy 
Rectilinear scintigrams were obtained 24 hours after oral ingestion of 7.5-11.1 
MBq of iodine-131, using a Magna Scanner 1000 (Picker, Illinois, USA) with a 
5 inch crystal probe and a high energy collimator, 5 inch focus, 0.5 inch res­
olution. Each of two other independent observers (Observers 3 and 4) evalu­
ated the real size (1:1) images of the thyroid and again after an interval of 
2 months. The traced surface on the scan was measured planimetrically and 
thyroid volume was calculated using the formula of Doering [6]: thyroid volume 
(ml) = 0.326 χ (planimetrie surface)3/2. 
Statistical analyses 
Mean values ± SD are given. Intraobserver variability and interobserver vari­
ability of MR and SC measurements and differences between MR and SC volume 
measurements were determined by calculating the mean coefficient of variation 
(CV). Correlations between two series of measurements were tested using Spear­
man's rank correlation test (r); level of significance denoted as p. 
72 
6.3 Results 
MR imaging 
Figure 6.1a shows excellent reproducibility of the first and second measurements 
in the coronal plane by Observer 1. Intraobserver CV was only 2.2% ± 2.0% 
(Spearman's rank correlation r = 0.994, ρ < 0.001). 
Figure 6.1 Results of thyroid volume measurements (in ml) with MR imag­
ing (a and b) and scintigraphy (c and d): a. first versus second 
measurement of Observer 1 in coronal MR images, b. first mea­
surement of Observer 1 versus measurement of Observer 2 in coro­
nal MR images, с first versus second measurement Observer 3 in 
scintigraphic images, d. first measurement of Observer 3 versus 
first measurement of Observer 4 in scintigraphic images 
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Interobserver CV for the coronal measurements of Observer 1 (first measure­
ment) and 2 was also low: 4.1% ± 2.2% (r = 0.985, ρ < 0.001; Figure 6.1b). Mea­
surements by Observer 1 in the three imaging planes correlated very well. CVs 
were as follows: coronal/sagittal 3.1% ± 2.3% (r = 0.981, ρ < 0.001), coronal/axial 
2.3% ± 1 . 8 % (r = 0.993, ρ < 0.001) and sagittal/axial 3.2% ± 2 . 6 % (r = 0.983, 
ρ < 0.001). 
Figure 6.2 (a) Coronal and (b) axial Tj-weighted (TR = 270 ms, TE = 15 ms) 
MR images showing bilateral tracheal compression (arrows), 
(c) MR image in another patient showing intrathoracic goiter and 
collateral veins (arrows) 
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Figure 6.2 Continued 
Intrathoracic extension of the thyroid of more than 2 cm was present in 18 pa­
tients. In all 20 patients signs of mechanical compression were found: tracheal 
deviation in 19, tracheal compression in 17 and distended neck veins and/or col­
lateral vessels in six. An example is shown in Figure 6.2. T2-weighted images 
showed cysts of more than 2 cm in diameter in 11 patients. Cysts localized at 
the periphery of the thyroid were present in seven patients. 
Scintigraphy 
Figure 6. lc shows the results of the two measurements by Observer 3 and Fig­
ure 6.Id the results of the first measurements of Observers 3 and 4. Intraob-
server and interobserver variability for scintigraphic measurements were higher 
than for MR measurements. Intraobserver CV was 7.5% ± 5.7% for Observer 3 
and 5.4% ±5.1% for Observer 4 (r = 0.939, ρ < 0.001 and r = 0.973, ρ < 0.001, 
respectively). Interobserver variability (first measurements) was considerable: 
CV 10.1% ± 6.1% (r = 0.941, ρ < 0.001). 
Comparison of MR imaging and scintigraphy 
For each patient the mean of the MR coronal measurements of Observers 1 
(first measurement) and 2 was compared with the mean of the first SC mea­
surements of Observers 3 and 4. The results are shown in Figure 6.3. Although 
statistically significant (p = 0.0038), the correlation between measurements with 
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Figure 6.3 Results of thyroid volume measurements (in ml) with MR imaging 
(mean of first measurements in the coronal plane of Observers 1 
and 2) and scintigraphy (mean of first scintigraphic measure­
ments of Observers 3 and 4) 
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both methods was not strong (r = 0.665) and the resulting CV was as high as 
17.3% ± 14.2% . 
SC volume differed 0%-10% from MR volume in five patients, ll%-20% in 
five, 21%-30% in five, 31%-40% in two and more than 40% in three patients. 
In one patient the difference between measurements with both techniques was 
80%. In 10 patients SC volume was larger than MR volume, in the other 10 pa­
tients SC volume was smaller than MR volume. 
Cysts (without radioiodine uptake) in central parts of the thyroid are not 
likely to have influenced SC volume measurements. Cysts at the thyroid surface, 
however, may have caused an underestimation of SC volume: four of the patients 
in whom SC volume was smaller than MR volume had peripheral cysts on MR 
images. The cysts, however, were not large enough to offer a full explanation 
of the difference between SC and MR volume in these four patients (range of 
difference 96-185 ml). In three other patients with peripheral cysts SC volume 
was larger than MR volume. 
• » · 
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6.4 Discussion 
Two types of thyroid volume can be distinguished: the functional and the 
anatomical volume. The functional volume, i.e. the volume of the hormone se­
creting thyroid tissue, is of importance for dosage calculations prior to radio-
iodine therapy. For evaluation of thyroid growth and of non-surgical treatment 
of goiters, however, the anatomical volume is essential. 
Thyroid volumes have been calculated scintigraphically [3-7, 9, 10, 22] 
with the use of formulae incorporating one or more of the following parameters: 
planimetrically determined thyroid surface on the scintigram, directly measured 
height and width and indirectly estimated thickness of the thyroid lobes. The 
scintigraphic technique has proved to be more accurate than palpation [3, 6, 8]. 
However, results vary considerably between studies [3, 4, 7, 9, 10]. Comparing 
scintigraphic measurements with postoperatively and post mortem measured 
volumes, Allen and Goodwin [3] found a mean difference of 10.6% (maximum 
difference 25%) and Fazakas et al. [7] reported a mean difference of 18% (max­
imum difference 30%). Compared with surgical specimens, Brown and Spencer 
[10] found a mean underestimation of 20% by scintigraphic measurements and 
the maximum difference between both methods was as large as 236%. 
The introduction of ultrasound has improved anatomical thyroid volume 
measurement. Highly significant correlations with both surgical and post 
mortem specimens have been reported by several authors [11, 14-16, 19]. Com­
paring ultrasound measurements with post mortem specimens, Von Gutjahr 
et al. [15] found a maximum difference of only 9%. Brunn et al. [13] reported 
higher mean and maximum differences compared to post mortem specimens 
(16% and 35%, respectively). In a comparison of ultrasound measurements with 
surgical specimens, Azagra et al. [18] found a mean difference of 26% (maxi­
mum 63%). 
The above mentioned studies on thyroid measurements using scintigraphy 
or ultrasound have been carried out in patients with a normal thyroid, a diffusely 
enlarged gland or, in some cases, a solitary thyroid nodule. Most of the formulae 
used for the calculation of thyroid volumes are based on the assumption that the 
thyroid lobes are ovoid. This assumption is valid for most normal and diffusely 
enlarged thyroid glands. However, in multinodular goiters thyroid shape is 
often distorted by the presence of nodules of varying size. It can, therefore, 
be assumed that the accuracy of both techniques will be lower in multinodular 
goiters. Ultrasound is probably sufficient for smaller multinodular glands if 
planimetry of serial slices is used instead of a formula based on an ovoid shape 
of the thyroid lobes [19]. However, as sternum and clavicles present anatomic 
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limitations for ultrasound measurements, this technique cannot be used for the 
measurement of large multinodular goiters, because of intrathoracic extension 
in most of these cases. 
In this study, MR imaging (Tj-weighted sequences) was used for the mea-
surement of the anatomical volume of large multinodular goiters. MR measure-
ments showed a very high precision (i.e. the degree to which repeated compu-
tations are reproducible). Intraobserver and interobserver variability were very 
small (CV 2% and 4%, respectively) and the correlations between measurements 
in the three imaging planes were excellent. Scintigraphic estimations showed 
considerably larger intraobserver and interobserver variability than MR esti-
mations (CV 7% and 10%, respectively). Although scintigraphic volume esti-
mations were significantly correlated with MR measurements, important differ-
ences were found in a considerable number of patients and comparison of the 
two methods showed a CV as large as 17%. 
There is no valid gold standard for volume measurements of large goiters. 
The volume of the surgical specimen does not represent the true thyroid volume 
because of manipulation, squeezing and bleeding during operation. Further-
more, (near-Complete removal of large goiters is virtually impossible (and visual 
estimation of the volume of the retained tissue adds to the inaccuracy). Thus, 
because surgical, and even post mortem, specimens [12] cannot be regarded as 
a true gold standard, it is impossible to determine the accuracy of MR mea-
surements (i.e. the closeness of the computations to the true values) in patients 
with a large multinodular goiter. However, as MR measurements showed a 
very good reproducibility, this technique should be reliable in the evaluation of 
thyroid growth and the assessment of non-surgical treatment of goiters. 
It is concluded that MR imaging can be used for in vivo thyroid volume esti-
mation in large multinodular goiters. The high precision of MR measurements 
makes this technique potentially useful for the evaluation of thyroid growth and 
impact of non-surgical therapy of goiters. Scintigraphic volume measurements 
do not suffice for this purpose. An additional advantage of MR imaging is the 
detailed anatomical information it provides with regard to mechanical compli-
cations of large goiters. 
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Objective: lb evaluate the effectiveness of radioiodine therapy as an 
alternative for surgery in elderly patients with a large, compressive goi­
ter using objective methods for measuring thyroid volume and tracheal 
compression. 
Design: Prospective study. 
Setting: University hospital in the Netherlands. 
Patients: 19 patients aged 66 ± 14 years (mean ± SD) with a large, 
compressive multinodular goiter who had a high operative risk or re­
fused to have thyroid surgery. 
Intervention: A single intravenous dose of 1 3 1 I at 2.6 ± 1.0 GBq 
(70 ± 28 mCi; 3.7 MBq or 100 \LC\Jg of thyroid tissue), followed by daily 
administration of L-thyroxine in doses that did not suppress thyroid-
stimulating hormone. 
Measurements: Clinical evaluation and measurements of thyroid vol­
ume, maximal tracheal deviation, and the smallest cross-sectional area 
of the tracheal lumen with magnetic resonance imaging before and 
1 year after 1 3 1 I treatment. 
Results: No exacerbation of compressive symptoms after 1 3 1 I therapy 
was observed. Thyroid volume was 269 ± 153 mL before treatment 
and 154 ± 73 mL 1 year after treatment (p < 0.001). Thyroid volume 
was reduced 40% ± 15% (range, 19% to 68%). Maximal tracheal devi­
ation (1.9 ±0.8 cm before and 1.5 ±0.7 cm 1 year after therapy) had 
decreased by 20% ± 20% (range, -4% to 73%; ρ < 0.001), and the small­
est cross-sectional area of the tracheal lumen (0.78 ± 0.38 cm2 before 
and 1.04 ± 0.48 cm2 1 year after therapy) had increased by 36% ± 38% 
(range, - 3 % to 125%; ρ < 0.001). Clinical signs and symptoms improved 
in 8 of 12 patients with dyspnea and inspiratory stridor and in both pa­
tients with compression of the superior vena cava. 
Conclusions: Therapy with 1 3 1 I is an effective alternative to surgery 
for elderly patients with a large, compressive multinodular goiter. 
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7.1 Introduction 
Surgical treatment is considered standard therapy for patients with a large, 
compressive multinodular goiter. However, although thyroid surgery leads to 
rapid tracheal decompression in most patients [1], it is not without risk [2-4]. 
Moreover, goiters recur after surgery in 10% to 20% of patients [5, 6]. Surgical 
morbidity (hemorrhage and infection, dyspnea caused by tracheomalacia or re­
current nerve damage, and hypoparathyroidism) and mortality are highest in 
patients with very large goiters and in those who have another operation [2, 4, 
7]. In elderly patients, surgical treatment of a large, compressive goiter may 
be contraindicated because of cardiac or pulmonary disease; in addition, some 
patients refuse to be operated on. Berghout and colleagues [8] reported that in 
about half of their patients with a smaller nontoxic goiter (mean volume, 53 mL), 
thyroid volume decreased by 25% during treatment with L-thyroxine in thyroid-
stimulating hormone (TSH)-suppressive doses. The efficacy of this treatment 
in large, compressive nodular goiters is probably much lower [9]. Radioiodine 
therapy may be an alternative for these patients. However, most clinicians are 
reluctant to use radioiodine in patients with a large, compressive multinodular 
goiter because until now, reduction of thyroid volume by radioiodine therapy 
had not been assessed with objective methods and reversibility of compressive 
symptoms had not been shown. We treated 21 patients with a large, compres­
sive multinodular goiter using a single dose of radioiodine followed by daily 
administration of a nonsuppressive dose of L-thyroxine. Before and 1 year after 
radioiodine treatment, anatomical assessment was done by magnetic resonance 
imaging (MRI). This technique allows high-precision measurements of thyroid 
volume, tracheal compression, and tracheal deviation [10]. We used medical in­
terview, physical examination, and pulmonary function tests to assess functional 
results. 
7.2 Methods 
Patients 
Twenty-one patients, 18 women and 3 men aged 67 ± 14 years (mean ± SD; 
range, 46 to 86 years), were entered into the study. All patients had a large, 
multinodular goiter (greater than 100 mL) that caused tracheal compression. 
Multinodularity was confirmed by thyroid scintigraphy that was done 2 hours 
after intravenous administration of 37 MBq (1 mCi) of sodium iodide (1 2 3I). 
Nineteen patients had intrathoracic extension of the goiter of more than 2 cm, 
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as shown on MRI. One patient had a completely intrathoracic goiter. There 
was no clinical suspicion of thyroid malignancy in any patient. In two patients 
with a large cold nodule, examination of fine-needle aspiration biopsy specimens 
showed no signs of malignancy. Radioiodine treatment was chosen because of 
the high operative risk primarily related to cardiopulmonary disease or because 
the patient refused to have surgery. 
Seventeen patients were clinically euthyroid and had serum free thyroxine 
(1T4) and total triiodothyronine (T3) levels within the normal range of our labo­
ratory (1T4, 9.0 to 17.0 pmol/L; T3 1.5 to 3.5 nmol/L). In five of these patients, the 
serum TSH level was clearly suppressed (<0.1 mU/L). For treatment of hyper­
thyroidism, four patients received a thyroid-blocking dose of methimazole, which 
was combined with L-thyroxine to prevent hypothyroidism. Thyroid surgery had 
been done in eight patients (in one patient twice and in another three times) 4 to 
50 years before radioiodine treatment. One euthyroid patient had been treated 
with 1.1 GBq (40 mCi) of radioiodine for hyperthyroidism 4 years before enter­
ing into our study. In three of the euthyroid patients, previous TSH-suppressive 
treatment with L-thyroxine had not reduced goiter size and had been stopped 
3 months before radioiodine treatment. 
Radioiodine therapy 
Radioiodine was given as a single intravenous dose on an in-patient basis. 
Corticosteroids were not administered routinely. The administered activity 
was aimed at delivering 3.7 MBq (100 цСі) of 131I/g of thyroid tissue retained 
at 24 hours according to the following formula [11]: administered activity 
(GBq) = thyroid weight (g) χ 0.37 / 24-hour thyroid radioactive iodide uptake (%). 
Twenty-four hours after patients orally ingested 7.4 MBq (200 цСі) of 1 3 1 I , we 
measured 1 3 1 I thyroid radioactive iodide uptake (normal range, 10% to 59%) 
and made a rectilinear thyroid scintigram. We estimated thyroid weight from 
the planimetrie surface on the scintigram using the formula of Doering and 
Kramer [12]: thyroid weight (g) = 0.326 χ (surface in cm2)372. After radioiodine 
therapy, euthyroid patients were treated with L-thyroxine to keep serum TSH 
levels below 1.5 mU/L. Hyperthyroid patients continued to receive the combina­
tion therapy with methimazole and L-thyroxine during the first 6 months after 
radioiodine therapy (patients did not receive methimazole for 3 days before and 
3 days after therapy). 
Assessment of anatomical and functional results 
We assessed anatomical and functional measurements before and 1 year after 
radioiodine therapy. In a medical interview and physical examination, special 
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attention was paid to compressive symptoms and signs (such as inspiratory 
stridor, dyspnea, voice changes, and the Homer syndrome). The same observer 
measured maximal neck circumference and central venous pressure before and 
1 year after radioiodine therapy. Blood samples were obtained for measurement 
of serum levels of TSH (Delfia hTSH Ultra, Wallac Oy, Turku, Finland), T4 (in-
house radioimmunoassay), T3 (Amerlex-M T3, Kodak Clinical Diagnostics Ltd, 
Amersham, United Kingdom), fT4 (SPAC fT4, Byk-Sangtec Diagnostica, Diet­
zenbach, Germany) and thyroglobulin (IRMA-mat Thyroglobulin, Byk-Sangtec 
Diagnostica). We determined 24-hour thyroid radioactive iodide uptake as de­
scribed above. 
Thyroid volume was measured with MRI (Siemens Magnetom 63SP, Erlan­
gen, Germany) operating at a field strength of 1.5 tesla. We obtained ^-weighted 
images (TR = 270 ms, ТЕ = 15 ms) by using a Helmholtz neck coil and covering 
the entire thyroid in the coronal, sagittal, and axial planes. The thyroid out­
line was drawn manually on each slice, and a computer program calculated the 
surface of the traced areas. To calculate the thyroid volume, we multiplied the 
sum of the traced surfaces in each plane by the slice distance (0.88 cm). Thy­
roid volume, as used hereafter, is the mean of the measurements in the three 
imaging planes. Precision of this method is high. In patients with a large, mul­
tinodular goiter, the intraobserver coefficient of variation is 2.2% ±2.0%, and 
the interobserver coefficient of variation is 4.1% ± 2.2% (10). We used axial MRI 
slices to measure the largest deviation of the center of the tracheal lumen from 
the midline (orientated on the center of the vertebral canal and the spinous 
processes and supraspinal ligaments). The smallest cross-sectional area of the 
tracheal lumen, a measurement of tracheal compression (13), was measured 
planimetrically in axial MRI slices. All measurements were done blinded. 
We measured forced inspiratory volume in 1 second (FrVj) as a functional 
index of upper-airway obstruction. We compared values of our patients with 
values obtained from age- and sex-matched normal persons (14). Reference 
values are described by the following equation: ПЛ^ (mL) = (-0.0025 χ age in 
years+0.69) χ total lung capacity (mL). An FrVj that was more than 20% less 
than the reference value was considered below normal. An otolaryngology spe­
cialist tested the vocal cord motility of all patients before and 1 year after radio-
iodine therapy. 
Statistical analyses were done using the Wilcoxon sign-rank test for paired 
observations (p-values denoted as p) and the Spearman rank-correlation test 
(p-values denoted as p*). The mean values ± 1 standard deviation are given. 
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7.3 Results 
After intravenous administration of 1 3 1 I in a dose of 2.6 ±1.0 GBq (71 ± 26 mCi; 
range, 1.4 to 5.6 GBq or 37 to 150 mCi), patients were hospitalized for 5 to 
21 days. We observed no exacerbation of compression symptoms after patients 
received radioiodine. Two patients had a sore throat that was probably caused 
by radiation sialadenitis or esophagitis, but spontaneous and complete recovery 
was reached within 4 weeks. We observed no symptoms or signs of thyrotoxicosis 
caused by radiation thyroiditis. 
Of the 21 patients who entered the study, 19 could be evaluated 1 year after 
radioiodine therapy. An 84-year-old euthyroid woman had died of an unrelated 
cardiac cause 1 month after radioiodine therapy. A 67-year-old hyperthyroid 
woman had thyroid surgery because of insufficient relief of tracheal compression 
despite a second dose of 1 3 1 I that was given 7 months after the first dose (total 
dose, 6.4 GBq or 173 mCi). Thyroid volume was reduced 10% as measured 
by MRI at the time of operation (10 months after the first dose of 1 3 1I), and 
the smallest cross-sectional area of the tracheal lumen and the FIV1 had not 
changed. 
Anatomical results 
Table 7.1 shows anatomical results of the 19 patients who were evaluated be­
fore and 1 year after radioiodine therapy. Before therapy, thyroid volume as 
measured with MRI was 269 ± 153 mL (range, 109 to 825 mL). One year af­
ter radioiodine therapy, thyroid volume was 154 ±73 mL (range, 57-381 mL; 
ρ < 0.001). Expressed as the percentage of pretreatment thyroid volume, re­
duction was 40% ±15% (range, 19% to 68%; Figure 7.1). Neck circumference 
decreased by 3 ± 2 cm (range, 0 to 8.0 cm). The circumference of one patient 
with a completely intrathoracic goiter decreased 0 cm. The decrease in neck cir­
cumference was significantly correlated with the percentage of volume reduction 
(r = 0.557; p*< 0.02). 
The maximal deviation of the trachea from the midline was 1.9 ±0.8 cm 
(range, 0.2 to 3.1 cm) before and 1.5 ± 0.7 cm (range, 0.2 to 2.6 cm) 1 year after 
radioiodine therapy (p < 0.001). The mean decrease was 20% ±20% (range, 
-4% to 73%; Figure 7.1). In 13 patients, tracheal deviation decreased more 
than 10% (including a 20% to 30% decrease in 4 patients and a greater than 
30% decrease in 4 patients). 
The smallest cross-sectional area of the tracheal lumen was 0.78 ± 0.38 cm2 
(range, 0.29 to 1.70 cm2) before therapy and 1.04 ±0.48 cm2 (range, 0.30 to 
2.19 cm2; ρ < 0.001) after therapy. The mean increase was 36% ±38% (range, 
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- 3 % to 124%; Figure 7.1). We observed an increase of more than 10% in 15 pa-
tients (including an increase of 50% to 100% in 6 patients and an increase of 
more than 100% in 2 patients). In four patients, the smallest cross-sectional 
area of the tracheal lumen changed very little (<5%). Increase of the smallest 
cross-sectional area of the tracheal lumen was significantly correlated with the 
decrease of thyroid volume (r = 0.727; p*< 0.001). 
Figure 7.1 Thyroid volume deft), maximal deviation of the tracheal center 
from the midline (middle), and smallest cross-sectional area of 
the tracheal lumen (SCAT; right) measured before and 1 year af-
ter radioiodine therapy in 19 patients with a large, compressive 
multinodular goiter. Data are expressed as percentages of pre-
treatment values 
Thyroid Volume (%) Tracheal Deviation (%) SCAT (%) 
120 120 
100 
before after before after before after 
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Functional results 
The FIV! was 2285 ± 1145 mL before therapy (range, 675 to 4450 mL) and 
2515 ± 1129 mL after therapy (range, 775 to 4600 mL; ρ < 0.01). In 8 of 18 pa­
tients, the FrV
x
 increased more than 10% (11% to 20% in 3 patients, 21% to 
30% in 2 patients, 31% to 50% in 2 patients, and 120% in 1 patient). Before 
radioiodine treatment, FrV
x
 was below normal (that is, more than 20% less than 
the reference value) in 6 patients. One year after therapy, it had returned to 
normal in 2 of these patients and had considerably improved in 2 others. The 
2 patients in whom FIVj had not improved had vocal cord paralysis caused by 
previous surgery. Symptoms of superior vena cava obstruction disappeared in 
1 patient (Figure 7.2), and elevated central venous pressure returned to normal 
in another patient. 
Figure 7.2 Patient 17 before and 1 year after treatment with 5.6 GBq (150 
mCi) of 131I. Note the distended neck veins and edematous face 
as signs of compression of the superior vena cava before therapy 
(A) and their improvement 1 year after therapy (B). Published by 
permission of patient 
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Table 7.2 shows the effects of radioiodine treatment on subjective patient 
reports that were related to compression of the trachea and esophagus. Dyspnea 
and stridor improved in 8 of 12 patients, and dysphagia improved in 7 of 8 pa-
tients. As reported by the patients, the most important subjective improvement 
was achieved within the first 3 months after radioiodine treatment. 
Table 7.2 Functional results of treatment with radioiodine and L-thyroxine 
in 19 patients with a large, compressive multinodular goiter * 
Before 131I 1 year after 131I therapy 
therapy 
No changea Improved Cured 
Dyspnea 12 4 1 7 
Inspiratory stridor 12 4 2 6 
Dysphagia 8 1 1 6 
* Numbers of patients are given; functional data obtained before and 1 year after 
radioiodine therapy 
a
 Two of the patients in whom dyspnea and stridor were unchanged after therapy had 
vocal cord paralysis caused by previous thyroid surgery 
Thyroid function after radioiodine therapy 
Hyperthyroidism was eliminated within 6 months in the four hyperthyroid pa-
tients. Patient 9, who was clinically euthyroid before therapy and had nor-
mal fT4 and T3 levels and a suppressed TSH level, developed hyperthyroidism 
7 months after radioiodine treatment. At that time, antithyroglobulin and an-
timitochondrial antibodies were negative. The 3-hour thyroid radioactive iodide 
uptake was 64% (normal range, 5% to 30%), and examination of a scintigraph 
of the thyroid showed an almost diffuse 123I uptake in the whole thyroid gland. 
The patient was treated with methimazole for 9 months and received a second 
dose of radioiodine (1.8 GBq or 67 mCi) 16 months after the first radioiodine 
treatment. We could not accurately assess the effects on thyroid function in 
the other euthyroid patients because of L-thyroxine treatment after radioiodine 
therapy. The 24-hour thyroid radioactive iodide uptake was 40% ± 15% (range, 
24% to 72%) before radioiodine treatment and 19% ± 14% (range, 2% to 58%) 
1 year after therapy. One year after therapy, four patients had a 24-hour thy-
roid radioactive iodide uptake that was less than normal (<5%). We observed 
no consistent changes in serum thyroglobulin levels. 
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7.4 Discussion 
Our study clearly shows the efficacy of treatment with radioiodine in patients 
with a large, compressive multinodular goiter. One year after radioiodine ther­
apy, thyroid volume as measured with MRI was reduced by 40%. Even more 
clinically important is our finding of a significant decrease of tracheal compres­
sion after radioiodine treatment: We observed a widening of the tracheal lumen 
at its narrowest point by an average of 36%. The tracheas of 15 of 19 patients 
widened more than 10%, and deviation of the trachea from the midline decreased 
more than 10% in 13 of 19 patients. Improvement of these anatomical measure­
ments was accompanied by improvement of clinical signs and symptoms in 8 of 
12 patients with dyspnea and inspiratory stridor. Furthermore, symptoms of 
obstruction of venous flow improved in both patients with compression of the 
superior vena cava. Forced inspiratory volume in 1 second improved by more 
than 10% in 8 patients. 
Few other reports have described the results of radioiodine therapy on vol­
ume reduction of large goiters [15-18]. However, the techniques used to esti­
mate volume reduction in these studies — palpation, measurement of maximal 
neck circumference, and planar thyroid scintigraphy — are notoriously impre­
cise; none of these investigators evaluated tracheal compression with objective 
methods. Having used ultrasound to measure thyroid volume, Nygaard and col­
leagues [19] recently reported effects of radioiodine treatment in small nontoxic 
goiters (median volume, 73 mL). These investigators observed a 42% volume 
reduction 1 year after radioiodine therapy. However, ultrasound cannot be used 
for large goiters because of frequent intrathoracic extension [20, 21]. We there­
fore used MRI, which is not limited by intrathoracic extension of the goiter, 
to evaluate the effect of radioiodine treatment in large goiters (mean volume, 
269 mL). 
The routine prescription of L-thyroxine after radioiodine treatment pre­
vented us from accurately assessing the rate of hypothyroidism. However, only 
4 of 19 patients had a below-normal 24-hour radioiodine uptake 1 year after 
therapy. Nygaard and colleagues [19] also observed a relatively low rate of hy­
pothyroidism. They calculated a 22% rate of hypothyroidism after 5 years using 
the life table method. In contrast, Vereist and colleagues [18], despite the use 
of doses of radioiodine similar to those used by Nygaard and coworkers, found 
that 30% of the patients studied had hypothyroidism 3 years after therapy; after 
8 years, all living patienta were hypothyroid. Hyperthyroidism developed in one 
of our euthyroid patients 7 months after radioiodine treatment. Other investi­
gators [19, 20] have also observed this late development of hyperthyroidism and 
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have suggested that it is an autoimmune phenomenon triggered by irradiation-
induced antigen release [22]. Furthermore, patients should be watched carefully 
for signs of thyrotoxicosis caused by radiation thyroiditis, especially in the first 
weeks after radioiodine therapy for a large goiter. 
Radioiodine is a widely accepted treatment for thyrotoxicosis. However, 
most clinicians are reluctant to administer radioiodine to reduce the volume of 
large, compressive goiters for fear of exacerbating compressive symptoms and 
because of concern for too-high absorbed doses of radiation. We observed no 
exacerbation of compression symptoms necessitating corticosteroid medication 
after radioiodine treatment. This is in accordance with the experience of other 
investigators [15-19]. Thus, radiation thyroiditis causing thyroid swelling and 
increase of compression symptoms appears to be rare. In our study, patients 
received 3.7 MBq (100 μϋΐ) of 131I/g of thyroid tissue, a dose commonly used 
for treating hyperthyroidism caused by diffuse or nodular goiter [23]. For toxic 
nodular goiter, even higher doses are frequently used [24-26]. In a separate 
dosimetric study in patients with large toxic and large nontoxic multinodular 
goiters (mean thyroid volume, 200 mL in both groups), we calculated mean radi­
ation absorbed doses of 80 Gy (8000 rad) in the thyroid, 4 Gy (400 rad) directly 
near the thyroid, and 0.05 to 0.6 Gy (5 to 60 rad) in other tissues; we observed 
no significant differences between hyperthyroid and euthyroid patients. The 
effective dose to the whole body was 4 sievert (400 rem) for both hyperthyroid 
and euthyroid patients. The observed absorbed doses in extrathyroidal tissues 
are higher than those after radioiodine treatment of small goiters. The risk 
for leukemia and cancer after radioiodine therapy in patients with small goiters 
does not appear to be elevated [27]. Such data are not available for large goiters 
treated with higher doses of radioiodine. Because radiation-induced carcinogen­
esis is a late effect, this risk is less important in elderly patients. In view of 
these considerations, we believe radioiodine treatment of large goiters should 
be restricted to elderly patients. 
Our study has some limitations. First, follow-up was restricted to 1 year 
after radioiodine treatment. Further follow-up will show whether the excellent 
anatomical and functional results, as shown in our study, persist. In this respect, 
it is of interest that, in the study of Nygaard and colleagues [19], the volume of 
small nontoxic goiters was reduced 42% 1 year after radioiodine therapy but was 
reduced 60% after a median follow-up of 60 months. Second, we cannot exclude 
with certainty the possibility that the observed effects of radioiodine therapy are 
influenced by the use of L-thyroxine after radioiodine treatment in the euthyroid 
patients or by the combination therapy of methimazole and L-thyroxine in the 
hyperthyroid patients. It is unlikely, however, that the routine prescription of 
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L-thyroxine after radioiodine therapy in our study contributed substantially to 
the observed reduction in thyroid volume because this medication was admin­
istered in non-TSH-suppressive doses and because even TSH-suppressive doses 
are not likely to effectively reduce the volume of large, multinodular goiters [9]. 
Methimazole, which shortens the biological half-life of radioiodine in the thy­
roid, could have negatively affected the effectiveness of radioiodine. However, 
in three of the four hyperthyroid patients, thyroid volume was reduced more 
than 35% 1 year after therapy. Third, the administered amounts of radioiodine 
in our study were not based on accurate measurements of the functional vol­
ume within the thyroid gland. Single-photon emission computed tomography or 
positron emission tomography may prove to be useful tools for more accurate 
planning of therapeutic doses of radioiodine for nodular goiters. The accuracy of 
these techniques and the therapeutic surplus value of more accurate measure­
ments of the functional volume of nodular goiters should be evaluated in further 
studies. 
In conclusion, our study shows a 40% reduction of thyroid volume and clin­
ically significant decompression of vital structures 1 year after treatment with 
radioiodine and L-thyroxine in patients with a large, compressive goiter. We 
recommend this treatment as an effective alternative for surgery in elderly pa­
tients. 
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In patients with a large, multinodular goiter OlOOg), radiation ab-
sorbed doses in the thyroid, surrounding tissues and remainder of the 
body were estimated after therapeutic administration of 131I (3.7 MBq/g 
of thyroid tissue retained at 24 h). 
Methods: Thermoluminescent dosimeter (TLD) measurements were 
performed in 23 patients (12 eu- and 11 hyperthyroid; thyroid weight 
222 ±72 g (mean ± SD); administered activity 2.1 ±0.9 GBq) on the 
skin over the thyroid, over the submandibular gland and over the 
parotid gland. Thyroid radioactivity measurements were done daily in 
6 eu- and 6 hyperthyroid patients (thyroid weight 204 ± 69 g; adminis-
tered activity 1.9 ± 0.9 GBq). An iodine biokinetic model and the MIRD 
method were used to estimate absorbed doses in organs. Cancer risks 
were calculated using ICRP Publication 60. 
Results: Cumulated absorbed doses on the skin (TLD measurements) 
were 4.2 ± 1.4 Gy over the thyroid, 1.2 ± 0.6 Gy over the submandibular 
gland and 0.4 ± 0.2 Gy over the parotid gland. All these values were 
significantly correlated with the amount of radioiodine retained in the 
thyroid at 24 h and no significant differences were present between eu-
and hyperthyroid patients. Absorbed doses in the thyroid of 84 ± 22 Gy 
for eu- and 83 ± 15 Gy for hyperthyroid patients were calculated (thyroid 
radioactivity measurements). Extrathyroidal absorbed doses (averages 
of 12 patients) were 0.88 Gy in the urinary bladder, 0.57 Gy in the small 
intestine, 0.38 Gy in the stomach, and ranged from 0.05 to 0.30 Gy in 
other organs (no significant differences between eu- and hyperthyroid 
patients). A 1.6% life-time risk of development of cancer outside the 
thyroid gland was calculated. When applied to people of 65 years and 
older the estimated risk is approximately 0.3%. 
Conclusions: These data may help in choosing the treatment in the 
individual patient with a large, multinodular goiter, who has to be 
treated for hyperthyroidism or compressive problems. In younger pa-
tients surgery may be preferred. However, for elderly patients and pa-
tients with cardiopulmonary disease, the profits of non-invasive radio-
iodine treatment will outweigh the life-time risk of this mode of therapy. 
8.1 Introduction 
Surgery is standard therapy for patients with a large, toxic or nontoxic, compres-
sive goiter. However, it is not without risk, especially in elderly patients with 
cardiopulmonary disease [1, 2, 3]. Radioiodine, a widely accepted treatment for 
patients with toxic, non-compressive goiters, is an alternative for these patients. 
In a recent study, we have shown that radioiodine therapy can induce an average 
reduction in thyroid volume of 40% after one year and a significant widening of 
the tracheal lumen in patients with a large, compressive multinodular goiter [4]. 
However, a cause for reluctancy to treat these patients with radioiodine may be 
a concern for too-high radiation absorbed doses. Many commonly used dosage 
schedules for radioiodine therapy are aimed at delivering a certain amount of 
radioiodine per gram of thyroid tissue retained in the thyroid gland at 24 hours. 
The use of such a dosage schedule implies that large amounts of radioiodine are 
administered to patients with a large, nodular goiter. 
The present study is focused on the dosimetric aspects of radioiodine ther-
apy in patients with such a large goiter. We have estimated absorbed doses 
in the thyroid, in tissues directly near the thyroid and in tissues and organs 
in the remainder of the body after therapeutic administration of radioiodine in 
hyperthyroid and in euthyroid patients with a large, multinodular goiter. Ther-
moluminescent dosimetry was used to estimate the radiation burden of tissues 
directly near the thyroid gland. Estimations of absorbed doses in the thyroid 
and in the remainder of the body were made using thyroid radioactivity mea-
surements and a model of iodine kinetics in the body as described by Robertson 
and Gorman [5]. Risks of the development of radiation-induced cancer were 
assessed, based on the 1990 Recommendations of the International Commission 
on Radiological Protection [6]. 
8.2 Patients and methods 
Patients and radioiodine treatment 
Twenty three consecutive patients with a multinodular goiter of more than 100 g, 
as estimated from palpation and planar thyroid scintigraphy [7], were treated 
with radioiodine. The diagnosis of multinodular goiter was based on the pres-
ence of one or more thyroid nodules at palpation and an irregular distribution 
of [123I] or [131I] sodium iodide on a thyroid scan. Patients with a solitary hot 
nodule were excluded. In the 11 patients with toxic multinodular goiter the pri-
mary aim of radioiodine therapy was to treat hyperthyroidism. Eight of them 
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had compressive symptoms. All euthyroid patients (n = 12) sought treatment 
for compressive symptoms. In these patients radioiodine therapy was chosen be­
cause of contraindications for surgery (n = 8; mainly because of cardiopulmonary 
disease) or refusal of the patient to undergo surgery (n = 4). Patients were classi­
fied as euthyroid when they had serum free thyroxine (fT4) and triiodothyronine 
(T3) levels within the normal range of our laboratory (fT4, 9.0-17.0 ртоІЛ; T3, 
1.5-3.5 птоІЛ) and were not taking antithyroid or thyromimetic drugs. The 
serum level of thyroid-stimulating hormone (TSH) was subnormal (<0.4 mU/1) 
in seven of them. In two euthyroid patients prior TSH-suppressive treatment 
with L-thyroxine had failed to diminish goiter size. L-thyroxine had been with­
drawn 2 months before radioiodine treatment in these patients. All hyperthyroid 
patients used methimazole and L-thyroxine. They did not receive methimazole 
for 3 days before and 3 days after radioiodine therapy. Radioiodine was given 
as a single intravenous dose on an in-patient basis. The administered activity 
was aimed at delivering 3.7 MBq of 1 3 1 I per gram of thyroid tissue retained 
at 24 hours, according to the formula: administered activity (GBq) = thyroid 
weight (g) χ 0.37 / 24-hour thyroid radioactive iodide uptake (%) [8]. Thyroid 
radioactive iodide uptake (RAIU) was measured 24 hours after oral ingestion 
of 7.4 MBq (200 цСі) of 1 3 1 I (normal range 10%-59%). The thyroid weight was 
estimated from the planimetrie surface on a rectilinear thyroid scintigram using 
the formula of Doering and Kramer: thyroid weight (g) = 0.326 χ (surface 'in 
c m
2)3/2 [ 7 ] 
Thermoluminescent dosimeter measurements; dosimetric calculations 
Thermoluminescent dosimeter (TLD) measurements were performed following 
the therapeutic administration of radioiodine in 12 euthyroid and in 11 hyper­
thyroid patients. Two freshly annealed TLDs (LiF TLD 100, Harshaw, Ohio) 
sealed in a thin polyethylene bag were positioned with sticking plaster on the 
skin on each of the following three locations: directly over the thyroid gland, 
over the submandibular gland and over the parotid gland. The TLD on the thy­
roid gland was placed over the center of the most prominent nodule, which was 
checked not to be "cold" on thyroid scintigraphy. Distances between the TLDs 
on the salivary glands and the palpated ipsilateral top of the thyroid were mea­
sured. The TLDs were left in position for 24 hours, and replaced daily for 5 to 
15 days after the therapeutic administration of radioiodine. After preanneal-
ing, TLDs were read for light output (in nanocoulombs) on a TLD reader under 
dry N 2 (Harshaw Model 4000, Ohio, software WINTLDM 2.1). The calibration 
factor of TLDs for the gamma irradiation of 1 3 1 I , as checked in vitro, was 100 mi-
crogray per nanocoulomb (цОу/пС). From a previous study [4] in patients with a 
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large, multinodular goiter (nine of whom also participated in the present study) 
it appeared that the distance between the surface of the thyroid and the surface 
of the skin, as determined from axial magnetic resonance imaging slices, was 
more than 5 mm. Therefore, the contribution of beta irradiation was assumed 
to be negligible on the surface of the skin. 
TLD measured values from day 2 onward were fitted monoexponentially and 
extrapolated to infinity. The measured values and the integral of the extrapo­
lated function were summed for each location in order to determine cumulated 
absorbed doses on the skin (Gy). 
Thyroid radioactivity measurements; dosimetric calculations; risk esti­
mates 
In 6 euthyroid and in 6 hyperthyroid patients, thyroid radioactivity measure­
ments were performed every 24 hours after the therapeutic administration of 
radioiodine for 7 to 14 days. A 3" χ 3" Nal(Tl) detector was used with a lead-
shield placed in front of it in order to reduce the count rate and avoid dead-time 
effects. Measurements were corrected for a standard with a known activity of 
1 3 1 I and all values were corrected for background radioactivity, for thyroid ra­
dioactivity from 1 3 1 I previously injected for diagnostic purposes and for physical 
decay. 
Thyroid radioactivity measurements were implemented in a simplified 
model for iodine biokinetics as described by Robertson and Gorman [5]. In this 
model, intravenously administered radioiodide is removed from the extrathy-
roidal inorganic iodide compartment (B) by excretion into the urinary iodide 
compartment (U), with fractional removal rate η (in h-1), and by uptake into 
the thyroid (T), with fractional uptake rate r2 (in h-1). In the thyroid radioiodide 
is incorporated in thyroglobulin. A 24 hour delay in the secretion of radioiodi-
nated thyroid hormones is assumed [5]. After that time, the loss of radioactivity 
from the thyroid into the compartment of extrathyroidal radioiodinated thyroid 
hormone (P) is indicated by the fractional secretion rate r3 (in h-1). Degradation 
of the radioiodinated thyroid hormone is assumed to be instantaneous [5]. The 
rate of (renal) excretion of radioiodide resulting from thyroid hormone degrada­
tion is supposed to equal that of the administered inorganic iodide. The model 
does not take into account re-uptake into the thyroid of radioiodide resulting 
from thyroid hormone degradation outside the thyroid. A system of differential 
equations, using the three rate constants, rlt r2 and r3, and the physical decay 
constant λ (0.00359 h"1) describes the rates of changes of radioactivity in the 
four compartments (B, T, U and P). The solutions of the differential equations 
describe the fractional activities, i.e. the fractions of the administered activity at 
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time t in each of the compartments. These fractional activities are integrated in 
order to obtain the cumulated (time-integrated) fractional activities (cumulated 
activity per MBq of administered activity in MBq.h/MBq, i.e. in h; this param­
eter is also referred to as residence time) in each of the four compartments 
(Appendix, formulas 1-4). Time-integrated activities resulting from the total 
administered activities of radioiodine are referred to as cumulated activities (in 
MBq-h). 
Serum creatinine levels were within the normal range in all patients. There­
fore, an r
x
 of 0.072 h_1 based on a normal renal function was assumed for all 
patients in our study [9]. The r2 was calculated from the radioactivity mea­
surement at 24 hours and from η (Appendix, formula 5). Thyroid radioactivity 
measurements from day 2 onward (corrected for physical decay) were fitted as 
a monoexponential function. The rate constant of this function was used as r3. 
In the biokinetic model of Robertson and Gorman [5] the extrathyroidal thy­
roid hormone and inorganic iodide compartments are combined and assumed to 
be evenly distributed throughout the body, outside the thyroid and urinary blad­
der. We made the following amendments to the biokinetic model based on data 
in MIRD pamphlet no. 12 and MIRD report no. 5 f 10, 11]. Of the extrathyroidal 
inorganic iodide compartment 15% was assumed to be located in the stomach 
and 17% in the small intestine. Of the extrathyroidal thyroid hormone compart­
ment 40% was assumed to be located in the liver (and, proportional to the weight 
of the liver, 2.4% of the inorganic iodide compartment). Corresponding percent­
ages of the residence times in the extrathyroidal inorganic iodide and thyroid 
hormone compartments were assigned to the stomach, small intestine and liver. 
The remaining parts of these residence times were assigned to the "total body" 
(i.e. evenly distributed throughout the body outside the thyroid, urinary bladder, 
stomach, small intestine and liver). In order to obtain the residence time in the 
urinary bladder, the cumulated fractional activity in the urine was corrected for 
voiding with a voiding interval of 4 hours. 
Radiation absorbed doses in organs were calculated using the MIRD method 
with tabulated S values for adults (i.e. the mean radiation absorbed dose in a 
target organ per unit cumulated activity in a source organ) [12]. The calculated 
residence times in the source organs thyroid, urinary bladder, stomach, small 
intestine and "total body" were entered in the MIRDOSE2 computer program 
(Oak Ridge, Tennessee). In all patients absorbed doses in the thyroid, as calcu­
lated in the MIRDOSE2 program, were corrected for the ratio normal thyroid 
weight (20 g) / measured thyroid weight. 
ICRP Publication 60 [6] was used to estimate the risk of radiation-induced 
cancer in our patients. In ICRP Publication 60, absorbed doses weighted by 
102 
a radiation factor (which is 1 for radiopharmaceuticals) are called equivalent 
doses (H; in sievert, Sv) [6]. The sum of the fatal cancer risk (estimated at 
5%/Sv), non-fatal cancer risk (estimated at 1%/Sv) and the risk of severe hered­
itary effects (estimated at 1.3%/Sv) is 7.3% per sievert total body irradiation 
and is called the total detriment [6]. These probability coefficients are appli­
cable to all equivalent doses resulting from absorbed doses below 0.2 Gy and 
from higher absorbed doses when the dose rate is less than 0.1 Gy per hour. 
The relative importance of each of the various organs in contributing to this 
detriment is expressed by its weighting factor Wj [6]. The detriment for each 
organ is expressed as WT Χ 7.3%/SV organ dose. The weighting factor for the 
gonads applies for 90% to the risk of severe hereditary effects and for only 10% 
to the gonadal (especially ovarian) cancer risk. For other organs the weighting 
factor only applies to the cancer risk. Furthermore, the values for tissue weight­
ing factors were used to determine the effective dose which is the sum of the 
weighted equivalent doses in all the tissues and organs of the body (effective 
dose = 52 WT · HT) [6]. Only the contributions of the organs and tissues out­
side the thyroid were summed, because equivalent and effective doses are not 
applicable to high doses as received by the thyroid during radioiodine therapy. 
Statistical analyses 
The mean values ± SD are given. Statistical analyses were done using the 
Mann-Whitney U test for unpaired observations (p-values denoted as p), the 
Wilcoxon sign-rank test for paired observations (p-values denoted as p*) and 
the Spearman rank correlation test (p-values denoted as p**). The level of sig­
nificance was 0.05. 
8.3 Results 
For detailed information on the effectiveness of radioiodine treatment for large, 
multinodular goiters with respect to reduction of thyroid volume and decompres­
sion of vital structures the reader is referred to a recently published study from 
our group [4]. Suffice it to mention here, that in the present group of patients 
thyroid volume reduction was satisfactory and that only one patient had to be 
treated with a second dose of radioiodine because of persistent hyperthyroidism. 
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Thermoluminescent dosimeter measurements 
Table 8.1 shows patient characteristics and data of TLD measurements on the 
skin over the thyroid, the submandibular and the parotid gland in 12 eu- and 
11 hyperthyroid patients. 
Table 8.1 Patient characteristics and data of thermoluminescent dosime­
try measurements after radioiodine treatment of euthyroid and 
hyperthyroid patients with a large multinodular goiter (>100 g). 
The mean values ± SD are given (in parentheses ranges are given) 
Euthyroid Hyperthyroid 
Number of patients 
Age (years) 
Female : male ratio 
Thyroid weight(g) 
24h RAIU (%) 
Administered activity 
of «il (GBq) 
Cumulated dose on skin 
thyroid (Gy) 
Cumulated dose on skin 
submandibular gland (Gy) 
Cumulated dose on skin 
parotid gland (Gy) 
Distance from thyroid to 
submandibular gland (cm) 
Distance from thyroid to 
parotid gland (cm) 
TLD measured effective 
half-time thyroid (days) 
12 
62 ±12 (44-81) 
11:1 
221 ± 8 1 (122-351) 
36 ±11 (21-56) 
2.3 ±0.8 (1.2-4.0) 
4.4 ±1.5 (2.4-7.2) 
1.2 ±0.6 (0.5-2.4) 
0.3 ±0.1 (0.2-0.8) 
4.7 ±2.0 (2.5-7.5) 
11 
71 ± 8 (57-82) 
8:3 
224 ±65 (130-312) 
51 ±14 (32-78) • 
1.8 ±0.8 (0.8-3.3) 
4.1 ±1.4 (2.0-6.3) 
1.3 ±0.6 (0.5-2.0) 
0.4 ±0.1 (0.2-0.7) 
4.3 ±1.7 (2.5-7.5) 
10.7 ±1.8 (8.5-13.5) 10.5 ±2.0 (8.0-13.5) 
6.1 ±0.8 (4.4-7.3) 5.5 ±0.7 (4.2-6.5) b 
a
 p<0.02 eu- versus hyperthyroid patients 
ь
 p<0.03 eu- versus hyperthyroid patients 
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The thyroid weight was similar in both groups of patients. The 24-h thy­
roid radioactive iodide uptake was significantly lower in euthyroid patients 
(p < 0.02). The total administered activity was higher in euthyroid than in 
hyperthyroid patients, although the difference was not significant. No signif­
icant differences in cumulated absorbed doses between eu- and hyperthyroid 
patients were observed at any of the three locations on the skin. 
Cumulated absorbed doses at all three locations were significantly corre­
lated with the total activity retained in the thyroid at 24 hours (administered 
activity χ 24-h RAIU) (r = 0.64, p**< 0.001 for the thyroid location; r = 0.70, 
p " < 0.001 for the submandibular location; r = 0.58, p**< 0.005 for the parotid 
location). The correlation between absorbed doses on the skin over the salivary 
glands and the total activity retained in the thyroid at 24 hours divided by the 
distance of these locations from the ipsilateral top of the thyroid gland was even 
higher (administered activity χ 24-h RAIU / distance) (r = 0.80, p**< 0.001 for 
the submandibular location and г = 0.68, p " < 0.003 for the parotid location). 
The correlation of the cumulated absorbed dose on the skin with the total ad­
ministered activity was only significant for the location over the thyroid gland 
(r = 0.56, p**< 0.01) and no correlation of cumulated absorbed doses on the skin 
with 24-h RAIU was found (p**> 0.1). The effective half-time of 1 3 1 I in the thy­
roid gland, as measured by TLDs, was significantly higher for euthyroid patients 
(6.1 ± 0.8 days) than for hyperthyroid patients (5.5 ± 0.7 days; p**< 0.03). 
Thyroid radioactivity measurements; dosimetric calculations; risk esti­
mates 
Table 8.2 shows patient characteristics and data of thyroid radioactivity mea­
surements in 6 eu- and 6 hyperthyroid patients. The thyroid weight was similar 
for eu- and hyperthyroid patients. 
There were no significant differences in administered activity, 24-h RAIU or 
effective half-time of 1 3 1 I in the thyroid (thyroid radioactivity measurements) be­
tween both groups. Residence times in source organs, as calculated from thyroid 
radioactivity measurements and the aforementioned biokinetic model [5] with 
modifications [10, 11], did not differ significantly between eu- and hyperthy­
roid patients, except for the residence time in the liver, which was significantly 
higher for hyperthyroid patients ( p " < 0.03) (Table 8.2). Effective half times of 
1 3 1 I in the thyroid resulting from thyroid radioactivity measurements were not 
significantly different from those measured with TLDs in the same 12 patients 
(Wilcoxon sign-rank test, p* = 0.7). Moreover, a highly significant correlation 
was found between the cumulated activity (in MBq-h) in the thyroid and the 
cumulated absorbed dose on the skin overlying the thyroid as measured with 
TLDs in the same 12 patients (r = 0.75, p " < 0.01). 
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Table 8.2 Patient characteristics and data of thyroid radioactivity measure­
ments after radioiodine treatment of euthyroid and hyperthyroid 
patients with a large multinodular goiter (>100 g). The mean 
values ± SD are given (in parentheses ranges are given) 
Euthyroid Hyperthyroid 
Number of patients 
Age (years) 
Female : male ratio 
Thyroid weight (g) 
24-h RAIU tracer 
activity (%) 
24-h RAIU therapeutic 
activity (%) 
Therapeutic activity 
of " i l (GBq) 
Effective half-time 
of « i l in thyroid (d) 
Biological half-time 
of 1 3 1 I in thyroid (d) 
Cumulated activity 
thyroid (MBq-h) 
Residence time of 1 3 1 I in 
- thyroid (h) b 
- stomach ( h ) c 
- small intestine ( h ) c 
- liver ( h ) c 
- rest body ( h ) c 
- urinary bladder ( h ) c 
65 ± 1 0 (52-81) 70±6 (63-80) 
5 : 1 3:3 
203 ± 8 4 (126-351) 206 ± 5 9 (130-274) 
37 ± 1 1 
37 ± 1 6 
(21-48) 
(17-58) 
51 ± 1 1 
52±5 
(35-63) • 
(47-59) » 
2.2 ± 1 . 1 (1.2-4.0) 
5.7 ± 0 . 4 (5.1-6.1) 
1.6 ± 0 . 6 (0.8-2.2) 
5.3 ± 0 . 5 (4.7-6.1) 
2 1 ± 6 (14-31) 1 8 ± 5 
160 ±110 (67-377) 155 ± 5 7 
(11-25) 
(82-215) 
77 ± 3 4 (37-120) 
1.23 ± 0 . 3 1 (0.84-1.62) 
1.40 ±0.35 (0.95-1.83) 
0.70 ±0.17 (0.47-0.90) 
6.3 ± 1 . 1 (4.9-7.6) 
1.5 ± 0 . 2 (1.2-1.7) 
99 ± 1 1 (82-116) 
0.96 ±0.08 (0.82-1.04) 
1.09 ±0.10 (0.93-1.18) 
1.00 ±0.16 (0.71-1.16) d 
5.5 ± 0 . 4 (5.0-6.0) 
1.3 ± 0 . 1 (1.2-1.4) 
a
 p<0.02 eu- versus hyperthyroid patients 
ь
 calculated from thyroid radioactivity measurements 
c
 calculated using thyroid radioactivity measurements and the biokinetic model of 
Robertson and Gorman [51 with amendments based on MIRD pamphlet no. 12 [10] 
and MIRD report no. 5 [11] 
d
 p<0.03 eu- versus hyperthyroid patients 
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Table 8.3 shows the calculated absorbed doses in the tissues and organs 
for which a tissue weighting factor has been determined [6], expressed as dose 
per unit of administered radioiodine (in mGy/MBq) and as dose resulting from 
the total administered activities of radioiodine (in Gy). Outside the thyroid 
gland the highest absorbed doses per MBq of administered 131I were calculated 
for the urinary bladder, followed by the stomach and small intestine. Inverse 
correlations were found between the 24-h RAIU and the absorbed doses per MBq 
in the stomach (r = -0.97, p**< 0.001), small intestine (r = -0.98, p**< 0.001) 
and urinary bladder (r = -0.85, p**< 0.01). The absorbed dose per MBq in the 
liver was positively correlated with the 24-h RAIU (r = 0.83, p**< 0.001). The 
absorbed dose per MBq in the liver was significantly higher in hyperthyroid than 
in euthyroid patients (p** < 0.03). There were no other significant differences 
for organ doses per MBq between eu- and hyperthyroid patients. 
Extrathyroidal doses resulting from the total administered activities ranged 
between 0.06 Gy (testes) and 1.06 Gy (urinary bladder) in euthyroid patients and 
between 0.04 Gy (testes) and 0.71 Gy (urinary bladder) in hyperthyroid patients 
(average values of six patients in both groups). No significant correlations of 
absorbed doses (Gy) with 24-h RAIU were found. The mean absorbed doses in 
most tissues were about similar for eu- and hyperthyroid patients (p > 0.3). 
The mean absorbed doses in stomach, small intestine and urinary bladder were 
higher for eu- than for hyperthyroid patients. However, these differences were 
not significant. 
The effective dose for the combined organs and tissues outside the thy-
roid gland was not significantly different for eu- (0.26 ± 0.14 Sv) and hyperthy-
roid patients (0.19 ±0.07 Sv). Using the total detriment of 7.3%/Sv given in 
ICRP Publication 60 [6], the life-time risk of cancer for the combined organs 
and tissues outside the thyroid can be estimated as 1.8% ± 1.0% for euthyroid 
patients and 1.3% ± 0.5% for hyperthyroid patients in the present study (differ-
ence eu- versus hyperthyroid not significant). A total detriment of 7.3% / Sv is, 
however, an average for a population of all ages. For people of 65 years and older 
the probability of radiation-induced cancer is only about one-fifth of the average 
[6]. Because 8 of 12 patients in the present study were older than 65 years and 
only one patient was younger than 60 years an estimate of approximately 0.3% 
life-time risk of cancer (outside the thyroid gland) seems more appropriate. 
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Table 8.3 Radiation absorbed doses in target organs after radioiodine treat-
ment of eu- and hyperthyroid patients with a large multinodular 
goiter (>100g) calculated with the MIRD method, using thyroid, 
urinary bladder, stomach, small intestine, liver and remainder of 
the body as source organs. The mean values ± SD are given 
Target organ Absorbed dose per unit Absorbed dose (Gy) 
administered activity (mGy/MBq) 
Euthyroid Hyperthyroid Euthyroid Hyperthyroid 
Number of patients 
Thyroid a 
Red bone marrow 
Ovaries 
Testes 
Colon ь 
Lung 
Stomach 
Urinary bladder 
Breast 
Liver 
Skin 
Bone surface 
Remainder d 
Effective dose 
outside thyroid (Sv) 
6 
46 ± 2 1 
0.092 ± 0.024 
0.044 ±0.008 
0.025 ±0.004 
0.044 ±0.008 
0.089 ±0.028 
0.33 ± 0.08 
0.48 ± 0.08 
0.045 ± 0.010 
0.078 ±0.012 
0.056 ±0.015 
0.116 ±0.037 
0.085 ± 0.006 
6 
58 ±17 
0.108 ±0.008 
0.039 ± 0.002 
0.023 ±0.001 
0.038 ±0.002 
0.107 ±0.009 
0.26 ± 0.02 
0.43 ± 0.03 
0.051 ±0.003 
0.099 ±0.011« 
0.066 ± 0.005 
0.140 ±0.013 
0.088 ± 0.003 
6 
84 ±22 
0.19 ±0.11 
0.10 ±0.06 
0.06 ±0.03 
0.10 ±0.06 
0.19 ±0.11 
0.74 ±0.49 
1.06 ±0.63 
0.10 ±0.05 
0.17 ±0.08 
0.12 ±0.07 
0.24 ±0.14 
0.18 ±0.09 
0.27 ±0.14 
6 
83 ±15 
0.16 ±0.08 
0.06 ±0.02 
0.04 ±0.01 
0.06 ±0.02 
0.17 ±0.06 
0.41 ±0.16 
0.71 ±0.30 
0.08 ±0.03 
0.16 ±0.06 
0.11 ±0.03 
0.22 ± 0.09 
0.14 ±0.05 
0.19 ±0.07 
Thyroid absorbed doses as calculated with MIRDOSE2 are corrected for the ratio 
normal thyroid weight (20 g) / measured actual thyroid weight 
0.57 χ dose upper large intestine + 0.43 x dose lower large intestine [6] 
ρ<0.03 eu- versus hyperthyroid patients 
The absorbed dose in the "remainder of the body" is the average dose in the following 
organs and tissues: adrenals, brain, upper large intestine, small intestine, kidney, 
muscle, pancreas, spleen, thymus and uterus [6] 
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8.4 Discussion 
In the present study thermoluminescent dosimeter (TLD) measurements showed 
cumulated (i.e. time-integrated) radiation absorbed doses of 4.2 ± 1.4 Gy on the 
skin directly overlying the thyroid, of 1.2 ±0.6 Gy on the skin over the sub-
mandibular gland and of 0.4 ± 0.2 Gy on the skin over the parotid gland, after 
therapeutic administration of 131I in patients with a large, multinodular goiter 
(mean thyroid weight 222 ± 72 g). There were no significant differences between 
eu- and hyperthyroid patients. Absorbed doses at all three locations were sig-
nificantly correlated with the amount of radioiodine retained in the thyroid at 
24 hours. Absorbed doses in the spinal cord must have been lower than the 
doses measured on the skin over the thyroid because the distance between the 
posterior edge of the thyroid and the spinal cord is considerably larger than the 
distance between the anterior edge of the thyroid and the surface of the skin. 
This implies that the cervical spinal cord has absorbed less than one tenth of the 
dose which in external radiation therapy is considered the threshold dose above 
which necrosis of the spinal cord may be induced (approximately 55 Gy delivered 
over 5 to 6 weeks) [13]. On the other hand, it is likely that in a number of our 
patients the esophageal and tracheal mucosa at the level of the thyroid gland 
have absorbed higher doses of gamma radiation than those measured with ther-
moluminescent dosimeters (TLDs) on the skin, because in many patients with 
a large goiter, thyroid tissue is immediately adjacent to the trachea and esoph-
agus on the anterior as well as on the right and left side. However, it is not to 
be expected that significant doses of beta radiation have been absorbed in the 
esophageal and tracheal mucosa, because the maximal range of beta particles 
of 131I in tissues is 3 mm and the average range only 0.3 mm. 
The significant correlation between absorbed doses on the skin overlying 
the salivary glands on one hand and the amount of radioiodine in the thyroid at 
24 hours divided by the distance between the TLDs and the thyroid on the other 
suggests that these doses were for a large part caused by gamma radiation from 
radioiodine in the thyroid gland. Absorbed doses within the salivary glands will 
have been higher than those measured on the skin, because of beta irradiation 
from inorganic 131I concentrated in these glands. The methods we used do not 
permit further quantification of the absorbed doses within the salivary glands. 
Our TLD measurements in 23 patients showed a small but significant dif-
ference in effective half-times of 131I in the thyroid between eu- and hyperthyroid 
patients (6.1 ±0.8 days and 5.5 ±0.7 days, respectively). Thyroid radioactivity 
measurements with a Nal detector in 12 patients showed similar effective half-
times of 131I in the thyroid. Using this method the difference between eu- and 
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hyperthyroid patients was not significant (5.7 ± 0.4 days and 5.3 ± 0.5 days, re­
spectively). The effective half-time of approximately 5.5 days for hyperthyroid 
patients found in our study is comparable to other reports on hyperthyroid pa­
tients [14-17]. However, the observed effective half-times in hyperthyroid as 
well as in euthyroid patients are considerably lower than those reported in the 
dose estimate reports for radioiodine in ICRP Publication 53 (7.3 days) [18] and 
MIRD report no. 5 (6.9 days) [11] which apply to tracer doses of 1 3 1 I in euthyroid 
adults. The fast release of 1 3 1 I from the thyroid found in our study is probably 
caused by radiation-induced damage to thyroid cells from therapeutic activities 
of radioiodine [5,17,19, 20]. In view of the small difference between eu- and hy­
perthyroid patients, the elimination rate of therapeutic activities of radioiodine 
from the thyroid appears to be less dependent on the functional state of the 
thyroid at the time of therapy. 
A highly significant correlation between the cumulated dose on the skin 
overlying the thyroid and the cumulated activity within the thyroid as mea­
sured with a Nal detector was found. However, TLD measurements depend too 
much on thyroid mass, depth and geometry to warrant their use in estimating 
absorbed doses within the thyroid [21]. Therefore, we used radioactivity mea­
surements with a Nal detector to estimate absorbed doses in the thyroid. The 
absorbed dose in the thyroid of approximately 85 Gy for both eu- and hyper­
thyroid patients, found in our study, is in the lower range of doses commonly 
used for the treatment of toxic multinodular goiter (80-200 Gy) [22-25]. This is 
explained by the combination of a relatively low administered activity per gram 
of thyroid tissue and a short effective half-time in the thyroid. Uncertainty in 
our calculations of thyroid absorbed doses is caused by the inaccuracy of thyroid 
weight estimations by planar scintigraphy [26, 27]. Furthermore, the calculated 
absorbed dose in the thyroid is an average value for the whole thyroid gland. In 
a nodular goiter, considerable regional differences in absorbed doses are caused 
by inhomogeneous radioiodine uptake within the goiter. 
Using radioactivity measurements and the biokinetic model of Robertson 
and Gorman [5], the mean values for absorbed doses in extrathyroidal tissues 
and organs ranged from 0.024 to 0.46 mGy/MBq of administered radioiodine. Ab­
sorbed doses per MBq in the urinary bladder, stomach and small intestine were 
inversely correlated with 24-h RAIU, because a larger uptake of inorganic iodide 
into the thyroid gland reduces the residence time of inorganic 1 3 1 I in the uri­
nary bladder and other extrathyroidal organs. The liver, unlike stomach, small 
intestine and urinary bladder, is the organ where 1 3 1 I incorporated in thyroid 
hormones is collected and metabolized. This was accounted for by assigning 40% 
of the extrathyroidal thyroid hormone compartment to the liver [10, 11]. This 
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explains why the absorbed dose per MBq in the liver was positively correlated 
with the 24-h RAIU, which is an indicator of the synthesis of thyroid hormones. 
However, for the absorbed doses resulting from the total administered activities 
of radioiodine no significant correlations with the 24-h RAIU were found, prob-
ably because the administered activities depended for an important part on the 
thyroid weight. 
The absorbed doses per MBq of administered 131I found in our study are 
in accordance with data in the literature, obtained by other techniques of mea-
surement and other biokinetic models [11, 18, 28-30]. However, our patients 
with large, multinodular goiters and a low thyroid radioiodide uptake received 
considerably larger total activities of radioiodine than the amounts that are 
commonly used in patients with Graves' disease. Therefore, extrathyroidal ra-
diation absorbed doses (in Gy) were about four times as high as those reported 
for patients with Graves' disease in the literature [5, 31-34]. 
The risk of induction of thyroid cancer by external radiation is dose-
dependent [35]. Absorbed doses in the thyroid during radioiodine therapy are 
more than 10 times as high as doses reported for external irradiation. How-
ever, in studies with a long-term follow-up of large numbers of patients treated 
with radioiodine for hyperthyroidism no significantly increased risk of thyroid 
cancer was found [33, 34, 36, 37]. It has been suggested that high doses, as 
absorbed in the thyroid during radioiodine therapy for hyperthyroidism, lead to 
substantial cell killing and cell sterilization instead of the production of carcino-
genic mutations in the cell's DNA [33, 35, 38]. Although our patients with large 
goiters received higher total amounts of radioiodine than the patients in the 
aforementioned follow-up studies [33, 34, 36, 37] absorbed doses in the thyroid 
were similar. Therefore, an elevated risk of thyroid cancer is not to be expected 
in these patients with a large goiter. 
From studies with follow-up up to 35 years, there is no evidence that the 
overall cancer incidence and cancer mortality in patients with Graves' disease 
treated with radioiodine are elevated [33, 34, 39, 40]. Literature on cancer in-
cidences after radioiodine therapy relating specifically to patients with nodular 
goiter is sparse. In one study, a slightly elevated overall cancer incidence was 
reported in patients with toxic nodular goiter treated with radioiodine (average 
administered activity 700 MBq), possibly related to higher administered activ-
ities than those administered to patients with Graves' disease (average admin-
istered activity 360 MBq) [33]. This remains to be confirmed in other studies. 
With respect to the incidence of cancers of individual extrathyroidal organs and 
tissues in patients treated with radioiodine for hyperthyroidism (Graves' disease 
or nodular goiter), the risk of leukemia appears not to be elevated [41-43]. The 
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risk of cancer of the stomach may be slightly increased [33, 34]. In some stu-
dies, the incidences of bladder cancer and of breast cancer have been reported 
to be increased [42, 44, 45]. However, these findings have not been confirmed 
by other studies [33, 34, 42]. 
In our study, patients with a large, multinodular goiter were treated with 
considerably larger amounts of radioiodine (2000 MBq on average) than the 
average doses administered in the aforementioned studies. Using a total detri-
ment of 7.3%/Sv for a population of all ages [6], we calculated a 1.6% life-time 
risk of (fatal and non-fatal) cancer for the combined organs outside the thyroid. 
When applied to people over 65 years of age, the estimated risk is lower (0.3%). 
This figure is of the same order of magnitude as that reported for the surgical 
mortality of subtotal thyroidectomy [1, 3]. The risks of surgery are of course 
higher in elderly patients, in patients with a large goiter and in those with 
cardiopulmonary disease [2]. Furthermore, the morbidity of thyroid surgery, 
including non-fatal complications, is considerably larger [1-3]. However, it has 
to be stressed that the calculated risk of radioiodine therapy is only a rough 
estimate of risk and that no follow-up data on cancer incidence in patients with 
a large goiter treated with high doses of radioiodine are available. 
In conclusion, the estimated risks of both surgery and radioiodine should 
be carefully weighed in all patients with a large, multinodular goiter who have 
to be treated for hyperthyroidism or compressive problems. In younger patients 
surgery may be preferred, especially when the amount of radioiodine to be ad-
ministered, as calculated from a radioiodine tracer study, is high. However, for 
elderly patients and patients with cardiopulmonary disease, the profits of non-
invasive radioiodine treatment will outweigh the life-time risk of this mode of 
therapy. 
8.5 Appendix 
Cumulated fractional activities (i.e. residence times) in the 4 compartments (B, 
T, P, and U) are expressed as follows: 
œ 6(0,00) = , ^ 
(2) T(0,oo) = ^ { 1 ( 0 , 2 4 ) - B(0,24)} + ,А-{£Ш1 +T(24)} 
(3) Р(24, оо) =
І
£
г
Т(24,ос) 
(4) Ü(0, оо) = £Т(0,24) + ¿{П[В(24, оо) + Р(24, оо)] + U(24)} 
where ï(0,24) = £(1 - e _ m ) and where it is assumed that Bo = 1 and 
T0 = U0 = Po = 0 
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(5) T(24) = T F (1 - е - 2 4 ( Г і + Г з ) ) 
where Тр is the final or theoretical maximal thyroid 1 3 1 I uptake. 
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Summary 
Multinodular goiter is defined as a structurally and functionally heteroge-
neous thyroid enlargement. It arises from excessive replication of thyroid epithe-
lial cells with subsequent generation of new follicles of widely differing structure 
and function. The size of such a goiter tends to increase with age and, although 
the thyroid may be diffusely enlarged in the first phase of goitrogenesis, it will 
become more nodular with time. Moreover, euthyroidism may gradually change 
into hyperthyroidism in patients with a multinodular goiter. 
A solitary autonomous thyroid nodule is a discrete thyroid nodule that 
secretes thyroid hormone, independently of any known extrathyroidal stimulus. 
It may exist in close approximation to and within normal thyroid parenchyma 
that remains subject to the functional regulation of the pituitary. As a solitary 
autonomous thyroid nodule is generated from follicular cells with (most prob-
ably) genetically determined high replication rate and iodinating capacity, its 
size tends to increase with time, not infrequently leading to hyperthyroidism. 
Results of radioiodine therapy in patients with Graves' disease have been 
evaluated extensively. Considerably less has been reported on results of radio-
iodine treatment in patients with a uni- or multinodular goiter. This thesis is 
focused on various aspects of radioiodine therapy in such patients. Three groups 
of patients were studied: patients with a toxic solitary autonomous thyroid nod-
ule (chapters 2 and 3), those with a toxic multinodular goiter (chapters 4 and 5) 
and those with a compressive, toxic or non-toxic, multinodular goiter (chapters 
6, 7 and 8). Long-term effects of radioiodine treatment on thyroid function in 
patients with a toxic solitary autonomous thyroid nodule are evaluated in chap-
ter 3. In chapter 4 and 5 long-term effects of radioiodine treatment on thyroid 
function in patients with a toxic multinodular goiter are described. The effective-
ness of radioiodine therapy to reduce thyroid volume and to reverse compression 
of vital structures in patients with a large, compressive, multinodular goiter is 
studied in chapter 7, while dosimetric aspects of radioiodine treatment in this 
group of patients are discussed in chapter 8. Chapters 2 and 6 contain studies 
evaluating the value of imaging procedures in patients with a nodular goiter. In 
chapter 2, thallium-201 scintigraphy and iodine-123 scintigraphy after stimula-
tion with thyroid-stimulating hormone (TSH) for the visualization of suppressed 
extranodular thyroid tissue in patients with a toxic solitary autonomous thyroid 
nodule are compared. Chapter 6 contains a comparison of thyroid volume mea-
surements with magnetic resonance imaging (MRI) and those obtained with 
planar scintigraphy in patients with a large, multinodular goiter. 
In chapter 1, preceding the original studies, a review of current knowl-
edge of the pathogenesis and natural history of multinodular goiter and toxic 
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solitary autonomous thyroid nodules and a summary of cell biological effects of 
radioiodine on the thyroid gland are given. 
In chapter 2 the use of thallium-201 (201T1) scintigraphy for the visual­
ization of suppressed extranodular thyroid tissue is evaluated in 21 patients 
with a toxic solitary autonomous thyroid nodule. 201T1 scintigraphy is compared 
with 1-123 (123I) scintigraphy after stimulation with bovine TSH. In all patients 
similar results were obtained with both methods. The contralateral lobe of the 
thyroid was visualized in 20 patients and the extranodular part of the ipsilat-
eral lobe in 14 of these patients, on both 2οιχι scintigraphy and TSH stimulated 
1 2 3 I scintigraphy. In one patient no extranodular thyroid tissue was shown with 
either method. It is concluded that 2<>ιχΐ scintigraphy is a reliable and simple al­
ternative for TSH stimulated 1 2 3 I scintigraphy for the visualization of suppressed 
extranodular thyroid tissue in patients with a toxic solitary autonomous thyroid 
nodule. 201x1 does not induce allergic reactions, which are frequently seen after 
injections of bovine TSH. Iodide uptake in extranodular tissue is not stimulated 
by 20ΐχι and therefore, 20ΐχι scintigraphy and radioiodine therapy can be com­
bined on one day, without increasing the risk of post-treatment hypothyroidism 
due to radiation-induced damage of normal thyroid tissue. 
In chapter 3 the long-term effects of radioiodine treatment on thyroid func­
tion in patients with a toxic solitary autonomous thyroid nodule are evaluated. 
Fifty-two patients treated with a therapeutic dose of 740 MBq (20 mCi) of 1 3 1 I 
in the past were examined after a follow-up of 10 ± 4 (mean ± SD) years. All 
patients had become euthyroid within six months after radioiodine therapy. In 
one patient (2%) hyperthyroidism had recurred after 1.5 years, which was suc­
cessfully treated with a second dose of 740 MBq of radioiodine. At the end of 
follow-up, hypothyroidism was present in 6% of patients. It is concluded that 
a standard dose of 740 MBq of radioiodine is a highly effective treatment for 
patients with a toxic solitary autonomous thyroid nodule. The risk of develop­
ment of hypothyroidism is low if extranodular uptake of 1 3 1 I is minimized. This 
will be achieved when radioiodine treatment is only given when the serum TSH 
level is suppressed. 
In chapter 4 the long-term effects of two schedules of radioiodine therapy 
in patients with toxic multinodular goiter were evaluated. Forty-five patients 
(group A) were treated with fixed low doses and fifty-eight patients (group B) 
with calculated doses adjusted for thyroid weight (1.85-3.70 MBq/g) and ra­
dioactive iodide uptake. Follow-up (mean ± SD) was 4.3 ± 1.3 yr and 5.2 ± 2.3 yr, 
respectively (p > 0.1). At the end of follow-up, hyperthyroidism was successfully 
reversed in 73% (group A) and 88% (group B). In either group, hypothyroidism 
was present in 7%. The total dose per gram of thyroid tissue was not signifi­
cantly different in groups A and В (2.1 ± 1.5 versus 2.7 ± 1.3 MBq/g). However, 
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for patients treated with calculated doses the number of 1 3 1 I administrations was 
significantly lower (1.3 ± 0.8) than for patients treated with low doses (2.2 ± 1.3) 
and the percentage of patients who were adequately treated with a single dose 
was more than twice as high (66% in group В versus 27% in group A). Euthy-
roidism was reached within a significantly shorter time after treatment with 
calculated doses (median time 0.6 years in group В versus 1.5 years in group A; 
life table analysis). It is concluded that radioiodine is an effective treatment for 
toxic multinodular goiter with a low risk of post-treatment hypothyroidism and 
that calculated (higher) doses appear to be preferable to low doses. 
In chapter 5 a follow-up study is presented of patients, who were euthyroid 
at the end of the study presented in chapter four, 1 to 12 years after radioiodine 
treatment for toxic multinodular goiter. There were two reasons to perform such 
a follow-up study. First, we observed significant inverse correlations between 
serum fT4 and T3 levels on one hand and serum TSH levels on the other in the 
71 euthyroid patients of groups A and В at the end of the study reported in 
chapter four. Second, 30% of the euthyroid patients had a serum TSH level be­
low the normal range at that time. These observations suggest that, in spite of 
normal serum levels of fT4 and T3, autonomous thyroid function is still present 
in (a number of) these radioiodine treated patients and that they are at risk 
of recurrent hyperthyroidism. Forty-nine of these euthyroid patients were re­
examined 1 year later (February 1993). A subgroup of patients of group B, those 
who were rendered euthyroid after a single dose of radioiodine in the past, were 
also evaluated in February 1994 (group В select; η = 21). Our follow-up data 
demonstrated significant decreases of serum fT4 and T3 levels and a significant 
increase in serum TSH levels after 1 year. In the majority of patients, fT4 levels 
had decreased (34 of 49 patients) or stayed at the same level (3 of 49 patients) 
after one year. Even in 13 of 18 patients, who had a TSH value below the normal 
range in 1992, fT4 levels had decreased 1 year later. Significant decreases in 
serum fT4 and T3 levels were also observed between February 1992 and Febru­
ary 1994 in group В select. In 19 of the 21 patients of group В select fT4 levels 
in 1994 were lower than in 1992. On the other hand, in 12 patients of the 
whole group of 49 euthyroid patients and in 3 of the subgroup of 18 patients 
with a TSH level below normal in 1992, fT4 levels had increased after 1 year. 
An increase to fT4 levels just above the normal range was seen in only 3 of all 
49 euthyroid patients. It is concluded that in patients who have been treated 
with radioiodine for toxic multinodular goiter in the past and who have fT4 and 
T3 levels within the normal range, a further decrease of thyroid hormone levels 
can be anticipated, at least in the first decade after radioiodine therapy. This 
applies even for the subgroup of patients with a serum TSH level below the nor­
mal range. Theiefore, in these patients an expectative policy with yearly control 
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visits is indicated. Additional 1 3 1 I treatment has to be considered in patients 
with a serum TSH level below the normal range, when serial measurements 
show a further decrease in TSH levels (or TSH levels below the detection limit 
of the assay) in combination with increasing fT4 and T3 levels, especially when 
signs and symptoms of thyrotoxicosis recur. 
In chapter 6 the use of magnetic resonance imaging (MRI) for volume esti­
mations of large multinodular goiters is evaluated, in view of a currently growing 
interest in non-surgical treatment to reduce goiter size. Twenty patients (3 men 
and 17 women, age 61 ± 21 years; mean ± SD) with a multinodular goiter larger 
than 100 ml were studied. In addition, MRI measurements were compared to 
scintigraphic volume estimations. Intraobserver CV of MRI measurements was 
2.2% ± 2.0% (observer 1) and interobserver CV 4.1% ± 2.2% (observers 1 and 2). 
In all 20 patients signs of mechanical complications were shown on MRI images. 
For scintigraphic measurements intraobserver CV was 7.5% ± 5.7% (observer 3) 
and 5.4% ±5.1% (observer 4). Interobserver CVwas 10.1% ±6.1%. The correla­
tion between measurements with both methods was not strong (r = 0.665) and 
the resulting CV was 17.3% ± 14.2%. Underestimation of scintigraphic volumes 
could not be explained by the presence of cysts at the surface of the thyroid. It 
is concluded that magnetic resonance imaging can be used for in vivo thyroid 
volume estimation of large multinodular goiters. The high precision of MRI mea­
surements makes this technique potentially useful for the evaluation of thyroid 
growth and non-surgical treatment to reduce goiter size. Scintigraphic volume 
measurements do not suffice for this purpose. An additional advantage of MRI 
is the detailed anatomical information it provides on mechanical complications 
of large goiters. 
In chapter 7 the effectiveness of radioiodine treatment as an alterna­
tive for surgery is evaluated prospectively in 19 patients, aged 66 ± 14 years 
(mean ± SD) with a large, compressive multinodular goiter (>100 ml), who had 
a high operative risk or refused to undergo thyroid surgery. A single i.v. dose 
of 2.6 ± 1.0 GBq (70 ± 28 mCi) of 1 3 1 I (3.7 MBq or 100 μΟϊ per gram of thyroid 
tissue) was administered, followed by daily administration of L-thyroxine in non 
TSH-suppressive doses. Clinical evaluation and MRI measurements of thyroid 
volume, maximal tracheal deviation from the midline and the smallest cross-
sectional area of the tracheal lumen were performed before and 1 year after 
radioiodine treatment. Exacerbation of compressive symptoms after 1 3 1 I was 
not observed. Before treatment thyroid volume was 269 ± 153 ml and 1 year 
after radioiodine therapy 154 ± 73 ml (p < 0.001). Thyroid volume reduction 
was 40% ± 15% (range, 19% to 68%). Maximal tracheal deviation (1.9 ±0.8 cm 
before and 1.5 ±0.7 cm one year after therapy) had decreased by 20% ±20% 
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(—4% to 73%; ρ < 0.001) and the smallest cross-sectional area' of the tracheal 
lumen (0.78 ± 0.38 cm2 before and 1.04 ± 0.48 cm2 1 year after therapy) had in­
creased by 3%±38% (-3% to 125%; ρ < 0.001). Clinical signs and symptoms 
had improved in 8 of 12 patients with dyspnea and inspiratory stridor and in 
both patients with compression of the superior vena cava. It is concluded that 
radioiodine therapy is an effective alternative for surgery in elderly patients 
with a large, compressive multinodular goiter. 
In chapter 8 dosimetric aspects of radioiodine therapy in patients with a 
large, multinodular goiter are studied. Many commonly used dosage schedules 
for radioiodine therapy are aimed at delivering a certain amount of radioiodine 
per gram of thyroid tissue retained at 24 hours. The use of such a dosage sched­
ule implies that high doses of radioiodine are administered to patients with a 
large, multinodular goiter. We estimated absorbed doses in the thyroid, sur­
rounding tissues and rest of the body after therapeutic administration of radio­
iodine (3.7 MBq/g of thyroid tissue retained at 24 hours) in patients with a large, 
toxic or non-toxic, multinodular goiter (>100g). Thermoluminescent dosimeter 
(TLD) measurements on the skin over the thyroid, over the submandibular gland 
and over the parotid gland were used to estimate the radiation burden of neigh­
bouring tissues due to radioactive iodine in the thyroid gland. TLD measure­
ments in 23 patients (12 eu- and 11 hyperthyroid; thyroid weight 222 ± 72 g, 
mean ± SD; administered activity 2.1 ±0.9 GBq) showed cumulated (i.e. time-
integrated) radiation absorbed doses of 4.2 ± 1.4 gray (Gy) on the skin directly 
overlying the thyroid, of 1.2 ± 0.6 Gy on the skin over the submandibular gland 
and of 0.4 ± 0.2 Gy on the skin over the parotid gland. There were no significant 
differences between eu- and hyperthyroid patients. Absorbed doses at all three 
locations were significantly correlated with the total amount of radioiodine re­
tained in the thyroid at 24 hours. In 12 patients (6 eu- and 6 hyperthyroid; 
thyroid weight 204 ± 69 g; administered activity 1.9 ± 0.9 GBq) estimations of 
thyroid and total-body irradiation were made using thyroid radioactivity mea­
surements and the model of iodine kinetics in the body described by Robertson 
and Gorman. Absorbed doses in the thyroid were 84 ± 22 Gy for euthyroid and 
83 ± 15 Gy for hyperthyroid patients. The highest absorbed doses outside the 
thyroid were observed for the stomach, the small intestine and the urinary blad­
der (mean values of 12 patients, 0.38 Gy, 0.57 Gy and 0.88 Gy, respectively). 
Absorbed doses in all other extrathyroidal tissues were lower and ranged be­
tween 0.05 and 0.30 Gy (mean values of 12 patients). There were no significant 
differences in absorbed doses between eu- and hyperthyroid patients. Absorbed 
doses in extrathyroidal tissues were about four times as high as those reported 
for patients with Graves' disease in the literature. The effective dose, which 
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was primarily determined by the absorbed dose in the thyroid, was similar for 
eu- and hyperthyroid patients (4.5 ± 1.1 and 4.4 ± 0.8 sievert, respectively). Us-
ing official risk estimates [ICRP Publication 60] for a population of all ages, 
a 1.6% life-time risk of development of cancer outside the thyroid gland was 
calculated. When applied to people of 65 years and older the estimated risk 
is lower (about 0.3%). However, it has to be stressed that these data are only 
rough estimates of risk and that no real follow-up data on cancer incidence in 
patients with a large, multinodular goiter treated with high doses of radioiodine 
are available. It is concluded that in all patients with a large, multinodular goi-
ter, who have to be treated for hyperthyroidism or compressive problems, the 
estimated risks of both surgery and radioiodine should be carefully weighed. 
In younger patients surgery may be preferred, especially when the amount of 
radioiodine to be administered as calculated from a radioiodine tracer study is 
high. However, for elderly patients and patients with cardiopulmonary disease, 
the profits of non-invasive radioiodine treatment will outweigh the life-time risk 
of this mode of therapy. For these patients radioiodine therapy seems preferable 
to surgery. 
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Samenvatting 
Onder een multinodulaire struma wordt een, qua structuur en ftinctie, hete-
rogene schildkliervergroting verstaan. Zulk een schildkliervergroting ontstaat 
door een versnelde deling van schildklierepitheelcellen met als gevolg de vor-
ming van nieuwe schildklierfollikels die in structuur en functie sterk variëren. 
De grootte van een multinodulaire struma neemt toe met de leeftijd. Hoewel de 
schildklier in het begin diffuus vergroot kan zijn, zal deze op den duur steeds 
meer nodulair worden. Bij patiënten met een multinodulaire struma kan een 
normale schildklierwerking (euthyreoidie) geleidelijk overgaan in een versnelde 
schildklierwerking (hyperthyreoidie). 
Een solitaire autonome schildkliernodus is een geïsoleerde nodus in 
de schildklier die schildklierhormoon produceert, onafhankelijk van stimulatie 
door thyroid-stimulerend hormoon (TSH) vanuit de hypofyse of enige andere 
bekende stimulus buiten de schildklier. De nodus is meestal gelegen binnen het 
normale schildklierweefsel waarvan de functie afhankelijk blijft van regulatie 
vanuit de hypofyse. Een solitaire autonome schildkliernodus, ontstaand uit 
follikelcellen met een waarschijnlijk genetisch bepaalde hoge delingssnelheid en 
hoge joderingscapaciteit, neigt tot groei en leidt niet zelden tot hyperthyreoidie. 
Er zijn vele studies gepubliceerd waarin resultaten van behandeling met 
radioactief jodium bij patiënten met de ziekte van Graves gemeld worden. Er 
zijn veel minder studies over de resultaten van deze behandeling bij patiënten 
met een uni- of multinodulaire struma. In dit proefschrift worden verschillende 
aspecten van behandeling met radioactief jodium bij patiënten met een nodu-
laire struma bestudeerd. Hierbij worden drie groepen patiënten onderschei-
den: patiënten met een solitaire autonome schildkliernodus (hoofdstuk 2 en 3), 
patiënten met een hyperthyreotische, multinodulaire struma (hoofdstuk 4 en 5) 
en patiënten met een ongewoon grote, multinodulaire struma, al dan niet met 
hyperthyreoidie (hoofdstuk 6, 7 en 8). 
De effecten op lange termijn van behandeling met radioactief jodium op 
de schildklierfunctie bij patiënten met een toxische solitaire autonome schild-
kliernodus worden geëvalueerd in hoofdstuk 3. In hoofdstuk 4 en 5 worden 
de effecten van behandeling met radioactief jodium op de schildklierfunctie op 
lange termijn beschreven bij patiënten met een toxische, multinodulaire struma. 
De resultaten van behandeling met radioactief jodium, gegeven met als doel het 
volume van de schildklier te verkleinen en compressie van vitale structuren 
te verminderen bij patiënten met een grote, eu- of hyperthyreotische, multi-
nodulaire struma worden beschreven en becommentarieerd in hoofdstuk 7. In 
hoofdstuk 8 worden dosimetrische aspecten van therapie met radioactief jodium 
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bij deze groep van patiënten bediscussieerd. De hoofdstukken 2 en 6 bevatten 
studies waarin de waarde van beeldvormende technieken bij patiënten met een 
nodulaire struma aan de orde wordt gesteld. In hoofdstuk 2 wordt thallium-
201 scintigrafie voor de visualisatie van extranodulair schildklierweefsel bij 
patiënten met een toxische solitaire autonome schildkliernodus vergeleken met 
jodium-123 scintigrafie na stimulatie met TSH. Hoofdstuk 6 bevat een vergelij-
king van metingen van schildkliervolumina van grote multinodulaire strumas, 
gebruik makend van de magnetische resonantie techniek (MRI) en van planaire 
scintigrafie. 
In hoofdstuk 1, voorafgaand aan de studies, wordt een kort overzicht van 
de huidige kennis van de Pathogenese en natuurlijke historie van de multinodu-
laire struma en de toxische solitaire autonome schildkliernodus en een samen-
vatting van de celbiologische effecten van radioactief jodium op de schildklier 
gegeven. 
In hoofdstuk 2 wordt het gebruik van thallium-201 (201T1) scintigrafie ter 
visualisering van gesupprimeerd extranodulair schildklierweefsel geëvalueerd 
bij 21 patiënten met een toxische solitaire autonome schildkliernodus. 20114 
scintigrafie wordt vergeleken met 1-123 (123I) scintigrafie na stimulatie met 
runder-TSH. Met beide methoden werden bij alle patiënten gelijke resultaten 
verkregen. De contralaterale schildklierkwab werd bij 20 patiënten gevisu-
aliseerd en het extranodulaire deel van de schildklierkwab met de nodus bij 
14 van deze patiënten, zowel met 201T1 scintigrafie als met 123I scintigrafie na 
TSH-stimulatie. Bij één patiënt werd met geen van beide methoden extranodu-
lair schildklierweefsel afgebeeld. Geconcludeerd wordt dat 201T1 scintigrafie een 
betrouwbaar en simpel alternatief voor 123I scintigrafie na TSH-stimulatie is om 
bij patiënten met een toxische solitaire autonome schildkliernodus extranodulair 
schildklierweefsel zichtbaar te maken. 2<>iTl veroorzaakt geen allergische reac-
ties, die wel frequent gezien werden na injectie van runder-TSH. De opname 
van radioactief jodium in het extranodulaire weefsel wordt niet gestimuleerd 
door 201T1. Daarom kunnen 20ΐΤΊ scintigrafie en behandeling met radioactief 
jodium op één dag gecombineerd worden. Het risico van hypothyreoidie door 
stralingsschade van het normale extranodulaire schildklierweefsel wordt hier-
door niet verhoogd. 
In hoofdstuk 3 worden de effecten op lange termijn van behandeling met 
radioactief jodium op de schildklierfunctie bij patiënten met een toxische soli-
taire autonome schildkliernodus geëvalueerd. 52 patiënten, in het verleden be-
handeld met een standaard therapeutische dosis van 740 MBq (20 mCi) 131I, 
werden onderzocht na een follow-up van 10 ± 4 jaar (gemiddelde ± SD). Alle 
patiënten waren binnen 6 maanden na de behandeling euthyreotisch gewor-
den. Eén patiënt (2%), die na 1.5 jaar opnieuw hyperthyreotisch werd, is met 
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een tweede dosis van 740 MBq radioactief jodium met succes behandeld. Op het 
einde van de follow-up was slechts 6% van de patiënten hypothyreotisch. Gecon-
cludeerd wordt dat een standaard dosis van 740 MBq radioactief jodium een zeer 
effectieve behandeling is voor patiënten met een toxische solitaire autonome 
schildkliernodus. Het risico van het ontstaan van hypothyreodie is klein wan-
neer de opname van radioactief jodium in het extranodulaire schildklierweefsel 
geminimaliseerd wordt. Dit kan bereikt worden door alleen met radioactief 
jodium te behandelen wanneer de TSH-spiegel in het bloed onderdrukt is. 
In hoofdstuk 4 worden de resultaten op lange termijn van twee schema's 
van behandeling met radioactief jodium vergeleken bij patiënten met een toxi-
sche multinodulaire struma. Vijf en veertig patiënten (groep A) werden be-
handeld met lage standaarddoses en acht en vijftig patiënten (groep B) met 
berekende doses waarbij het schildkliergewicht (1.85 tot 3.70 MBq/g) en het 
percentage opname van radioactief jodium in de schildklier in de bereke-
ning meegenomen werden. De follow-up (gemiddelde ± SD) was respectievelijk 
4.3 ± 1.3 jaar en 5.2 ± 2.3 jaar. Op het einde van de follow-up was de hyperthy-
reoidie in 73% (groep A) en 88% (groep B) met succes bestreden. Hypothyreoidie 
was aanwezig in 7% van de patiënten in beide groepen. De totale dosis per gram 
schildklierweefsel verschilde niet significant tussen de groepen A en В (2.1 ± 1.5 
versus 2.7 ± 1.3 MBq/g). Wel was bij patiënten behandeld met berekende doses 
131I het aantal doseringen (1.3 ±0.8) significant lager dan bij patiënten behan-
deld met lage doses (2.2 ± 1.3) en het percentage patiënten dat adequaat was 
behandeld met één dosering 131I was meer dan twee maal zo hoog in groep В 
(66% in groep В versus 27% in groep A). Euthyreoidie werd binnen een sig­
nificant kortere tijd bereikt na behandeling met berekende doses (mediane tijd 
0.6 jaar in groep В versus 1.5 jaar in groep A; Kaplan-Meier analyse). Gecon­
cludeerd wordt dat therapie met radioactief jodium een effectieve behandeling is 
voor patiënten met een toxische multinodulaire struma met een kleine kans op 
hypothyreoidie na de behandeling. Berekende (hogere) doses zijn te prefereren 
boven lage doses. 
In hoofdstuk 5 wordt een follow-up studie gepresenteerd van patiënten die 
aan het einde van de in hoofdstuk 4 beschreven studie, 1 tot 12 jaar na behande-
ling met radioactief jodium wegens een toxische multinodulaire struma, in leven 
en euthyreotisch waren. Er waren twee redenen voor deze follow-up studie. Ten 
eerste namen wij waar, dat de serumspiegels van vrij T4 en T3 enerzijds en de 
serum TSH-spiegels anderzijds, negatief en significant gecorreleerd waren bij 
de 71 euthyreotische patiënten van groep A en В aan het einde van de studie 
beschreven in hoofdstuk 4. Voorts had 30% van de euthyreotische patiënten op 
dat moment een serum TSH-spiegel beneden de ondergrens van normaal. Beide 
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bevindingen suggereren dat, ondanks de aanwezigheid van normale spiegels 
van vrij T4 en T3 in het serum, de schildklier bij (een aantal van) deze, met 
radioactief jodium behandelde, patiënten nog steeds autonoom functioneert en 
dat zij het risico lopen opnieuw hyperthyreotisch te worden. Negen en veertig 
van deze euthyreotische patiënten werden eenjaar later opnieuw onderzocht (in 
februari 1993). Een subgroep van de patiënten van groep B, diegenen die na 
één dosis radioactief jodium euthyreotisch geworden waren, werden bovendien 
in februari 1994 opnieuw onderzocht (groep Bjj η = 21). De follow-up gegevens 
na 1 jaar lieten significante dalingen van de serumspiegels van vrij T4 en T3 
zien en een significante stijging van de serum TSH-spiegel. Bij de meerderheid 
van de patiënten was het vrije T4 gehalte gedaald (34 van 49 patiënten) of gelijk 
gebleven (3 van 49 patiënten). Zelfs bij 13 van 18 patiënten die in 1992 een 
verlaagde TSH-spiegel hadden was het vrije T4 gehalte een jaar later verder 
gedaald. Significante dalingen van de serumspiegels van vrij T4 en T3 wer-
den ook gezien in groep Β
λ
 tussen februari 1992 en februari 1994. Overigens 
was de vrije T4 spiegel niet bij alle patiënten tussen februari 1992 en februari 
1993 gedaald. Bij 12 patiënten van de gehele groep van 49 patiënten en bij 
3 van de 18 patiënten die in 1992 een verlaagde TSH-spiegel hadden was de 
vrije T4 spiegel na een jaar gestegen. Een stijging van de vrije T4 spiegel tot 
boven de bovengrens van normaal werd echter slechts bij 3 van de 49 patiënten 
waargenomen. Geconcludeerd wordt dat bij patiënten, die normale spiegels van 
vrij T4 en T3 in het serum hebben na in het verleden behandeld te zijn met ra-
dioactief jodium wegens een toxische multinodulaire struma, een verdere daling 
van de schildklierhormoongehalten verwacht mag worden, in ieder geval in de 
eerste decade na de behandeling. Dit geldt ook voor diegenen die een verlaagde 
serum TSH-spiegel hebben. Bij deze patiënten is een expectatief beleid met 
jaarlijkse controles geboden. Aanvullende behandeling met radioactief jodium 
dient overwogen te worden bij patiënten met een verlaagde serum TSH-spiegel 
wanneer bij volgende controles een verdere daling van de TSH-spiegel (of een 
TSH-gehalte beneden de detectielimiet van de assay) in combinatie met stij-
gende vrije T4 en T3 gehalten gezien wordt, zeker wanneer ook klachten en 
verschijnselen van thyreotoxicose terugkeren. 
In hoofdstuk 6 wordt magnetische resonantie (MRI) als techniek voor 
volumebepaling van grote multinodulaire strumae geëvalueerd. Dit met het 
oog op de toenemende belangstelling voor niet-chirurgische behandelingsvor-
men ter verkleining van struma?. Twintig patiënten (3 mannen en 17 vrouwen, 
leeftijd 61 ±21 jaargemiddelde ± SD) met een multinodulaire struma met een 
inhoud van meer dan 100 ml werden onderzocht. Bovendien werden MRI-
metingen vergeleken met scintigrafische volumemetingen. De intra-observer 
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variatiecoëfficiënt (CV) van MRI metingen was 2.2% ± 2.0% (ónderzoeker 1) en 
de inter-observer CV 4.2% ±2.1% (onderzoekers 1 en 2). Bij alle 20 patiënten 
waren tekenen van mechanische complicaties zichtbaar op de MRI-beelden. 
Voor scintigrafische metingen waren de verschillen aanzienlijk groter: de intra-
observer CV was 7.5% ±5.7% (onderzoeker 3) en 5.4% ±5.1% (onderzoeker 4) 
en de inter-observer CV was 10.1% ±6.1%. De correlatie tussen MRI metin-
gen en scintigrafische metingen was zwak (r = 0.665) en de resulterende CV 
was 17.3% ± 14.3%. Onderwaardering van schildkliervolumina door scintigrafie 
werd niet verklaard door de aanwezigheid van cysten aan het oppervlak van 
de schildklier. Geconcludeerd wordt dat MRI gebruikt kan worden voor in vivo 
schildkliervolumebepalingen bij grote multinodulaire strumae. De grote pre-
cisie van MRI-metingen maakt deze techniek dan ook goed bruikbaar voor de 
meting van schildkliergroei en voor evaluatie van niet-chirurgische behande-
ling van strumae. Scintigrafische volumebepalingen zijn hiervoor onvoldoende 
nauwkeurig. Een bijkomend voordeel van MRI is dat gedetailleerde anatomische 
informatie over mechanische complicaties van grote strumae verkregen wordt. 
In hoofdstuk 7 wordt de effectiviteit van behandeling met radioactief 
jodium als alternatief voor schildklierchirurgie op prospectieve wijze geëvalu-
eerd bij 19 patiënten (66 ± 14 jaar oud; gemiddelde ± SD) met een ongewoon 
grote, de trachea vernauwende, multinodulaire struma (>100 ml), die een hoog 
operatierisico hadden of chirurgische behandeling weigerden. Eén dosering van 
2.6 ±1.0 GBq (70 ± 28 mCi) 131I (3.7 MBq of 100 μΟϊ per gram schildklierweefsel) 
werd intraveneus toegediend, gevolgd door dagelijkse toediening van L-thyroxine 
in doseringen die de serum TSH-spiegel niet onderdrukten. MRI metingen van 
het schildkliervolume, van de maximale deviatie van de trachea uit de medi­
aanlijn en van de kleinste dwarsdoorsnede van het lumen van de trachea wer­
den uitgevoerd vóór en 1 jaar na de behandeling met radioactief jodium en het 
klinische resultaat werd beoordeeld. Kort na de 131I behandeling werd geen toe-
name van symptomen van tracheavernauwing waargenomen. Vóór de behan-
deling was het schildkliervolume 269 ± 153 ml en 1 jaar na de 131I behandeling 
154 ± 73 ml (p < 0.001). De reductie van het schildkliervolume was 40% ± 15% 
(spreiding 19% tot 60%). De maximale deviatie van de trachea (1.9 ±0.8 cm 
vóór en 1.5 ± 0.7 cm 1 jaar na de behandeling) was afgenomen met 20% ± 20% 
(-4% tot 73%; ρ < 0.001) en de kleinste dwarsdoorsnede van het lumen van 
de trachea (0.78 ± 0.38 cm2 vóór en 1.04 ± 0.48 cm2 1 jaar na de behandeling) 
was toegenomen met 36% ± 38% (-3% tot 125%; ρ < 0.001). Klachten en symp­
tomen waren verbeterd bij 8 van de 12 patiënten met kortademigheid en inspi-
ratoire stridor en bij beide patiënten met compressie van de vena cava superior. 
Geconcludeerd wordt dat behandeling met radioactief jodium een effectief al-
ternatief voor schildklierchirurgie is voor oudere patiënten met een ongewoon 
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grote, multinodulaire struma die compressie van de trachea en andere vitale 
structuren veroorzaakt. 
In hoofdstuk 8 worden dosimetrische aspecten van behandeling met ra-
dioactief jodium bij patiënten met een grote, multinodulaire struma bestudeerd. 
In veel van de gebruikelijke doseringsschema's voor behandeling met radioac-
tief jodium wordt gestreefd naar een bepaalde hoeveelheid radioactief jodium 
per gram schildklierweefsel, 24 uur na toediening aanwezig in de schildklier. 
Bij toepassing van een dergelijk schema worden hoge doseringen radioactief 
jodium toegediend aan patiënten met een grote, multinodulaire struma. Geab-
sorbeerde doses in de schildklier, in omgevende weefsels en in de rest van het 
lichaam werden geschat na therapeutische toediening van 131I (3.7 MBq per 
gram schildklierweefsel geretineerd in de schildklier na 24 uur) bij patiënten 
met een grote, multinodulaire struma (gewicht >100 gram). Thermolumines-
centie dosimetrie (TLD) metingen op de huid over de schildklier, over de sub-
mandibulaire speekselklier en over de parotis werden gebruikt om de stralen-
belasting voor de omgevende weefsels ten gevolge van radioactief jodium in de 
schildklier te benaderen. TLD-metingen bij 23 patiënten (12 eu- en 11 hyper-
thyreotisch; schildkliergewicht 222 ± 72 g, gemiddelde ± SD; toegediende dosis 
2.1 ± 0.9 GBq) toonden cumulatieve (i.e. in de tijd geïntegreerde) geabsorbeerde 
doses van 4.2 ±1.4 gray (Gy) op de huid over de schildklier, 2.1 ±0.9 Gy op 
de huid over de submandibulaire speekselklier en 0.4 ± 0.2 Gy op de huid over 
de parotis. Er waren geen significante verschillen in cumulatieve doses tussen 
eu- en hyperthyreotische patiënten. De geabsorbeerde doses op elke van de drie 
locaties waren significant gecorreleerd met de totale hoeveelheid 131I, gereti-
neerd in de schildklier na 24 uur. Bij 12 patiënten (6 eu- en 6 hyperthyreotisch; 
schildkliergewicht 204 ± 69 g; toegediende dosis 1.9 ± 0.9 GBq) werden schattin-
gen gemaakt van de stralenbelasting voor de schildklier en voor de rest van het 
lichaam. Hiervoor werd gebruik gemaakt van metingen van radioactiviteit in 
de schildklier en een sterk vereenvoudigd model van de jodiumkinetiek in het 
lichaam, zoals beschreven door Robertson en Gorman (1975). De geabsorbeerde 
dosis in de schildklier was 84 ± 22 Gy voor eu- en 83 ± 15 Gy voor hyperthyreo-
tische patiënten. De hoogste geabsorbeerde doses buiten de schildklier werden 
berekend voor de maag, de dunne darm en de blaas (gemiddelde waarden voor 
12 patiënten respectievelijk 0.38 Gy, 0.57 Gy en 0.88 Gy). De geabsorbeerde 
doses in alle andere weefsels en organen buiten de schildklier waren lager en 
varieerden van 0.05 Gy tot 0.30 Gy (gemiddelde waarden van 12 patiënten). Er 
waren geen significante verschillen in geabsorbeerde doses tussen eu- en hyper-
thyreotische patiënten. De geabsorbeerde doses in organen buiten de schildklier 
waren ongeveer vier maal zo hoog als die welke in de literatuur vermeld worden 
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voor patiënten met de ziekte van Graves na behandeling met 131I. Met behulp 
van risicoschattingen, door het gezaghebbende International Committee on Ra-
diation Protection voor een populatie van alle leeftijden gemaakt, werd een risico 
voor het ontstaan van kanker (al dan niet fataal) buiten de schildklier gedurende 
de rest van het leven berekend^van 1.6%. Voor personen van 65 jaar en ouder 
is het geschatte risico lager, ongeveer 0.3%. Hierbij moet echter vermeld wor-
den dat deze gegevens slechts risicoschattingen zijn en dat er geen werkelijke 
follow-up gegevens beschikbaar zijn over de kankerincidentie bij patiënten met 
een grote, multinodulaire struma behandeld met radioactief jodium. Bij alle 
patiënten met een grote, multinodulaire struma, die behandeld moeten worden 
wegens hyperthyreoidie of mechanische problemen, dienen de geschatte risico's 
van chirurgie en van behandeling met radioactief jodium tegen elkaar afgewogen 
te worden. Bij jongere patiënten heeft chirurgie, onzes inziens, de voorkeur, met 
name wanneer de toe te dienen hoeveelheid radioactief jodium, zoals berekend 
uit een tracer studie met 131I, hoog is. Daarentegen zullen bij oudere patiënten 
en patiënten met cardiale of pulmonale ziekten de voordelen van niet-invasieve 
behandeling met 131I groter zijn dan het risico ervan op lange termijn. Met 
name voor deze patiënten lijkt behandeling met radioactief jodium te verkiezen 
boven chirurgie. 
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